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3ABSTRACT
Objective: To investigate the neuroprotective approach of controlling
mitochondria-dependent apoptosis in Parkinson’s disease cellular models.
Background: Parkinson’s disease is a neurodegenerative disease and there is
evidence indicating that mitochondria-dependent apoptosis is related to
dopaminergic neuron loss. pUL37x1, an immediate early protein expressed during
cytomegalovirus infection, modulates mitochondria-dependent apoptosis by
inactivating Bcl-2-associated X protein (Bax), and meclizine is believed to increase
glycolysis and hyperpolarize mitochondria, which inhibits apoptosis.
Methods: The neuroprotective and anti-apoptotic effects of pUL37x1 over-
expression and meclizine were investigated in SH-SY5Y, a neuroblastoma cell line
and primary rat cortical culture cells. Cell death was induced by either
staurosporine or 6-hydroxydopamine and measured by lactate dehydrogenase
release and propidium iodide binding assay. Apoptotic markers were measured by
the release of cytochrome c and the activation of caspase-3. Mitochondrial
membrane potential was measured by Tetramethylrhodamine, methyl ester
fluorescence obtained by confocal microscope. Extracellular acidification rate
(ECAR), a glycolytic activity parameter and oxygen consumption rate (OCR) were
measured by XF analyser. Statistics was performed by either ANOVA with Dunnett’s
post-hoc analysis or two-tailed Student’s t-test.
Results: Both pUL37x1 over-expression and meclizine significantly protected
against toxin-induced cell death in SH-SY5Y and rat primary cortical culture cells.
4Both approaches also down-regulated apoptosis. In terms of meclizine, the
protection resulted from glycolysis-related mitochondrial hyperpolarization.
Hyperpolarization and protection would decline following glycolytic inhibition.
pUL37x1 over-expression prevented apoptotic cell death by two means: Bax-
dependent and glycolysis-dependent mechanisms. First, pUL37x1 over-expression
led to Bax mitochondria-translocation, and in contrast to control, Bax silencing did
not provide more protection on pUL37x1 over-expressing cells. Second, pUL37x1
over-expression increased cellular glycolysis and hyperpolarized mitochondria, and
glycolytic inhibitors attenuated the protection, indicating a glycolysis-dependent
protective mechanism.
Conclusions: The success of neuroprotection by pUL37x1 and meclizine in
Parkinson’s disease cellular models not only confirms the significance of controlling
mitochondria-dependent apoptosis, but also indicates two novel approaches to
neuroprotection.
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1 Introduction
1.1 Parkinson’s Disease
1.1.1 Clinical Presentation and Epidemiology of Parkinson’s Disease
1.1.1.1 History of Identification of Parkinson’s Disease
People have been aware of Parkinson’s disease since the times of ancient China
and India. Yellow Emperor’s Internal Classic, the first Chinese medicine classic
written around 425-221 BC, described a Parkinson’s disease-like symptom with
tremor and stiffness (Zhang et al., 2006). Ancient Indians named the disease
‘Kampavata’ and treated it with levodopa-containing Mucuna pruriens (Manyam,
1990). In the second century, the Greek physician Galen described a disease with
rest tremor, postural change and paralysis, which was almost identical with
Parkinson’s disease (Garcia Ruiz, 2004) and later, in 17th and 18th centuries, some
symptoms of Parkinson’s disease, such as rest tremor and festination, were noted
by doctors. (Goetz, 2011).
Before the middle of 19th century, Parkinson’s disease was known as paralysis
agitans (shaking palsy). It’s present name was adopted following the publication of
Dr. James Parkinson’s report “An essay on the shaking palsy” in 1817 based on his
observations of six patients. In this first medical document about Parkinson’s
disease, he described some key manifestations of the disease, including resting
tremor, stooped posture and festinating gait. Dr Charcot, a French neurologist,
suggested replacing the term ‘paralysis agitans’ by ‘Parkinson’s disease’, in 1872, as
there was no marked muscle weakness and that tremor was not an essential
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symptom of the disease. Dr Charcot also distinguished between Parkinson’s disease
and other tremulous disorders, such as multiple sclerosis, and identified
Parkinsonism-plus syndromes (Goetz, 2011).
The treatment of Parkinson’s disease progressed in line with the increased
understanding of the disease. Anticholinergics have been prescribed since the
middle of 19th century. The medical treatment of the disease entered a new era in
1960s due to the discovery of levodopa followed by dopamine agonists, amatadine,
monoamine oxidase B (MAO-B) inhibitors and catechol-O-methyl transferase
(COMT) inhibitors. Alongside this surgical intervention provided another treatment
option for Parkinson’s disease. Dr Cooper introduced thalamotomy as a treatment
of Parkinson’s disease in 1950s, but lesionectomy became less popular after the
development of levodopa until the emergence of deep brain stimulation in
1990s(Rascol et al., 2011b). However, both medical and surgical treatments were
only symptomatic therapies. The concept of a cure for the disease by either
neuroprotective treatment or cellular replacement has been investigated for
decades but none have, as yet, achieved the goal to cure the disease (Ganz et al.,
2011; Stocchi and Olanow, 2013).
1.1.1.2 Motor and Non-motor Symptoms of Parkinson’s Disease
The most remarkable clinical manifestations of Parkinson’s disease are the motor
symptoms, some of which have been described for centuries(Goetz, 2011; Zhang et
al., 2006). The cardinal ones are resting tremor, rigidity, bradykinesia, flexion
posture of neck, trunk and limbs, loss of postural reflex, and freezing
phenomenon(Fahn, 2003). These are essential for a diagnosis of Parkinson’s disease.
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According to UK Parkinson’s disease society brain bank clinical diagnostic criteria,
bradykinesia and one of the following three symptoms: muscular rigidity, 4-6Hz rest
tremor or postural instability not caused by primary visual, vestibular, cerebellar, or
proprioceptive dysfunction are fundamental for diagnosis of Parkinson’s
disease(Hughes et al., 1992). As well as these well-known symptoms, some
additional motor manifestations result from Parkinson’s diseases, such as
hypomimia, dysarthria, dysphagia, micrographia, scoliosis and
camptocormia(Jankovic, 2008).
However, the presenting symptoms of Parkinson’s disease are not limited to
motor problems. Even in the 19th century, Dr Charcot noticed that dysautonomia
and pain accompanied with Parkinson’s disease(Goetz, 2011). Nowadays,
neurologists recognized five major spectrums of non-motor symptoms in
Parkinson’s disease, including neuropsyciatric disorders, sleep disorders, autonomic
disorders, gastrointestinal disorders and sensory symptoms. Even more important
is that some of these non-motor symptoms present years before the clinical motor
symptoms. For example, rapid eye movement sleep behaviour disorder,
constipation, olfactory deficit and depression have been strongly correlated to the
pre-clinical characteristics of Parkinson’s disease(Chaudhuri et al., 2006).
1.1.1.3 Epidemiology of Parkinson’s Disease and the
Impact on Quality of Life
Parkinson’s disease affects a great number of people and, in general, the
prevalence is 0.3% worldwide(de Lau and Breteler, 2006). It is an age-related
19
disorder and rarely develops in patients below the age of 50, but the prevalence
increases to 1% in people over 60 years old, and rises to 4% in over 80 year olds(de
Rijk et al., 1995; Nussbaum and Ellis, 2003). In addition, according to different
epidemiological surveys from various countries and races, the disease prevalence
seems to be lower in Asian and Black populations compared to White and , is
slightly male-predominant, with a male to female ratio of 0.9-2.6.(de Lau and
Breteler, 2006).
Parkinson’s disease has crucial negative impacts on quality of life. The motor
symptoms, non-motor symptoms and medication-related effects all contribute to
this. Among all these factors the most significant to quality of life are shuffling,
difficulty turning, falls, difficulty in dressing, fatigue, confusion, autonomic
disturbance particularly urinary incontinence, unpredictable on/off fluctuations,
and sensory symptoms such as pain (Rahman et al., 2008). Parkinson’s disease also
leads to an economic burden for the patients and society. Average disease related
medical costs around £1400 per annum for a newly diagnosed patient(Kaltenboeck
et al., 2012), which could result in total costs of up to £62,147 for an advanced
patient who spent more than 75% of their time in off-status(Findley et al., 2011).
1.1.2 Pathology of Parkinson’s Disease
1.1.2.1 Basal Ganglia Pathology
The hallmark pathological observation of Parkinson’s disease is the loss of
pigmentation of substantia nigra and locus ceruleus pontis(Lewis, 1971). In the 19th
century, James Parkinson postulated that the lesion responsible was located in the
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cervical spinal cord or lower brain stem because of preservation of intellectual
function(Pearce, 2001). However, the role of midbrain and substantia nigra in
Parkinson’s disease was recognized in 1893, when a 38-year-old man with left side
Parkinsonism signs was shown to have a 2.5cm lesion in the contralateral substantia
nigra. In the early 20th century, Tretiakoff, Foix and Nicolesco’s works eventually
demonstrated the importance of substantia nigra lesion in Parkinson’s disease.
Tretiakoff’s works into the pathology of Parkinson’s disease not only identified the
loss of pigmented cells in substantia nigra, but also mentioned a cytoplasmic
inclusion in the nigral cells(Lewis, 1971). This inclusion body was identical with one
that Friederich Lewy had described in 1912 hence these inclusions are now referred
to as Lewy bodies in memory of him.
Lewy bodies are nearly always found in the substantia nigral neuromelanin-
positive neurons of Parkinson’s disease patients, particularly in the posterolateral
diameter and most consist of a central body surrounded by a pale-staining halo.
The ultra-structural appearance of a Lewy body is like a sunflower with a dense
central core of circular shaped structures and a rim of radiating filaments (7 to 20
nm in diameter). The larger filaments are at the periphery, which corresponds to
the halo (Pearce, 2001; Gibb and Lees, 1988). Nowadays, the presence of Lewy
bodies in the substantia nigra is a gold standard for a pathological diagnosis of
Parkinson’s disease(Hughes et al., 1992).
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1.1.2.2 Extra-Basal Ganglia Pathology
Although the core motor symptoms of Parkinson’s disease can be explained by the
loss of substantia nigra dopaminergic neurons, there are still plenty of non-motor
symptoms which do not result from that lesion. Actually, the first place Dr. Lewy
identified Lewy bodies was in the dorsal motor nucleus of the vagus, a region within
the medulla oblongata, of Parkinson’s disease patients. Since then, Lewy bodies
have been found in the both peripheral and central nervous system of Parkinson’s
disease patients. In peripheral nerves, Lewy body pathology has been found in
enteric, sympathetic and parasympathetic neurons, which accounts for certain non-
motor symptoms such as constipation, orthostatic hypotension and excessive
sweating. In the central nervous system, Lewy bodies are not only found in the
dorsal motor nucleus of vagus, but also in the medullary reticular formation, the
raphe nuclei, the locus ceruleus, the pedunculopontine nuclei and the ventral
tegmental area, suggesting Lewy bodies are widespread in the central nervous
system of Parkinson’s disease patients(Surmeier and Sulzer, 2013). These
pathological findings are also able to explain some non-motor symptoms like
dementia, depression and rapid eye movement sleep behaviour disorder.
1.1.2.3 The Correlation Between Pathology with the Severity of Disease
Braak and his colleagues were the first group to propose that the distribution of
Lewy bodies correlated to the severity of disease(Braak et al., 2003a). They studied
110 autopsy cases presented with Lewy body pathology of which only 41 had a
clinical diagnosis of Parkinson’s disease. Considering the pattern of neuronal
inclusion and the severity of disease, they postulated that the progression of Lewy
22
body pathology starts from medulla oblongata. The pons and midbrain areas
become involved later while, in the advance stage, Lewy bodies can be found in the
neocortex, including premotor and primary motor cortex. This finding has led to the
hypothesis that the pathogenic process of Parkinson’s disease can spread trans-
synaptically in the central nervous system(Braak et al., 2003b). Some researchers
further suggested that certain components within the Lewy body may have prion-
like processes in order to progress the inclusions from caudal to rostral(Visanji et al.,
2013).
1.2 Pathogenesis of Parkinson’s Disease
The pathogenesis of Parkinson’s disease is multi-factorial. Although some genetic
mutations have been identified that cause hereditary Parkinson’s disease, about
90% patients have idiopathic Parkinson’s disease(Trimmer and Bennett, Jr., 2009).
In the idiopathic group, the aetiology and pathogenesis of disease are still a puzzle
and inflammation are all suspected to play a role. Likewise, in hereditary
Parkinson’s disease, generally classified as either autosomal dominant or autosomal
dysfunction or excessive oxidative stress depending on the loss/gain function of
mutant gene.
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1.2.1 Pathogenesis in Idiopathic Parkinson’s Disease
1.2.1.1 -synuclein aggregation
The most striking pathological finding of Parkinson’s disease is the presence of
expressed in the brain at the presynaptic terminals and its expression is induced
during neuronal development, following determination of neuronal phenotype and
establishment of synaptic connections. Based on this specific localization and
synuclein is thought to be control of neurotransmitter release, providing a subtle
break for neurotransmitter release under circumstances of repeated firing,
modulating vesicular biogenesis and controlling compartmentalization(Stefanis,
terminal portion with molecular chaperone 14-3-3 and binds to many proteins that
14-3-3 binds to as well. With both structural and functional homology with 14-3-3,
conditions(Recchia et al., 2004).
amyloid fibrils. Lipidic environments and some post-translational modifications,
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such as phosphorylation at Ser-129 and nitration on Tyr-125, -133, and -136
Hansen and Li, 2012; McLean and Hyman, 2002; Takahashi et al., 2002). In addition,
macromolecular crowding, pesticide exposure and interactions with manganese,
iron, and aluminium(Breydo et al., 2012).
involved, such as blocked endoplasmic reticulum-golgi transport leading to
endoplasmic reticulum stress and golgi fragmentation, decreased synaptic vesicle
release, impaired energy production and apoptosis induction in mitochondria,
accumulation of chaperone-mediated autophagy substrates and proteasomal
component of Lewy bodies, it is still debatable whether the insoluble form is toxic
or not(Goldberg and Lansbury, Jr., 2000). Plenty of evidence from post-mortem
studies and animal models reveals that the presence of Lewy bodies does not
always mediate neuronal loss, indicating that Lewy bodies are not necessarily
synuclein oligomers contribute to toxicity. Some studies found that higher oligomer
levels were associated with the disease, and others have demonstrated that
significant neuronal loss in experimental models(Kalia et al., 2013).
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1.2.1.2 Oxidative Stress
Oxidative stress is a state of imbalance between the generation of reactive oxygen
species (ROS) with the ability of a biological system to detoxify the reactive
intermediates. The majority of ROS are superoxide anion radicals (O2 ), hydroxyl
radicals (•OH) and hydrogen peroxide (H2O2)(Dias et al., 2013). Mitochondrial
complexes I and III of the electron transport chain are the main sources of
superoxide while peroxisomes can reduce them to hydrogen peroxide and convert
this to water(D'Autreaux and Toledano, 2007). In the physiological condition, ROS
also serve as a signalling molecule so the level of ROS is tightly controlled by
adaptive responses such as defensive enzymes, molecular chaperones and
antioxidant molecules. However, if production overwhelms clearance, the excessive
levels of ROS induces oxidative stress which causes peroxidation of cellular
membrane lipids, protein oxidation and fragmentation, and the oxidation of DNA
and RNA(Dias et al., 2013).
There are numerous studies concerning oxidative stress and subsequent oxidative
damage in the brains of Parkinson’s disease. Lipid peroxidation and DNA damage
increases in the nigrastriatum of Parkinson’s disease (RajaSankar et al., 2009;
Dexter et al., 1994) and markers of protein oxidative damage, such as carbonyl
modifications of soluble proteins, and markers of lipid peroxidation, including
malondialdehyde, 4-hydroxy-2,3-nonenal, and thiobarbituric acid reactive
substance are elevated in the substantia nigra of Parkinson’s disease(Yoritaka et al.,
1996; Dexter et al., 1989; Floor and Wetzel, 1998). In contrast, the level of
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glutathione, a natural antioxidant, was lower in Parkinson’s disease, which also
indicated the over-production of ROS (Pearce et al., 1997; Sofic et al., 1992).
There are several reasons as to why Parkinson’s disease is closely associated with
oxidative stress. First of all, dopamine tends to auto-oxidate in the dopaminergic
neurons inducing a chronic oxidative stress. Dopamine can be metabolized by
monoamine oxidase but may also directly react with oxygen and generate quinones
and free radicals(Graham, 1978). In addition, increased iron levels in the substantia
nigra leads to the reduction of hydrogen peroxide to produce the highly reactive•
OH (Jenner, 2003). Mitochondrial dysfunction in the brains of Parkinson’s disease is
another crucial factor to support the oxidative stress hypothesis. Decreased
complex I activity, which is found in the substantia nigra of Parkinson’s disease,
results in the generation of ROS(Schapira et al., 1989). Complex I inhibitors, such as
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP), also cause Parkinson’s
disease through impaired mitochondrial function and subsequent oxidative
stress(Hasegawa et al., 1990).
1.2.1.3 Inflammation and Lysosomal Dysfunction
Inflammation is recognized as a possible pathogenic factor of Parkinson’s disease
based on some vital epidemiological findings. Patients using non-steroidal anti-
inflammatory drugs had lower risk of Parkinson’s disease and there was a
consistent association between the human leukocyte antigen locus and Parkinson’s
disease risk from a meta-analyses of genome-wide association studies(Foltynie and
Kahan, 2013). Post-mortem studies have also revealed the presence of activated
microglia in the substantia nigra of Parkinson’s disease (McGeer et al., 1988). It has
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also been postulated that excessive activation of microglia leads to over-production
of cytokines and other inflammatory mediators, as well as ROS(Tansey and
Goldberg, 2010), but activation of inflammation could only trigger
protein aggregation and inflammation in the pathogenesis of Parkinson’s disease
(Gao et al., 2008).
The relationship between lysosomal dysfunction and Parkinson’s disease emerged
after the discovery that glucocerebrosidase (GBA) gene mutation accounts for 4-7%
of idiopathic Parkinson’s disease(Murphy and Halliday, 2014). The GBA gene
encodes the glucocerebrosidase enzyme which is involved in lysosomal function.
Post-mortem data revealed that glucocerebrosidase is reduced not only in the
substantia nigra of patients with heterozygous GBA mutations, but also in the
substantia nigra of sporadic Parkinson’s disease patients (Gegg et al., 2012).
1.2.2 Pathogenesis in Hereditary Parkinson’s Disease
A genetic aetiology for Parkinson’s disease has begun to emerge in the past 15
years. Although hereditary Parkinson’s disease accounts for less than 10% of
Parkinson’s disease patients, understanding the pathogenesis from these hereditary
cases can enrich our knowledge about disease mechanism and also help to model
the disease experimentally. At present, there are more than 10 gene mutations
which have been identified as the loci of hereditary Parkinson’s disease(Klein and
Westenberger, 2012). Two autosomal dominant hereditary genes, SNCA and LRRK2,
and three autosomal recessive ones, Parkin, Pink1 and DJ-1 are discussed below.
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1.2.2.1 Autosomal Dominant
The first genetic mutation associated to hereditary Parkinson’s disease was found
th or
5th decade and the presentations are similar to idiopathic Parkinson’s disease.
However, the progress of disease is more rapid and associated with the early
development of dementia. Pathologically, Lewy bodies are widespread in the brain
of SNCA mutation patient, including in the limbic and neocortal
regions(Polymeropoulos et al., 1996) .
A30P speeds up fragmentation of the fibrils, which then accelerates the seeding
process for forming new fibrils (Hansen and Li, 2012; Polymeropoulos et al., 1996).
Also, duplication or triplication of SNCA gene leads to a corresponding 50% or 100%
Parkinson’s disease identical to the idiopathic form, which had been described in
previous section 1.2.1.1.
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most frequent
known cause of late-onset autosomal dominant and sporadic Parkinson’s disease,
with a mutation frequency ranging from 0.5% to 40% in different
populations(Shulman et al., 2011). Clinical presentations of LRRK2 mutation-related
Parkinson’s disease include a mid-to-late onset, slow progression, favourable
response to levodopa therapy and less chance of dementia. Pathological findings
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are those typical of PD in the majority of cases, although there may be some
variation with pure nigral degeneration without Lewy bodies have been reported
(Giasson et al., 2006) and with tau pathology.
LRRK2 has well-defined GTPase and kinase functions. It also exhibits multiple
biological roles in striatal neurotransmission, neuronal arborisation, endocytosis,
autophagy and immunity(Trinh and Farrer, 2013), but it is still uncertain how
mutations of LRRK2 lead to Parkinson’s disease. Researchers have postulated that
gain of function caused by LRRK2 mutation is responsible for the neuronal loss in
Parkinson’s disease. The toxicity of LRRK2 is closely associated with GTPase activity,
1.2.2.2 Autosomal Recessive
Parkin mutations are the most common cause of recessive hereditary Parkinson’s
disease and account for 10% of early onset patients(Houlden and Singleton, 2012).
The clinical phenotype of homozygous or compound PARK2 mutation cases is slow
disease progression, levodopa-responsiveness and late motor complications
(Lohmann et al., 2003). The pathological findings of Parkin mutation is very unlike
the majority of Parkinson’s disease, and includes severe neuronal loss and gliosis
without lewy bodies in the substantia nigra. These pathological findings echo the
previously mentioned concept that Lewy body formation is not always necessary
for the pathogenesis of Parkinson’s disease.
Parkin is an E3 ubiquitin protein ligase. Similar to other RING finger containing
proteins, it targets misfolded proteins to the ubiquitin proteasome pathway for
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degradation and loss of E3 ligase function is responsible for the pathogenesis of
disease (Thomas and Beal, 2007). Under physiological conditions, Parkin has an
important influence on mitochondria. It modulates mitochondrial biogenesis
ubiquitination of mitofusin 1&2 (Gegg et al., 2010). Parkin also plays an important
role in mitophagy in conjugation with PINK1(Deas et al., 2011).
It is rare that Parkinson’s disease results from mutations in PINK1, which only
accounts for up to 1% to 8% of the cases with early onset(Singleton et al., 2013).
PINK1 is a mitochondria-associated protein kinase and mutations result in loss of
the kinase function. Clinically, patients have a later age of onset compared with
Parkin mutations, usually presenting in their 5th or 6th decade but slow progression
and levodopa-responsiveness similar to Parkinson’s disease associated with Parkin
mutations(Houlden and Singleton, 2012). At present, the only autopsy from PINK1
mutation associated Parkinson’s disease revealed the presence of Lewy bodies
(Samaranch et al., 2010).
Both Parkin and PINK1 are essential for mitophagy and PINK1 works upstream to
Parkin(Deas et al., 2011). PINK1 detects dysfunctional mitochondria and
accumulates on the mitochondrial outer membrane. Mitochondria-localization of
PINK1 recruits Parkin to the damaged mitochondria, and subsequently
ubiquitination of mitochondrial outer membrane by Parkin. Eventually, the
PINK1/Parkin machinery triggers mitophagy for the clearance of damaged
mitochondria. Mutations in either PINK1 or Parkin impair the pathway and lead to
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accumulation of dysfunctional mitochondria, which triggers the further neuronal
loss by oxidative stress and apoptosis(Grenier et al., 2013).
DJ-1 mutations in Parkinson’s disease are rare. The clinical presentation of
psychological and behavioural disturbances, amyotrophy and cognitive impairment
help to distinguish it from other early onset Parkinson’s disease(Trinh and Farrer,
2013). It is believed that DJ-I is an anti-oxidant protein which translocates to
mitochondria in response to oxidative stress. To date, there is no pathological
report from DJ-1 mutations associated Parkinson’s disease(Klein and Westenberger,
2012).
1.2.3 The Vulnerability of Dopaminergic Neurons in Parkinson’s Disease
Substantia nigral dopaminergic neurons are the most vulnerable population of
neurons in Parkinson’s disease. Most of the motor symptoms results from the loss
of these neurons. However, current pathological findings reveal that lewy body
inclusions are not exclusive to this specific area. Therefore, there must be other
explanations for the relatively specific degeneration of midbrain dopaminergic
neurons.
The aforementioned auto-oxidation of dopamine is a significant source of
oxidative stress in the dopaminergic neurons, which could explain their
vulnerability. Also, the morphology of the substantia nigral dopaminergic neurons is
distinct from neurons elsewhere. These neurons have long, thin, mostly
unmyelinated axons and up to 150,000 presynaptic terminals per neuron (Braak et
al., 2006; Sulzer, 2007). Mitochondria present in these nigral dopaminergic neurons
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are burdened with the high energy demand required to support synaptic activity,
compensate for the potential risk of depolarization in the unmyelinated membrane,
and sustain axonal transport over long distances(Fujita et al., 2013). Impaired
energy production and failure of mitochondrial axonal transport have been shown
to induce parkinsonism and the loss of dopaminergic neurons, supporting a role for
this energy-failure concept in Parkinson’s disease(Schapira, 2008).
A unique characteristic of midbrain dopaminergic cells is the intrinsic pacemaking
activity, which is believed to be important in maintaining basal dopamine levels in
the striatum. This distinct electrophysiological feature relies on the influx of calcium
through L-type Ca2+ channels and leads to increase cytosolic calcium(Gonzalez-
Hernandez et al., 2010). The excessive episodic calcium needs to be pumped out,
which requires adenosine-5’-triphosphate (ATP); failure to meet the demand for
ATP or the sustained opening of the calcium channels leads to undesirable
increases in cellular calcium and further endoplasmic reticular stress(Paschen and
Mengesdorf, 2005). In addition, increased ATP generation inevitably contributes to
increased ROS and oxidative stress(Chan et al., 2009). Excessive intracellular
calcium, endoplasmic reticular stress and oxidative stress are all notorious for
inducing apoptotic cell death and contributing to the vulnerability of nigral
dopaminergic neurons.
33
1.3 The Role of Mitochondria in Parkinson’s Disease
1.3.1 The Physiological Characteristics of Mitochondria
Mitochondria are organelles composed of separate and functionally distinct outer
and inner membranes that encapsulate the intermembrane space and matrix
compartments. They also contain a circular mitochondrial DNA that encodes 13
mitochondrial proteins. Physiologically, mitochondria play an important role in
controlling energy supply, calcium homeostasis and apoptosis. The balance of
mitochondrial biogenesis and mitophagy regulates the mitochondrial content of the
cell and is also responsible for the quality control of mitochondria. As mitochondria
are involved in many physiological pathway, it is no surprise that mitochondrial
dysfunction leads to several human diseases.
1.3.1.1 Electron Transport Chain and Reactive Oxygen Species
Aerobic glucose oxidation begins with glycolysis in the cytoplasm and the end-
product is pyruvate. The pyruvates are then transported into the mitochondrial
matrix, followed by conversion to acetyl-CoA and eventual entry into the
tricarboxylic acid cycle where they are oxidized to CO2 and water. The purpose of
glucose oxidation is ATP generation and it is completed by the electrons donated
from NADH and succinate enter into electron transport chain. The electron
transport chain links with the phosphorylation of ADP (ATP synthesis ) by a
protonmotive force across the mitochondrial inner membrane, generated by its
hydrogen pump effect (Nicholls et al., 2002).
The electron transport chain is composed of four major protein complexes (I–IV).
Complex I (NADH-Coenzyme Q oxidoreductase) and complex II (succinate-
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coenzyme Q oxidoreductase) pass electrons down to an electron transporter,
ubiquinone (coenzyme Q). Then the electrons pass down through coenzyme Q-
cytochrome c oxidoreductase (complex III), to another carrier, cytochrome c. In the
final step, electrons carried by cytochrome c are transferred to cytochrome c
oxidase (complex IV) and reduced oxygen to water(Venditti et al., 2013). During this
electron transport, protons are pumped out from the mitochondrial matrix to the
intermembrane space by complex I, III and IV in order to generate the
protonmotive force. Eventually, the protons re-enter the matrix through complex V
(ATP synthase) and release energy generated by the electrochemical gradient. ATP
synthase utilizes this energy to phosphorylate ADP to ATP (Walker et al., 1995).
ROS are a by-product of the electron transport chain and the electron leak in
complex I and III is mainly responsible for the generation of the superoxide species.
Electrons carried by NADH are transported to the flavin mononucleotide (IF) site in
complex I, where they normally pass down a chain of Fe–S centres to the
ubiquinone-binding site (IQ). At both the IF and IQ sites, these electrons react with
oxygen, forming superoxide (O2 ) within the matrix. In complex III, QH2 binds to the
QO site, where the electrons can bypass the ordinary route in the Q-cycle and react
directly with oxygen to form superoxide that is released to either side of the
mitochondrial inner membrane(Jastroch et al., 2010).
1.3.1.2 Calcium Homeostasis
Mitochondrial Ca2+ transport was discovered in the early 1960s. Ca2+ uptake is
driven by the negative mitochondrial membrane potential and consumes the
potential. Ca2+ enters mitochondria through Ca2+ uniporter, a highly selective Ca2+
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channel which is sensitive to ruthenium red(Brookes et al., 2004). Ca2+
accumulation in the mitochondria is counteracted by mitochondrial Na+/ Ca2+
exchangers and mitochondrial H+/Ca2+ exchangers, which are insensitive to
ruthenium red but inhibited by benzothiazepine analogues(Rizzuto et al., 2012).
Mitochondria and the endoplasmic reticulum work closely to stabilise intracellular
calcium homeostasis. When excitatory stimulation induces the influx of Ca2+,
leading to the increase in intracellular calcium, endoplasmic reticulum releases Ca2+
from the inositol 1,4,5 trisphosphate and ryanodine receptors. At this moment,
mitochondria serve as a calcium buffer to modulate cytoplasmic calcium
concentration. Increased cytoplasmic calcium causes a microdomain of high calcium
at the mouth of the mitochondrial Ca2+ uniporter channels and allows rapid Ca2+
uptake. This Ca2+ is not only stored in the mitochondria matrix but also boosts
certain mitochondrial metabolism processes(Brini, 2003).
1.3.1.3 Apoptosis
Apoptosis is a process mediating programmed cell death. It is characterised into
two pathways: intrinsic and extrinsic. The extrinsic pathway is initiated by
stimulation of the surface receptors to extracellular tumor necrosis factor (TNF) or
Fas. On the other hand, the intrinsic apoptosis pathway is triggered by intracellular
stress and mitochondria play an important role in its mediation. This intrinsic cell
programmed-death starts with the mitochondrial membrane permeabilization
(MMP) regulated by the Bcl-2 (B-cell lymphoma-2) family of proteins. The MMP
allows the release of some apoptotic activators, normally sequestered in the
mitochondrial intermembrane space, into cytoplasm, inducing full-blown apoptotic
36
cell death. These activators include cytochrome c, Smac/DIABLO and apoptosis-
inducing factor (AIF). As well as being a key component of electron transport chain
during oxidative phosphorylation (OXPHOS), cytochrome c plays an important role
in caspase activation following MMP. In the cytoplasm, cytochrome c binds to
apoptotic protease-activating factor 1(APAF1), and induces oligomerization of
APAF1. The conformational change leads to the formation of apoptosome, which
further recruits and activates the caspase initiator. Smac/DIABLO binds to the X-
linked inhibitor of apoptosis protein (XIAP). The original function of XIAP is
inhibition of caspase activity by directly binding to active caspases, such as caspase
9, caspase 3 and caspase 7. Smac/DIABLO directly antagonises this caspase
inhibition ability of XIAP. Although the physiological role of AIF in apoptosis is not
clear, it has been shown to trigger a caspase-independent cell death.(Tait and
Green, 2010; Zamzami and Kroemer, 2001)
1.3.1.4 Mitochondrial Membrane Potential
Mitochondrial membrane potential is the electric gradient across the
mitochondrial inner membrane. It is generated by the pumping out of protons
during the mitochondrial electron transport chain. Both the electron and pH
gradients across the membrane are components of the protonmotive force for the
ATP synthesis although the former is the main energy source (Skarka and Ostadal,
2002). Mitochondrial membrane potential is highly negative, approximately -180
mV and the maintenance of it is vital for several mitochondrial functions, such as
ATP synthesis, calcium buffering and apoptosis(Nicholls, 2004).
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1.3.1.5 Mitochondrial Quality Control
Mitochondria are essential for many vital cell functions. However, the energy-
generating organelle is the source of ROS and can be damaged by its own products.
The mitochondrial quality control system is crucial as it prevents damaged
mitochondria from triggering the apoptotic cell death, especially in the post-mitotic
cells, such as neurons(de Castro et al., 2011).
Mitochondria are dynamic organelles and morphological change, regulated by
mitochondrial fusion and fission, has a very close relationship with quality control.
Mitochondrial fusion allows the repair of unhealthy organelle by healthy ones. In
contrast, by means of fission, the damaged part can be separated from the normal
part. Defective mitochondria can either be repaired through molecular quality
control pathways, or selectively removed through autophagy using a mechanism
that involves the PINK1-dependent recruitment of the ubiquitin ligase Parkin.
Accumulation of malfunctioning mitochondria activates the apoptotic pathway and
leads to cell death (Fischer et al., 2012; McCoy and Cookson, 2012).
1.3.2 Mitochondrial Dysfunction in Parkinson’s Disease
1.3.2.1 Idiopathic and Toxin-induced Parkinson’s Disease
The relationship between mitochondrial dysfunction and Parkinson’s disease was
not identified until the 1980s. MPTP is a by-product of the synthesis of a
meperidine analogue. It crosses the blood–brain barrier and is oxidized to MPP+ by
MAO-B in glial cells. MPP+ can be taken up into dopaminergic neurons via the
dopamine transporter and become concentrated in mitochondria. MPP+ inhibits
complex I of the electron transport chain and causes dopaminergic neuronal cell
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death due to activation of apoptosis(Winklhofer and Haass, 2010). The pathological
presentations from the brains of MPTP-induced parkinsonism, however, are not
totally identical to idiopathic Parkinson’s disease as it shows dopaminergic neuronal
loss in substantia nigra without Lewy body formation(Davis et al., 1979). MPTP is
widely used as an animal model of Parkinson’s disease to reflect dopamine cell loss.
In non-human primates, MPTP administration induces parkinsonism symptoms
which are similar to the human disease and which are responsive to levodopa and
causes the key pathological finding of the loss of dopaminergic neurons in
substantia nigra (Jenner, 2009; Langston et al., 1999). Another mitochondrial toxin,
rotenone, is also a complex I inhibitor and causes dopaminergic neuronal loss in
substantia nigra has been associated with Parkinson’s disease(Martinez and
Greenamyre, 2012)
In terms of idiopathic Parkinson’s disease, the association between mitochondrial
dysfunction and loss of dopaminergic neurons in substantia nigra was identified
soon after the awareness of MPTP-induced parkinsonism. About a 30% reduction of
complex I activity has been reported in the substantia nigra and frontal cortex of
Parkinson’s disease patients at autopsy (Schapira et al., 1989). Moreover, the
reduced complex I activity is not selective to the brain but is also found in platelets
from 25% of Parkinson’s disease patients, which suggests this reduction may result
from genetic or environmental factors(Parker, Jr. et al., 2008; Schapira et al., 1990;
Schapira, 2008). In addition, post-mortem studies have shown increases in
mitochondrial DNA deletions in the dopaminergic neurons of the substantia nigra
from parkinsonian patients(Bender et al., 2006).
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The notion of mitochondrial dysfunction in Parkinson’s disease was applied to
experimental models to identify the mechanisms of dopaminergic neuronal loss.
Cybrid cells, containing mitochondria from patients’ platelets, demonstrated
increased levels of oxidative stress and decreased basal mitochondrial complex I
activity with concomitant enhanced susceptibility to cell death by complex I
inhibition (Swerdlow et al., 1996). The MPTP/MPP+ model clearly demonstrated
that mitochondrial dysfunction contributed to neuronal death and the pathogenesis
of Parkinson’s disease in several areas. First, MPP+ inhibits mitochondrial complex I,
which causes the decrease of endogenous antioxidants and the generation of
oxidative stress from complexes I and III. Oxidative stress triggers the apoptotic
signal, inducing MMP and release of further apoptotic factors such as cytochrome c.
Second, inhibition of mitochondrial complex I decreases ATP levels and leads to a
bioenergetic crisis, compromising the function of the ubiquitin proteasome system
resulting in cell death(Martinez and Greenamyre, 2012). Last but not the least,
MPTP/MPP+
while simultaneously increasing the cytosolic counterpart, leading to depolarization
of the mitochondrial membrane and subsequent caspase activation and cell
death(Petit-Paitel et al., 2009).
1.3.2.2 Genetic Parkinson’s Disease
PINK1 and parkin are the best genetic models to demonstrate the linkage between
mitochondrial dysfunction and Parkinson’s disease. As mentioned in the previous
section, mutations in either of them causes the impairment of the clearance of
damaged mitochondria, leading to accumulations which induce apoptotic cell death.
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The majority of evidence that support this concept is obtained from animal models
and cellular experiments due to the shortage of post-mortem human data. In the
Drosophila model, parkin knockout contributed to abnormal mitochondrial
morphology, increased apoptotic cell death in the muscle cells and increased
oxidative responsive component (Greene et al., 2005; Greene et al., 2003a).
Drosophila lacking PINK1 exhibit mitochondrial degeneration which leads to
apoptosis in flight muscles and mitochondria swollen with reduced ATP levels,
mitochondrial DNA, and mitochondrial proteins(Dawson et al., 2010).
Stronger support for this theory is seen in PINK1 and Parkin mutations cell models
of Parkinson’s disease. Parkin knockout resulted in reduced Bax ubiquitination and
more sensitivity to apoptotic cell death in primary cortical neurons (Johnson et al.,
2012). Parkin regulates mitochondrial biogenesis through ubiquitination of a parkin
and neurodegeneration (Shin et al., 2011). As well as the aforementioned
PINK1/Parkin machinery, which involves mitophagy, the PINK1/Parkin pathway is
also in charge of the mitochondrial quality control by controlling mitochondrial
dynamics, either by inducing protective mitochondrial hyperfusion or the
mitochondrial fission that precedes mitochondrial degradation. Drp1 is a
ubiquitinous substrate of Parkin and Parkin mutation or knockout causing the
accumulation of Drp1 and further mitochondrial fragmentation (Wang et al., 2011).
Another mitochondrial dynamics related protein, Mfn2, is also a substrate of Parkin
and the ubiquitination of Mfn2 requires phosphorylation by PINK1(Chen and Dorn,
2013).
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The remaining genetic mutations which cause Parkinson’s disease also have some
mitochondria with inclusions and damaged mitochondrial DNA in a mouse model.
result in complex I inhibition and increasing mitophagy(Chinta et al., 2010). Another
common autosomal dominant genetic mutation, LRRK2, also affects mitochondrial
function. G2019S mutation of LRRK2 causes mitochondrial depolarization and
decreased cellular ATP levels through mitochondrial uncoupling (Papkovskaia et al.,
2012) . The function of DJ-1 is also relevant to mitochondria as loss of DJ-1 results in
increased ROS production, reduced mitochondrial membrane potential and
MMP(Giaime et al., 2012).
1.4 The Role of Apoptosis in Parkinson’s Disease
1.4.1 Apoptosis
Apoptosis, a programmed cell death process, is critically important for the survival
of multicellular organisms. It helps to get rid of damaged or infected cells that may
interfere with normal function(Portt et al., 2011) and, during development,
apoptosis of excess cells contributes to organ and tissue formation(Meier et al.,
2000). The word apoptosis originates from Greek meaning "falling off or dropping
off", and is used as an analogy of leaves falling off trees or petals dropping off
flowers. Apoptotic cells can be recognized by stereotypical morphological changes,
such as cell shrinkage, deformation and loss of contact with neighbouring cells,
chromatin condensation, blebbing or budding of the plasma membrane, and the
presence of apoptotic bodies containing cytosol, condensed chromatin, and
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organelles(Saraste and Pulkki, 2000). Necrosis, as opposed to apoptosis, results in a
loss of membrane integrity, swelling and rupture of the cells, strong inflammatory
response and damage to neighbouring cells(Leist and Jaattela, 2001).
1.4.1.1 Extrinsic Pathway of Apoptosis
The extrinsic pathway of apoptosis is mediated by a sub-group of TNF receptors, a
superfamily that includes TNFR, Fas and TRAIL. All members of the TNFR family
have cysteine rich extracellular subdomains which binds their ligands with
specificity and results in the trimerization and activation of the respective death
receptor. Activation of these death domain-containing receptors leads to the
recruitment and activation of initiator caspases such as caspases 8 and 10 via
processes that involve the formation and activation of complexes such as the death
inducing signalling complex (DISC). Procaspase-8 molecules at the DISC result in
autocatalytic activation and caspase-8 activation. Activated caspase-8 further
triggers downstream activation of effector caspases, typically caspase 3. Activated
caspase 3 is responsible for the cleavage of a number of so-called death substrates
that cause the well-known characteristic hallmarks of apoptotic cell including DNA
fragmentation, nuclear fragmentation, membrane blebbing and other
morphological and biochemical changes(Portt et al., 2011; Naismith and Sprang,
1998; Scaffidi et al., 1998). As well as acting on downstream effector caspases,
activated caspase-8 also initiates mitochondria-dependent apoptosis by cleavage of
Bid. The truncated form of Bid then translocates to the mitochondria where it acts
in concert with the proapoptotic Bcl-2 family members Bax and Bak to induce the
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release of cytochrome c and other mitochondrial proapoptotic factors into the
cytosol(Luo et al., 1998).
1.4.1.2 Intrinsic Pathway of Apoptosis
The intrinsic pathway of apoptosis is induced by a variety of stimuli such as DNA
damage, oxidative stress, starvation or cytotoxic drugs(Kaufmann and Earnshaw,
2000; Wang, 2001). These stresses lead to the activation of BH3-only members by
transcriptional upregulation (Noxa, Puma), subcellular relocalization (Bim, Bmf),
dephosphorylation (Bad),or proteolysis (Bid). Activated BH3-only proteins inhibit
anti-apoptotic Bcl-2 members. In addition, they may directly induce a
conformational change of Bax and Bak which causes these proteins to oligomerize
and insert into the mitochondrial membrane resulting in MMP(Wyllie, 2010). This
permeabilization causes the release of apoptogenic factors including cytochrome c,
endonuclease G and apoptosis Inducing Factor (AIF). Cytochrome c interacts with
pro-caspase 9, APAF-1 and dATP to form an apoptosome. Procaspase-9 molecules
can bind to the inner “hub” region of the apoptosome and are activated by dimer
formation. Activated caspase-9 dimers further proteolytically activate the effector
procaspases-3, -6, and -7, which subsequently found the peptide sequence DEVDG
(Asp-Glu-Val-Asp-Gly) in the cells and cleave the carboxy side of the second aspartic
acid residue (between D and G). The widespread proteo-cleavage effects result in
the amplification of the death signal and eventually in the execution of cell
death(Earnshaw et al., 1999). As well as cytochrome c, other factors releasing from
mitochondria also trigger the further apoptotic pathway. For example, the release
of AIF causes a caspase-independent apoptosis.
44
MMP also causes several metabolic alterations. The permeability created across
the membrane leads to dissipation of the mitochondrial membrane potential,
resulting in the loss of ATP synthesis and calcium outflow from matrix.Additionally ,
ROS generation is increased due to dysfunction of respiratory chain, which amplifies
the apoptotic cascade(Kroemer et al., 2007).
1.4.1.3 Modulation of Apoptosis
Apoptosis can be modulated by certain endogenous and exogenous factors acting
at various points including the initiation of apoptosis, the balance of pro-apoptotic
proteins and pro-survival proteins, some pro-survival pathways and autophagy, a
cellular self-repair system(Portt et al., 2011).
Pre-conditioning is a situation where cells experience a brief period of sub-lethal
stress. Ischemia/reperfusion is the most well-known model to induce pre-
conditioning whilst heat and ROS exposure also work(Stetler et al., 2010; Carriere et
al., 2009). Based on different time-courses, there are two types of pre-conditioning.
Classical pre-conditioning provides protection minutes after exposure to stress. A
number of signalling proteins including extracellular signal-regulated kinases and
the Akt pathway are responsible for the anti-apoptotic effect. Late onset pre-
conditioning provides long-term protection that lasts 24 to 72 hours. This
protection requires protein synthesis and involves the increased expression of a
number of genes that encode proteins such as heat shock proteins, anti-oxidants,
ceramide utilizing enzymes, as well as a number of other anti-apoptotic genes(Portt
et al., 2011).
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Cancer cells alter the balance between growth and death in order to keep
themselves multiplying. It is therefore not surprising that cancer cells utilise several
of these factors and pathways to achieve the goal of anti-apoptosis. Either
increased Bcl-2 expression or decreased Bax expression has been found in cancer
cells which shifts the balance of Bcl-2 family toward survival(Fulda, 2009; Fulda,
2010). Upregulation of other anti-apoptotic factors including a variety of heat shock
proteins, chaperones and genes encoding scavengers of ROS have also been
noted(Fulda et al., 2010). Cancer cells can also make use of pre-conditioning and
have been shown to up-regulate a number of anti-apoptotic genes to resist
chemotherapy treatment(Fulda, 2010).
Apoptosis is induced during the period of viral infection to limit viral replication. So
some viral proteins have the ability to modulate apoptosis in order to maintain the
viral production. These anti-apoptotic viral proteins can either block the extrinsic
apoptotic pathway through generating soluble fake TNF receptor, inhibiting
caspase-8 activation, or inducing nuclear factor kappa-light-chain-enhancer of
apoptotic pathway. To block the intrinsic apoptotic pathway, virus’ can modulate
apoptosis by inactivating BH3-only proteins, antagonizing the pro-apoptotic Bcl-2
family proteins or inhibiting caspase activation(Benedict et al., 2002).
Autophagy is the process of recycling cellular constituents. It is a critical adaptive
response to starvation. In addition, physiologically, low levels of autophagy serves
as general housekeeping, getting rid of unwanted or damaged material in the cell.
Removing damaged mitochondria and endoplasmic reticulum could save the cell
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from excessive endoplasmic reticular stress and avoid the initiation of apoptosis by
cytochrome c released from unhealthy mitochondria. Under apoptotic stimuli,
upregulation of autophgy increases the expression of some anti-apoptotic genes
and interferes with the pro-apoptotic function of activated Bax in order to prevent
cell death(Portt et al., 2011).
1.4.2 Apoptosis in Parkinson’s Disease
The contribution of apoptosis to the loss of nigrostriatal dopaminergic neurons in
Parkinson’s disease remained controversial during the 1990s(Mochizuki et al., 1996;
Anglade et al., 1997; Kosel et al., 1997; Banati et al., 1998), due to the dynamic and
short-lived nature of apoptosis(Elmore, 2007). The number of apoptotic neurons in
brains of Parkinson’s disease at a given time cannot reflect the whole course of
disease. During this time, the use of terminal deoxynucleotidyl transferase dUTP
nick-end labelling (TUNEL) staining limited the sensitivity of apoptosis detection.
However, after the emergence of combined TUNEL staining with fluorescent DNA
binding dyes to detect chromatin condensation and DNA cleavage, the role of
apoptosis in Parkinson’s disease was confirmed(Tatton et al., 1998; Tatton, 2000).
Increased levels of apoptotic signal molecules were found in the post-mortem
studies. Immunoreactive Bax, increased immunostaining of caspase-3, caspase-8,
and caspase-9 and elevated caspase 1 and 3 activities were identified in the
substantia nigra of Parkinson’s disease patients(Tatton, 2000; Hartmann et al., 2000;
Hartmann et al., 2001b; Mogi et al., 2000).
MPTP produced parkinsonism results in apoptosis of nigrostriatal dopaminergic
neurons in mouse models(Tatton and Kish, 1997) as some apoptotic markers, such
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as the release of mitochondrial cytochrome c and the activation of caspase-9 and
caspase-3 are increased in MPTP treated mice. Moreover, MPTP leads to Bax
upregulation through activated p53 and the translocation of Bax to the
mitochondria, which can be prevented by the genetic ablation of Bax(Perier et al.,
2005; Vila et al., 2001). MPTP also activates caspase-8 and the extrinsic apoptotic
pathway(Perier et al., 2012).
Considering the genetic models of Parkinson’s disease, virtually all types of genetic
mutation enhance apoptosis. Apoptotic markers were found in neocortex,
activation of caspase-9 and caspase-3(Martin et al., 2006; Yamada et al., 2004).
Parkinson’s disease related LRRK2 mutation increases the level of Bim, a pro-
apoptotic BH3 only protein and apoptosis in the Drosophila model, while in the
neuroblastoma cell line, over-expression of mutant LRRK2 activates caspase-3 and
induces apoptosis(Iaccarino et al., 2007; Kanao et al., 2010). Flight muscles of
Drosophila parkin null mutants undergo apoptotic degeneration, while parkin
prevents cytochrome c release in an E3 ubiquitin ligase-dependent manner and
protects against apoptosis (Greene et al., 2003b; Darios et al., 2003). DJ-1 prevents
apoptosis by inhibiting p53 transcriptional activity and Parkinson’s disease related
mutation or knockdown of DJ-1 results in hypersensitivity to apoptosis(Fan et al.,
2008; Shinbo et al., 2006).
Over-expression of PINK1 attenuates apoptosis by reducing mitochondrial release
of cytochrome c and the subsequent activation of caspases(Wang et al., 2007). On
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the other hand, mutation or depletion of PINK1 sensitizes the cell to apoptotic
death(Venderova and Park, 2012).The anti-apoptotic effect of PINK1 is related to its
phosphorylation of two substrates, TNFR-associated protein 1 (TRAP1) and HtrA2.
Phosphorylation of TRAP1 by PINK1 prevents cytochrome c release and apoptotic
cell death induced by hydrogen peroxide. Phosphorylation of HtrA2 protects mouse
embryonic fibroblasts against 6-hydroxydopamine, rotenone, or stress-induced
apoptosis(Perier et al., 2012).
1.5 Mitochondria-dependent Apoptosis as a Target of
Neuroprotection in Parkinson’s Disease
1.5.1 Mitochondria-dependent Apoptosis
Mitochondria are essential in the apoptotic pathway. As mentioned in the
previous sections, the intrinsic pathway of apoptosis is not only initiated from
mitochondria, but can also be triggered by part of the extrinsic apoptotic pathway
through the activation of caspase-8. The term ‘mitochondria-dependent apoptosis’
refers to the signal pathway of apoptosis that relies on mitochondria involvement.
Considering all the apoptotic events which happen in the mitochondria, MMP is the
most critical point in mitochondria-dependent apoptosis because it is the point of
no return in the majority of circumstances. Once MMP takes place, the apoptotic
cascade is triggered by the release of mitochondrial apoptotic factors.
MMP is tightly controlled and the key modulating factors are the Bcl-2 family of
proteins. The Bcl-2 family can be divided to three groups. The first group of proteins
are anti-apoptotic and include Bcl-2, Bcl-xL, Bcl-w, A1 and Mcl-1. In general, these
anti-apoptotic Bcl-2 proteins attach to the mitochondrial outer membrane, inhibit
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MMP, bind to and sequester pro-apoptotic Bcl-2 proteins. The second group of
proteins are pro-apoptotic and include Bax and Bak. Following an apoptotic
stimulus, Bax and Bak attach to the mitochondrial outer membrane and undergo
conformational changes that lead to the formation of homo-oligomers, these then
form pores in the outer membrane and induce the permeabilization. The last group
are the BH3-only proteins, including Bim, Bid and Puma. They do not permeabilize
the outer mitochondrial membrane like Bak and Bax, but promote the activation of
Bak and Bax through either direct activation of them and/or neutralization of the
anti-apoptotic proteins(Parsons and Green, 2010)
Hyperpolarization of mitochondria tends to reduce the permeability while
mitochondrial depolarization, caused by Carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (CCCP), results in the opposite
outcome(Petronilli et al., 1993). Additionally, acidification of the mitochondrial
matrix, cyclophilin D and quinones can all lead to less permeability (Bernardi et al.,
1999).
MMP could be modulated by BH3 mimetics as well. Antimycin A is a Bcl-2
antagonist, which binds to Bcl-2 in competition with a peptide corresponding to the
BH3 domain of Bak and causes collapse of mitochondrial membrane potential and
mitochondrial swelling through MMP(Tzung et al., 2001). Some signalling
molecules, including the phosphatases and kinases acting on Bcl-2-like proteins, as
well as transcription factors, including p53 and TR3/Nur-77/NGFI-B, could trigger
MMP and apoptosis. A neutral or acidic environment may also lead to less chance
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of MMP in contrast to a maximum permeability at a matrix pH around 7.3(Zamzami
and Kroemer, 2001).
However, MMP does not always result in apoptosis. On some occasions, the
protective and recovery systems rescue the cell, and these situations are most
frequently seen in post-mitotic cells, such as neurons and cardiomyocytes. The
insufficient release of cytochrome c from mitochondria may account for this MMP
without apoptosis as levels fail to reach the threshold required to trigger caspase
activation (Khodjakov et al., 2004). In addition, these cells may have less apoptotic
protease-activating factor 1 expression and are less responsive to exogenous
cytochrome c-induced apoptosis(Wright et al., 2004; Potts et al., 2005). A high level
of glycolysis contributes to the rescue as well as this raises the intracellular levels of
glutathione synthase (GSH) though the pentose–phosphate shunt. GSH reduces and
inactivates cytochrome c which subsequently inhibits caspase activation(Tait and
Green, 2010).
1.5.2 Neuroprotection in Parkinson’s Disease
1.5.2.1 Definition of Neuroprotection
Neuroprotection is defined as the prevention of neuronal cell death and
maintenance of function without necessarily affecting the underlying biochemical
mechanisms involved in pathogenesis. At a clinical level, this means stopping the
progress of the disease. Neurorescue can be considered a mechanism where
established metabolic abnormalities are reversed and normal neuronal function is
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restored. Clinically, this would manifest as an improvement in symptoms as well as
a halt in the progress of the disease(Schapira, 1999).
1.5.2.2 History of Anti-apoptotic Strategy of Neuroprotection in Parkinson’s
Disease
Plenty of anti-apoptotic agents have been proven to produce a neuroprotective
effect in cellular and animal models of Parkinson’s disease. For example, coenzyme
Q10 can inhibit mitochondrial depolarization and prevent apoptosis caused by
serum starvation, antimycin A, and ceramide(Papucci et al., 2003), and a novel
peptide, H-D-Arg-Dimethyl Tyr-Lys-Phe-NH2 (SS-31) is able to inhibit mitochondrial
depolarization, MMP, and the release of cytochrome c triggered by several
apoptosis inducers. In addition, treatment with SS-31 has also demonstrated
complete protection against MPTP neurotoxicity(Chaturvedi and Beal, 2008). These
examples illustrate that apoptosis-targeting strategies are effective for the
neuroprotection in both in vitro and in vivo models of Parkinson’s disease.
Unfortunately, two promising anti-apoptotic agents failed to demonstrate the
neuroprotective effect in clinical trials. The propargylamine TCH346 is an anti-
apoptotic factor that inhibits the glycolytic enzyme glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), which can initiate apoptosis. The neuroprotective effect
of TCH346 was highly potent in both 6-OHDA and MPTP animal models, however, in
a double-blind, randomized trial involving 301 patients it failed to show a significant
difference in clinical outcome(Olanow et al., 2006). Another anti-apoptotic agent,
CEP-1347, an inhibitor of mixed lineage kinases that can activate the c-Jun N-
terminal kinase (JNK) pathway involved in cell death, also showed encouraging
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results in preclinical studies, but again, the PRECEPT trial, involving 806 patients
with early Parkinson’s disease, was terminated early when an interim analysis
revealed a lack of efficacy in the experimental treatment(2007).
The discrepancy between the promising results in the animal models and the
failure of clinical trials raises questions about the application of anti-apoptotic
agents for neuroprotection in Parkinson’s disease. However, it is worth mentioning
some of the difficulties in the clinical trials of Parkinson’s disease. Currently, there
are no good biomarkers with which to measure disease progression. Clinical motor
symptoms are the main parameters used to assess the effectiveness of
neuroprotection, but they are not necessarily a good reflection of neuronal
viability(Kieburtz and Ravina, 2007). Although most trials enrol patients with early
motor symptoms, their brains have already undergone a more than 50% cell loss in
the substantia nigra(Cheng et al., 2010) and Lewy bodies are present in the lower
brainstem before motor symptoms are evident. This situation results in an
unfavourable environment for the neuroprotective agent in clinical trials so
considering these issues, the unpromising outcomes of previous trials should not
prevent further attempts to utilise anti-apoptotic neuroprotection in Parkinson’s
disease
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1.5.3 Target on Mitochondria-dependent Apoptosis in Parkinson’s
Disease
1.5.3.1 Mitochondria-Dependent Apoptosis, an Ideal Target for
Neuroprotection
Based on the statements in the previous sections, mitochondrial dysfunction,
apoptosis and Parkinson’s disease have a clear relationship. With the complex
connections with each other, it is natural to postulate that modulation to either
mitochondrial dysfunction or apoptosis would prevent the loss of dopaminergic
neurons in Parkinson’s disease brain. However, it is difficult to either prevent or
rescue mitochondria from dysfunction in Parkinson’s disease because many of the
environmental factors which cause mitochondrial dysfunction have not yet been
fully identified. Moreover, there is no practical way to amend the genetic mutations
which cause mitochondrial dysfunction. In addition, Parkinson’s disease is a multi-
factorial disease and protein misfolding, neuroinflammation and lysosomal
dysfunction are all relevant to the disease. In contrast, the contribution of
apoptosis in Parkinson’s disease has been widely studied. Generally speaking, all
the known pathogenetic pathways of Parkinson’s disease trigger neuronal death
through apoptosis. Modulating a shared, common pathway of cell death is logical
for a multi-factorial disease like Parkinson’s disease.
Unlike the lack of good options to restore mitochondrial function in Parkinson’s
disease, there are plenty of apoptosis inhibitors available. Unfortunately none of
them act on a common target point in apoptosis, for example, caspase inhibitors
are very potent for inactivating these executors of apoptosis, but have no influence
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on caspase-independent apoptosis. Mitochondria are involved in both extrinsic and
intrinsic pathways and the accumulation of damaged mitochondria, which is the
signature characteristic of Parkinson’s disease, can trigger apoptosis, making them
a key target for future therapies.
In summary, the trinity that is Parkinson’s disease, apoptosis and mitochondria
intertwine with each other and blocking mitochondria-dependent apoptosis could
be a tailor-made neuroprotection for Parkinson’s disease.
1.5.3.2 Maintain Mitochondrial Membrane Potential for Anti-apoptosis
The collapse of mitochondrial membrane potential highly correlates to initiation of
apoptosis so it is not surprising that keeping membrane potential in a more
negative voltage (hyperpolarization) could be anti-apoptotic and, therefore,
neuroprotective. Bonnet et al found that mitochondrial hyperpolarization is
responsible for the apoptosis resistance in cancer cells(Bonnet et al., 2007) and
Heerdt et al demonstrated that cancer cells with hyperpolarized mitochondria are
more resistant to chemotherapy(Heerdt et al., 2005). In human mesenchymal stem
cells, a more negative mitochondrial membrane potential correlated with less
apoptosis and cell death(Pietila et al., 2010).
Maintaining mitochondrial membrane potential by hyperpolarization could protect
cells against apoptotic stimuli in several ways. Membrane potential is responsible
for calcium storage and ATP synthesis. Depolarization during apoptosis causes
calcium release and cessation of ATP synthesis, which would amplify the apoptotic
stimuli due to increase intracellular calcium and energy depletion(Kroemer et al.,
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2007), and depolarization enhances the permeability of the mitochondria
membrane, which also facilitates apoptosis. In addition, mitochondrial membrane
potential regulates the mitochondrial matrix configuration and normopolarized
mitochondrial membrane potential keeps cytochrome c in the cristae and resistant
to release by agents that disrupt the mitochondrial outer membrane(Gottlieb et al.,
2003).
The potential gradient across the mitochondrial inner membrane is generated by
pumping out protons from the electron transport chain and these protons re-enter
the matrix through complex V (F1F0-ATP synthase) accompanied with ATP synthesis.
Either inhibiting complex V by oligomycin or insufficient ADP supply for ATP
synthesis interferes with the protons re-entry and leads to mitochondrial
hyperpolarization. However, these situations also damage ATP synthesis and are
not beneficial. On the other hand, increasing the supply of NADH from the glycolytic
pathway boosts the electron transport chain and result in hyperpolarization
without damaging ATP synthesis. Glycolysis-generated ATP can also be utilized in
complex V, where the role of F1F0-ATP synthase changes to consume ATP and pump
out protons to increase the potential gradient(Iijima, 2006). In the PINK1 mutant
model, myocytes but not neurons are thought to make use of glycolysis-generated
ATP to maintain mitochondrial membrane potential and make them more resistant
to apoptotic stimuli(Yao et al., 2011).
1.5.3.3 Modulate the Bcl-2 Family Proteins for Anti-apoptosis
Adjusting the balance of pro-apoptotic/anti-apoptotic Bcl-2 family of proteins
could modulate apoptosis and provide neuroprotection. Over-expression or
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transfection of Bcl-2 , an anti-apoptotic protein, may prevent neuronal loss induced
by brain ischemia by inhibiting the release of cytochrome c, activation of caspase-3
and the translocation of AIF from mitochondria to the nucleus(Zhao et al., 2004;
Zhao et al., 2003). Modulating Bax also results in neuroprotection in experimental
models. Bax channel inhibitors prevented the release of cytochrome c, dissipation
of mitochondrial membrane potential, apoptotic cell death in vitro and reduced
neuronal loss in a global brain ischemia model(Hetz et al., 2005). In a traumatic
brain injury model, bax gene knockout mice were shown to be more resistant to
cell loss, had less apoptotic neurons and lower caspase-3 activity(Gibson et al., 2001;
Tehranian et al., 2008). In addition, models with knockout of BH3-only proteins,
such as Bid and Bim, also have demonstrated a neuroprotective effect(Galluzzi et al.,
2009).
Rasagiline (N-propargyl-1-(R)-aminoindan), a novel and highly potent irreversible
MAO-B inhibitor has been studied for neuroprotection in a Parkinson’s disease
clinical trial(Rascol et al., 2011a). The mechanism of action may include modulating
Bcl-2 family proteins. Rasagiline increased the levels of bcl-2 and bcl-xL mRNA, as
well as levels of Bcl-2 protein(Akao et al., 2002; Inaba-Hasegawa et al., 2012). Zhu
et al also found that rasagiline protected lactacystin-induced nigrostriatal
dopaminergic degeneration and reversed the reduction of Bcl-2 protein level by
lactacystin(Zhu et al., 2008).
57
1.6 Enhance Glycolysis to Maintain Mitochondrial
Membrane Potential: Meclizne Model
1.6.1 Glysolysis
1.6.1.1 The Glycolytic Pathway
Glycolysis, a metabolic pathway used by virtually all organisms, provides energy
and building blocks for biosynthetic reactions. It is recognized as a most ancient
metabolic pathway and occurs in the cytosol(Romano and Conway, 1996).
Glycolysis converts glucose to pyruvate and produces 4 ATP's and 2 NADH can work
both aerobically and anaerobically due to its oxygen-independent characteristic.
However, it also consumes 2 ATP's in the process so the net yield is 2 ATP’s and 2
NADH.
Glycolysis begins with the phosphorylation of glucose by hexokinases to form
glucose 6-phosphate. The first five steps are the preparatory phase, which
consumes energy to convert the glucose into two three-carbon sugar phosphates.
The second half is the pay-off phase, which produces ATP and NADH. The end-
product of glycolysis, pyruvate, is taken into mitochondria and converted to acetyl-
coenzyme A, which is fully oxidized to CO2 through the tricarboxylic acid cycle if
sufficient oxygen is available. However, under hypoxic conditions or following
inhibition of mitochondrial respiration, pyruvate is converted into lactate and
shunted out of the cell.
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1.6.1.2 The Physiological Characteristics of Glycolysis
Glycolysis is an alternative energy resource to OXPHOS, and though it might be
seen as bioenergetically inefficient, due to low ATP and NADP yield, because of the
fast reaction rate, glycolysis is able to provide sufficient energy to meet cellular
demand(Pfeiffer et al., 2001). In addition, the nature of the fast reaction can be
utilized by certain tissues in order to rapidly meet energy demand. Myocytes tend
to have higher glycolytic ability because of their fast and intensive contraction. The
variability of glycolytic activity between different tissues many account for the
disparities in resistance to hypoxia or energy deficit. PINK1 KO myocytes make use
of higher glycolytic activity to prevent cell death from mitochondrial dysfunction,
whereas neurons, that could not boost glycolysis, would die(Yao et al., 2011).
Cancer cells usually have higher glycolytic activity regardless of the oxygen
concentration, which is known as the Warburg effect. In these cancer cells,
glycolysis is the main energy resource and it works regardless of the aerobic
conditions. Shifting the energy supply from mitochondria to glycolysis results in less
ROS generation from electron transport chain and more resistance to
apoptosis(Wallace, 2005). Also, glycolysis enhances multiplication of cancer cells
and the intermediates of glycolysis could also be the building blocks for the
daughter cells(Bolanos et al., 2010).
1.6.1.3 The Regulation of Glycolysis
Glycolysis is tightly regulated at several stages. The purpose of this regulation is to
meet the demand for ATP cellular energy and factors for synthetic reactions.
During glycolysis, glucose is converted to pyruvate and the whole process is made
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up of ten steps and each step requires a specific catalysing enzyme. Among these
ten steps, only three are almost irreversible and they are the points of glycolysis
control.
Phosphofructokinase is the most crucial control point in the glycolytic pathway.
The enzymatic activity is tightly regulated by the ATP/AMP ratio: high levels of ATP
allosterically inhibits the enzyme while AMP reverses the inhibitory action of ATP.
Therefore, glycolysis is stimulated by deficits in energy charge. This key glycolytic
enzyme is also modulated by citrate, an early intermediate in the citric acid cycle,
however the inhibitory action of citrate is ATP-dependent. A high level of citrate
means that biosynthetic precursors are abundant and additional glucose should not
be degraded for this purpose(Mor et al., 2011).
Hexokinase, the enzyme responsible for the first step of glycolysis, is also a
regulatory point due to its irreversible characteristic. Its product, glucose 6-
phosphate, negatively feedbacks the reaction because higher intracellular glucose
6-phosphate indicates an energy-rich status of cell(Wilson, 2003). Pyruvate kinase
which controls the outflow of glycolysis is the third irreversible enzyme. The
destination of pyruvate, a central metabolic intermediate, is decided by the levels
of cellular ATP. High energy charge status results in inhibition of pyruvate kinase
and slowing down of glycolysis, or shifting the intermediates to be the build blocks
for synthetic reactions(Xiong et al., 2011).
Glucose transporters, which manage the entrance of glucose into the cell, also
modulate glycolysis. GLUT1 and GLUT3 are responsible for basal glucose uptake due
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to the low KM value for glucose. They continually transport glucose into cells at an
essentially constant rate. GLUT4, with a moderate KM value of glucose, transports
glucose into muscle and fat cells. The abundance of GLUT4 is regulated by the
presence of insulin which promotes the uptake of glucose by muscle and fat(Tirone
and Brunicardi, 2001).
In experiments, glycolysis can be upregulated by increasing glucose concentration
in the feeding medium(Williams et al., 2007), over-expressing certain glycolytic
enzymes(Herrero-Mendez et al., 2009) or pre-conditioning with sub-lethal stress,
including hypoxia and hydrogen peroxide (Wu and Wei, 2012; Malthankar-Phatak et
al., 2008). Mitochondrial respiratory chain inhibition by MPP+ or rotenone also
results in a compensatory glycolysis boost(Campello et al., 2013; Giordano et al.,
2012). Cancer cells are known to enhance glycolysis through several mechanisms,
including increasing expression of glucose transporters, glycolytic enzymes and
process of pre-conditioning(Cairns et al., 2011).
1.6.2 Glycolysis in Anti-apoptosis and Neuroprotection
1.6.2.1 Anti-apoptosis
As well as being a significant source of cellular energy, glycolysis also plays an
important role in apoptosis. The majority of studies focus on cancer cells because
they usually have higher glycolytic activity and are more resistance to apoptosis.
Chen et al found that overexpression hexokinase 2 in laryngeal squamous cell
carcinoma is responsible for the anti-apoptotic activity and proliferation of this
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cancer(Chen et al., 2013). Decreased expression of fructose-1,6-bisphosphatase-2,
an enzyme that works against glycolysis, also promoted tumour growth while over-
expression of it caused apoptosis(Li et al., 2013). Similar effects have been shown in
non-cancerous cells, for example, up-regulation of glycolysis in Chinese hamster
ovary cells upon tert-Butyl Hydroperoxide treatment resulted in less cytochrome c
release and less apoptotic cells (Jeong et al., 2004).
1.6.2.2 Neuroprotection
Based on the anti-apoptotic activity, it is reasonable to suggest that control of
highly associated with the pathogenesis of Alzheimer’s disease and Newington et al
increased pyruvate dehydrogenase kinase 1 and lactate dehydrogenase A and that
also demonstrated that over-expression of these glycolytic enzymes in neuronal
cells resulted in less ROS generation from mitochondria and the persistence of
Elevated glycolysis has also been proven to protect neuronal cells from MPTP, a
drug frequently used in Parkinson’s disease model. Glycolysis was up-regulated by
increasing the glucose concentration in the feeding media. The cells given higher
glucose utilized glycolysis to generate more ATP and had less dissipation of
mitochondrial membrane potential induced by MPTP. In both cell lines and primary
cerebellar granule cells, these effects contributed to neuroprotection against
MPTP(Williams et al., 2007; Mazzio and Soliman, 2003; Gonzalez-Polo et al., 2003).
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1.6.3 Meclizine, a Newly Identified Glysolysis-Enhancing and
Neuroprotective Drug
1.6.3.1 Traditional Pharmacological Mechanisms of Meclizine
Meclizine is a widely-used medicine for antiemetic and motion sickness.
Traditionally, it is a H1 receptor antagonist and classified as the first generation of
antihistamine in pharmacology. It is also a weak muscarinic acetylcholine receptor
antagonist and can cross the blood-brain barrier. The side effects of meclizine are
drowsiness, dry mouth, and tiredness. The use of meclizine is relative safe, even
during pregnancy(Larrauri et al., 2014).
1.6.3.2 Enhanced Glysolysis and Neuroprotection by Meclizine
Gohil et al first identified the enhanced glycolysis effect of meclizine in 2010(Gohil
et al., 2010). They used a nutrient-sensitized screen to discover agents that shift
energy metabolism. From 3695 agents tested, 25 clinically used agents exhibited
glycolysis-enhanced ability and of these, Meclizine was selected to test further due
to its safety profile and ability to penetrate the blood-brain barrier,. Meclizine
demonstrated a neuroprotective effect in a mouse stroke model. Pre-treatment
with meclizine, but not with other antihistamine and anticholinergic agents,
significantly reduced the infarct volume. In a following study, meclizine was shown
to have anti-apoptotic activity against serum-withdrawal induced apoptosis in
mutant huntingtin expressing mouse striatal neurons. In addition, meclizine
displayed a protective effect on neuronal dystrophy and cell death in C. elegans and
Drosophila models of polyQ toxicity, and the application of meclizine leads to a
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dose-dependent increase in glycolysis. However, the mechanism by which meclizine
1.7 Modulate Mitochondrial Outer Membrane Permeability:
Human Cytomegalovirus pUL37x1 Model
1.7.1 Cytomegalovirus Infection and Anti-apoptosis
Apoptosis is a powerful innate defence mechanism against viral infection because
viruses need the machinery of host cell for their own replication. Cell debris
containing viral proteins can be uptaken by antigen presenting cells and used to
prime the adaptive immune response. Thus, many viruses, including human
cytomegalovirus (CMV), encode proteins that attack this defence system. These
anti-apoptotic proteins target the system in different ways, including blocking the
activation of caspase-8 in the extrinsic apoptotic pathway, inhibiting the initiation
of intrinsic apoptotic pathway at mitochondria and the activation of the survival
pathway. Without these proteins, CMV is not able to resist the apoptosis of infected
cells and maintain the life long infection.
1.7.2 Anti-apoptotic Role of pUL37x1
UL37 exon 1 protein (pUL37x1), which is also known as a viral mitochondria-
localized inhibitor of apoptosis, is encoded by the immediate early UL37x1 gene.
Goldmacher et al found that transfection of pUL37x1 into HeLa cells resulted in
suppression of Fas-mediated apoptosis and the mitochondria-localization of
pUL37x1(Goldmacher et al., 1999). Hayajneh et al later on identified two domains
within the pUL37x1, between amino acids 5 to 34, and 118 to 147 that were
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responsible for the anti-apoptotic activity by deletion mutagenesis analysis. The
first of which targeted pUL37x1 to mitochondria(Hayajneh et al., 2001).
The detailed anti-apoptotic mechanism of pUL37x1 was revealed by Arnoult et al,
who demonstrated that pUL37X1 formed a complex with Bax and sequestered Bax
at mitochondria. Out of a variety of generated mutant pUL37x1s, only the ones with
preserved Bax-binding function prevented Bax-mediated MMP, but did not
associate with Bak nor suppress Bak-mediated MMP(Arnoult et al., 2004).
Subsequently, Norris and Youle showed that the mitochondrial translocation of Bax
was triggered by pUL37x1. They also found that m38.5, a functional ortholog of
pUL37x1 from murine CMV, protected Bak-KO but not Bax-KO cells from
staurosporine-induced apoptosis. These two studies both indicate that pUL37x1
interacts with Bax and that its anti-apoptotic activity is Bax-dependent(Norris and
Youle, 2008). By using nuclear magnetic resonance, Ma et al detected the binding
site of Bax within pUL37x1, which is opposite to the BH1 and BH2 domains, with its
N terminus close to the BH3 domain(Ma et al., 2012).
1.7.3 Other Biological Effects of pUL37x1
pUL37x1 not only affects host apoptosis but also modulates several other cellular
functions. Some of these are related to apoptosis while others are not. Expressing
pUL37x1 in human fibroblast leads to disruption of the mitochondrial network and
interferes with mitochondrial fusion/fission balance. This disruption, which is
associated with the anti-apoptosis and mitochondrial localization, was absent when
pUL37x1 mutants which lack the anti-apoptotic effect were expressed. The
phenomenon of fragmented mitochondria may result from the inactivation of Bax
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because Bax is thought to maintain mitochondrial elongation(McCormick et al.,
2003).
Because of its mitochondrial localization, it is not surprising that pUL37X1 is
believed to affect the mitochondrial respiratory chain and ATP synthesis. Poncet et
al demonstrated that expression of pUL37x1 reduced the cellular ATP level due to
ATP synthes inhibition(Poncet et al., 2006). However, Kaarbø et al found that
although the increase of respiratory capacity, which is accompanied by increased
ROS, after CMV infection is pUL37x1 dependent, there did not appear to be any
interaction between pUL37x1 and complex V, the ATP synthase. In addition,
biogenesis and viral replication(Kaarbo et al., 2011).
1.7.4 Utilization pUL37x1 in Neuroprotection, a Novel Approach
The anti-apoptotic activity of pUL37x1 has been demonstrated in several studies
mentioned previously. In brief, it can protect against a variety of apoptosis
pathways, including Fas-mediated apoptosis, caspase-3 independent apoptosis and
proteasome-inhibitor-induced apoptosis. In addition, the protection was
demonstrated in mouse NIH 3T3 cells, human HeLa cells and human fibroblasts.
However, it has not been tested as a neuroprotective agent in neurodegenerative
disease. Although one recent article revealed that pUL37x1 did not protect CMV
infection-induced cell death in human neural precursor cells(Hildreth et al., 2012),
the feasibility of using pUL37X1 to protect neuronal death is still unclear. Certainly,
apoptosis and rescue dopaminergic cell death in vitro and in animal models of
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Parkinson’s disease. Therefore, based on its strong Bax-related anti-apoptotic
effect(Reeves et al., 2007; Kuan et al., 2012), it is reasonable to suspect that
pUL37x1 could be beneficial to dopaminergic neurons in Parkinson’s disease, which
are highly susceptible to mitochondria-dependent apoptosis.
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1.8 Hypothesis and Aims
1.8.1 Hypothesis
Apoptosis contributes to the death of dopaminergic neurons in Parkinson’s disease;
manipulation of mitochondria to prevent activation of apoptosis represents a
possible therapeutic approach to provide neuroprotection. I hypothesise that
hyperpolarization of mitochondria by meclizine and inactivation of Bax by over-
expressing CMV protein pUL37x1 could prevent apoptosis and be neuroprotecitive
in Parkinson’s disease.
1.8.2 Aims
1.8.2.1 Meclizine Model
1. To confirm the alteration of glucose metabolism by meclizine in the SH-SY5Y
model
2. To evaluate the neuroprotective effect of meclizine in the SH-SY5Y model
3. To identify the neuroprotective mechanism of meclizine and its modulation of
the mitochondrial membrane potential
4. To confirm the glycolysis-dependent neuroprotective effect of meclizine
5. To investigate the glycolysis-enhanced mechanisms of meclizine
6. To evaluate the neuroprotective ability of meclizine in primary neurons.
1.8.2.2 pUL37X1 Model
1. To generate stable pUL37x1 expression in SH-SY5Y cells and characterise the
expression
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2. To evaluate the neuroprotective and anti-apoptotic effects of pUL37x1 in stable
expression cells
3. To clarify the Bax-dependent neuroprotective mechanism of pUL37x1
4. To investigate other cellular functional alterations of expression and identify the
possible beneficial and deleterious effects.
5. To express pUL37x1 in primary neurons and evaluate the neuroprotective effect.
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2 Materials and Methods
2.1 Cell culture
2.1.1 Human Neuroblastoma Cell line (SH-SY5Y)
2.1.1.1 Background Knowledge of SH-SY5Y Cell Line
The SH-SY5Y cell line was established from a bone marrow biopsy of a
neuroblastoma patient with sympathetic adrenergic ganglial origin(Biedler et al.,
1973). The SH-SY5Y cell line is a homogeneous neuroblast-like cell line and exhibits
neuronal marker enzymatic activity, norepinephrine uptake ability, and several
neuronal receptors, including opioid, muscarinic, and nerve growth factor receptors.
It also presents several characteristics similar to dopaminergic neurons, such as
dopamine synthesis, dopamine transporter expression and response to dopamine
agonists. These characteristics are the reason why SH-SY5Y cell line has been used
as a cellular research model of Parkinson’s disease(Xie et al., 2010). However, there
are some disadvantages which limit the use of this neuroblastoma cell line in
Parkinson’s disease research. First, it is a dividing cell line which is contrary to the
post-mitotic dopaminergic neurons. Besides, it is more resist to neurotoxins and
less sensitive to neuroprotective agents than primary neurons(Datki et al., 2003).
However, taking all the pros and cons into consideration, SH-SY5Y still receives
broad acceptance as a cellular model of dopaminergic neurons in Parkinson’s
disease research.
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2.1.1.2 Methods of Culturing SH-SY5Y Cell Line
The method of growing SH-SY5Y cells has been described previously (Chau et al.,
medium (Life Technologies, Paisley, UK) and Ham’s F12 medium (Life Technologies,
Paisley, UK), supplemented with 10% fetal bovine serum (Life Technologies, Paisley,
UK), 1mM pyruvate (Sigma, St. Louis, US), 0.01 mM nonessential amino acids (Life
Technologies, Paisley, UK), 100 U/ml penicillin (Life Technologies, Paisley, UK), and
5% CO2 atmosphere (Hera Cell 240, Thermo Scientific, Essex, UK). In over-expressing
cell lines, 400µg/ml geneticin (GE Healthcare, Little Chalfont, UK) were added into
the medium for the purpose of selection.
The adherent SH-SY5Y cells were passaged or harvested by trypsinization in
versene (Life Technologies, Paisley, UK), containing 0.1 % trypsin enzyme (Life
Technologies, Paisley, UK). Culture medium was removed and cells were washed
once by versene followed by 1 ml of trypsin solution applied to each 10 cm plate.
The detachment of cells was monitored under microscope. Trypsin was neutralised
with equal volume of culture medium containing serum and cells were re-plated at
1:4 dilutions. SH-SY5Y cells of passage number between 10~25 were used for the
experiments. Cell stocks were frozen slowly to -80 oC in fetal bovine serum
containing 10 % dimethyl sulfoxide (DMSO) and stored in liquid nitrogen.
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2.1.2 Primary Rat Cortical Culture
2.1.2.1 Background Knowledge of Primary Rat Cortical Culture
In the previous section, the limitations of using neuroblastoma cell lines has been
mentioned. The most recognised disadvantage of using cancer transformed cell
lines is their different response to neurotoxins and neuroprotective agents
comparing to neurons. Primary neuronal culture offers a solution to this problem.
Primary culture is the term given to culture cells isolated from tissue in vitro
without immortalization. Primary neuronal culture is usually obtained from
embryonic materials. At prenatal stages neurons have not yet developed extensive
neurites, which causes less damage during the preparation process (Sciarretta and
Minichiello, 2010). Primary neuronal cultures can mimic the nature and behaviour
of neurons in vivo so are a popular model for studying neuroprotection.
2.1.2.2 Methods of Primary Rat Cortical Culture
The method for primary rat cortical culture was adapted from previous well-
established protocols(Xu et al., 2012). Generally speaking, E18 primary rat cortical
cultures were obtained from pregnant Sprague Dawley rats. The pregnant rats were
asphyxiated in CO2 chamber and the death was confirmed by cervical dislocation.
Embryos were taken out from the sacs and decapitated. The embryo heads were
soaked in phosphate buffered saline (PBS) and brought to the tissue culture hood.
In the hood, the skull and meninges were removed and bilateral frontal lobes were
collected. Then the cortexes went through trysinization by versene containing 0.1 %
trypsin enzyme at 37°C for 15 minutes, followed by neutralization with fetal bovine
serum. In order to dissociate the neurons, the cell suspension was triturated and
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2 poly-D-lysine coated cover slips and maintained by
Neurobasal Medium with 0.5 mM of GLUTAMAX I, 2% B27 Supplement, 100 U/ml
penicillin and 100 mg/ml streptomycin (all from Life Technologies, Paisley, UK).
Culture medium was changed every three days. In some experiments, frozen
primary rat cortical cultures were obtained from Life Technologie and maintained
under the same conditions as mentioned before.
2.1.2.3 Validation of Primary Rat Cortical Culture
The growth of primary rat cortical cultures was monitored carefully.
Photomicrographs taken by light microscope illustrated in Figure 2-1 showed the
maturation of cultured neurons. On the second day of culturing, some neurons
started neurite outgrowth. Two days later, almost all the cells had produced
neurites. At the end of first week, not only had the neurites extended in length but
they had also formed networks. Morphologically, more than 90% of cells presented
with the neuronal features.
Fig 2-1.
Figure 2-1. Serial pictures of primary rat cortical culture revealed the maturation of
neurons. At the 2nd day of culturing, most cells remained round and only some cells
demonstrated the outgrowth of neurites. At the 4th day, most cells presented the features
of neurons with extension of neurites. One week after the start of culturing, the neurons
Day 2 Day 4 Day 7
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developed an extensive neuritic network. Morphologically, most cells were recognized as
neurons.
In order to further identify the purity of neurons in the primary rat cortical culture,
performed 1 week after the start of culturing. Figure 2-2 showed that the
Fig 2-2
clarify the purity of neurons in the culture. More than 90% of DAPI stained nuclei were
2.2 Chemicals
Meclizne was obtained from two different suppliers: Tocris Bioscience (Bristol, UK)
and Santa Cruz Biotechnology. In the cell death experiments, meclizine from both
suppliers were tested and the protective effect was identical. All other chemicals
were obtained from Sigma-Aldrich (St. Louis, US) or Merck Millipore (Darmstadt,
Germany) unless otherwise stated.
DAPI merge 20µm
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2.3 Cellular Bioenergetic Analysis
2.3.1 Oxygen Consumption Rate Measurement
2.3.1.1 Principle of Oxygen Consumption Rate Measurement
Oxygen consumption is the essential characteristic of mitochondrial respiration
which oxygen converts to water in complex IV. Therefore, oxygen consumption rate
(OCR) is recognized as a parameter of mitochondrial respiratory function. XFe
extracellular flux analyser, a powerful tool to measure OCR, can detect the tiny
change of dissolved oxygen in an isolated, extremely small amount of medium. This
technique has been widely used for assessing mitochondrial function (Cantu et al.,
2011; Trudeau et al., 2011). Basal OCR is defined as the rate difference between
resting status and oligomycin treatment, which inhibits the complex V and block the
OXPHOS.
2.3.1.2 Methods of Oxygen Consumption Rate Measurement
Cells were grown on the specific XF24 V7 cell culture microplate with four wells of
the plate left empty for calibration. The sensor cartridge was hydrated by calibrant
solution and placed into a non-CO2 incubator overnight before the assay. On the
day of the assay, each well of XF24 V7 cell culture plate was washed by warm assay
medium three times and then kept in non- CO2 incubator for 30 minutes to allow
equilibration. Meanwhile, the working solution containing different compounds,
including glucose, oligomycin, and rotenone were dispensed into each injection
port on sensor cartridge to achieve a final concentration at 25mM glucose, 1µg/ml
oligomycin and 2µM rotenone in each well. Then the sensor cartridge underwent
calibration in the XFe extracellular flux analyser. After calibration, the XF V7 cell
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culture microplate replaced the cartridge plate and the assay started. In all the
experiments, the protocol (mix/wait/measure cycle) was kept the same. Once the
assay had finish, the cells were trypsinised in order to measure the protein
concentration for cell number correction.
2.3.2 Extracellular Acidification Rate Measurement
2.3.2.1 Principle of Extracellular Acidification Rate Measurement
Extracellular acidification due to protons releasing into medium is an indirect way
to monitor the synthesis of lactic acid, an end-product of glycolysis. The XFe
extracellular flux analyzer can also monitor extracellular acidification rate (ECAR) in
a real-time manner (Anderson et al., 2013; Blouin et al., 2010). Basal glycolysis was
determined by the increase of ECAR after injection of glucose to a no-glucose
medium. Afterwards, injection of oligomycin stops mitochondrial respiration and
triggers the maximal capability of glycolysis to compensate the energy deficit. Both
parameters are vital in investigating the cellular glycolytic flux.
2.3.2.2 Methods of Extracellular Acidification Rate Measurement
Preparations and protocols were identical for the method of OCR measurement
(section 2.3.1.2) except for the working compounds in the injection pores. When
measuring the ECAR, the sequence of injections was glucose, oligomycin and 2-
deoxyglucose (2DG). The final concentration of these compounds in each well was
25mM glucose, 1µg/ml oligomycin and 100µM 2DG.
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2.3.3 ATP Synthesis Measurement
2.3.3.1 Principle of ATP Synthesis Assay
Mitochondrial ATP synthesis takes place in the respiratory chain, which is composed
of complex I-IV. By providing different substrates and inhibitors, the activity of each
complex can be investigated separately. The substrates and inhibitors include
glutamate and malate for complexes I, III, IV; succinate and rotenone for complex II,
III and IV; and ascorbate and N,N,N’,N’-tetramethyl-p-phenylenediamine for
complex IV.
2.3.3.2 Methods of ADP Phosphorylation Activity Measurement
The protocols used have been described previously (Gegg et al., 2009). SH-SY5Y
cells grown on 10-cm plate were scraped and washed with PBS. Cells were
resuspended with the reaction buffer (25 mM Tris, 150 mM KCl, 2 mM K+-EDTA, 10
mM K2HPO4, pH 7.4). An aliquot of cell suspension was mixed with an equal volume
of reaction buffer containing 1 mM ADP and substrates (complexes I, III, IV:
glutamate+malate (10 µM); complexes II, III, IV: succinate (10 µM)+rotenone (40
µg/ml); complex IV: ascorbate (2 mM)+N,N,N ,N -tetramethyl-p-
phenylenediamine (50 µM)), permeabilized with digitonin, and incubated at 37°C
for 20 minutes. The reaction was stopped with perchloric acid, and samples
neutralized with 3 M K2CO3 dissolved in 0.5 M tri-ethanolamine solution. Debris was
removed by centrifugation and ATP measured with the ATP Bioluminesence Assay
kit CLSII (Roche, Mannhein, Germany). The cell suspension was also taken for
protein quantification to allow cell number correction.
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2.3.3.3 Optimization of the Assay
Permeabilization by digitonin is a vital factor in this assay. Insufficient
permeabilization leads to less entry of substrates into the mitochondria whereas
over-permeabilization breaks down the mitochondrial membrane and results in
rupture of the organelle. In order to obtain the most appropriate dosage of
digitonin, the cell suspensions were supplied with ADP, glutamate, malate and
correlation between the concentration of digitonin with the amount of ATP
synthesis. However, the trend was reversed if the concentration of digitonin was
between permeabilization and toxicity. Therefore, in the following experiments,
this dosage of digitonin was applied universally.
Fig 2-3
Fig 2-3. The titration of digitonin to obtain the maximum ADP phosphorylation activity from
the mitochondrial respiratory chain complex I¬IV. 10µM of glutamate and malate were
incubated with cell suspension from SH- SY5Y cells containing different concentration of
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digitonin. It revealed that 60µg/ml digitonin gave rise to maximum ATP synthesis whereas
80 and 120µg/ml were likely to induce cell death due to over-permeabilization.
2.4 Protein Quantification by Bicinchoninic Acid Assay
2.4.1 Principle of Bicinchoninic Acid Assay
The bicinchoninic acid (BCA) assay includes two steps. The first step is the
reduction of Cu2+ to Cu1+ by protein in an alkaline medium. The second step is the
colour development reaction. BCA reacts with the cuprous and the chelation of two
molecules of BCA with one cuprous results in purple colorization, which can be
detected by measuring the light absorbance at 562nm.
2.4.2 Methods of Bicinchoninic Acid Assay
in a 96-well plate. Sample-free wells were used as blank controls while bovine
of the mixture added to each well. Samples were incubated at 37°C for 15~30
minutes depending on the colour change to avoid over-saturation. This
colourimetric reaction can be assessed by quantifying the light absorbance at 562
nm using a Synergy HT plate reader (BioTek, Winooski, US). Protein concentrations
were determined from the linear absorbance plot generated by measuring known
concentrations of BSA protein standards.
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2.5 Cell Death Measurements
2.5.1 LDH Release Assay
2.5.1.1 Principle of LDH Release Assay
Cell death was measured by the lactate dehydrogenase (LDH) release assay (Roche,
Basel, Switzerland). The principle of this assay is to detect the release of LDH from
cytosol to medium. Viable cells keep their cell membrane intact whereas dead cell
cannot. The rupture of cell membranes allows the leakage of cytosolic proteins.
LDH is a house-keeping protein widely expressed in the cytosol. Once the integrity
of cell membrane loss, LDH leaks out and can be detected in the medium. This assay
is a relative measurement. Following exposure to TRITON X-100, all cells are lysed
and the LDH in the medium under these conditions represents the high control (HC).
Cell-free medium is used as the low control (LC). All the readings need to
subtracted LC and be normalized by HC in order to obtain the percentage of LDH
release as a cell death parameter.
2.5.1.2 Methods of LDH release Assay
The protocols used are as described previously (Cleeter et al., 2013). When
performing the experiment, cells were plated as groups of wells in the either a 24 or
48-well plate. After 48-72 hours culturing of SH-SY5Y cells or 7 days culturing of rat
various treatments were applied for another 24/48/72 hours incubation. On the
to each well to achieve a final concentration at 1%. After 15 minutes incubation,
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wells in the same 96-well plate. The medium were then mixed with the reaction
reagents and incubated in room temperature for 30 minutes, before the plate was
read at the absorbance 500nm using a Synergy HT plate reader (BioTek, Winooski,
US). Results were expressed as a percentage of LDH release using the formula:
Percentage of LDH release= (Experiment-LC)*100 %/(HC-LC).
2.5.1.3 Validation of LDH release Assay
It is envisaged that the dosage of toxin is proportional to the degree of cell death
and, through the titration of toxin, the proper dosage of toxin which causes
substantial but not catastrophic cell loss could be identified. In the present work,
two toxins, 6-hydroxydopamine (6-OHDA) and staurosporine were used to induce
cell death. In terms of 6-OHDA, an oxidative stress inducer which has been widely
used in neurodegenerative models, there was an obvious dose-dependent increase
in the percentage of LDH release when the concentration of 6-OHDA was within the
resulted in substantial but not overwhelming LDH release mimicking the chronic
±
1.7%, n=6 ).
Another toxin utilized was staurosporine, a protein kinase C inhibitor and an
apoptotic inducer. It was used to test the anti-apoptotic theory of the hypothesized
neuroprotective effect. Similarly, it revealed a dose-dependent increase in the
percentage of LDH released within the range of 10 to 50nM staurosporine for 24
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hours treatment. Here, 30nM staurosporine treatment for 24 hours, lead to
remarkable but not catastrophic LDH release (no-toxin: 7.9±1.6, 30nM
staurosporine: 21.0±0.9%, n=8) (Figure 2-5). Therefore, this concentration of
staurosporine was applied to the later experiment to test the anti-apoptotic
neuroprotective effect.
These validation experiments also confirmed that the LDH release assay was a
suitable test for measurement of the toxin-induced cytotoxicity in the following
experiments.
Fig 2-4
Fig 2-4. The titration of 6-hydroxydopamine (6-OHDA) concentration was used to validate
the LDH release assay as a cell death parameters. After 24 hours incubation without 6-
OHDA, culturing SH-SY5Y cells exhibited less than 10% of LDH release (7.5±1.7%), which
was in line with the microscopic observation. The concentration of 6-OHDA within the
presented as mean±S.E.M.
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Fig 2-5
Fig 2-5. The titration of stauropsorine served the same goal as 6-OHDA titration. The
concentration of staurosporine within the range of 10-50nM led to a dose-dependent
increase of LDH release from SH-SY5Y cells (10nM: 7.1±0.3%, 20nM: 12.0±0.6%, 30nM:
21.0±0.9%, 50nM: 24.0±0.9%, n=8). Data were presented as mean±S.E.M.
2.5.2 Propidium Iodide Binding Assay
2.5.2.1 Principle of Propodium Iodide Binding Assay
Another method of cell death measurement is using the propidium iodide
binding assay. Propodium iodide (PI) is an intercalating agent and a fluorescence
molecule. When it binds to nucleic acid, the fluorescence excitation maximum is
535 nm and the emission maximum is 617 nm. The principle of this assay, as with
the LDH release assay, relies on the cell membrane integrity, as PI cannot penetrate
cell membrane, it can only bind to nucleic acid if the cell membrane is disrupted.
Again this gives a relative measurement, so, in a group of cells under the same
conditions, one or two samples need to be treated with either 1% TRITON X-100,
in SHSY5Y cells, or 4% paraformaldehyde, in primary rat cortical culture, in order to
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obtain a maximum PI fluorescence, and cell-free medium are also required as a
background control.
2.5.2.2 Methods of Propodium Iodide Binding Assay
Before performing the experiments, SH-SY5Y cells were cultured in 48-well plate
for 2 days and primary rat cortical cultures were prepared in the 24-well plate for
more than 7 days. Then the cells were treated according to the different conditions
required for another 24 or 48 hours. On the day of measurements, selected wells of
cells in each group were treated in order to obtain maximum PI fluorescence. SH-
SY5Y cells were treated with 1% TRITON X-100 whereas primary rat cortical
culture was washed with PBS twice before fixed by 4% paraformaldehyde. Fifteen
minutes later, PI was added directly into the medium of all the SH-SY5Y cultures.
For primary rat cortical culture, cells were washed with PBS twice, including the
were measured directly whereas the rat primary cortical culture underwent
another PBS washing before measurement. Different processes were required as
dead SH-SY5Y cells do not adhere on the bottom of well whereas rat primary
cortical culture grow on poly-D-lysine coated cover slips which tend to retain dead
neurons. The plates were measured at the fluorescence with 535nm excitation
maximum and 617nm emission maximum by a Synergy HT plate reader (BioTek,
Winooski, US). Background fluorescence was subtracted from this reading and then
the reading was divided by the maximum PI (and multiplied by 100) in order to get
the percentage of PI binding as another parameter of cell death.
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2.5.2.3 Validation of Propodium Iodide Binding Assay
As a second cell death measuring assay, the PI binding assay should fulfil the same
requirement met by LDH release assay: a dose-dependent increase of PI
fluorescence. In addition, the cell death reading from PI binding assay should be
similar to the former LDH measurement.
OHDA treated for 24 hours resulted in 28.9±3.2% of PI fluorescence (normalized by
the PI fluorescence from Triton X-100 lysed condition), which was very close to the
data obtained from LDH release assay. For staurosporine, the pattern was very
similar: the concentrations of staurosporine between 10-50nM induced a dose-
dependent increase of PI fluorescence (Figure 2-7), and, 30nM staurosporine
resulted in 16.0±1.2% PI fluorescence, which was also close to the result measured
by LDH release assay.
These validations revealed that both the LDH release assay and the PI binding
assay were reliable indicators of cell death, and that the results from each assay
were compatible.
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Fig. 2-6
Fig 2-6. The titration of 6-hydroxydopamine (6-OHDA) concentration was used to validate
the PI binding assay as another cell death parameters. After 24 hours incubation without 6-
OHDA, culturing SH-SY5Y cells exhibited less than 10% of PI fluorescence (6.8±0.8%), which
was in line with the LDH release assay. The concentration of 6-OHDA within the range of
normalized by the PI fluorescence from Triton X-100 lysed condition. Data were presented
as mean±S.E.M.
Fig 2-7.
Fig 2-7. The titration of stauropsorine served the same goal as 6-OHDA titration. The
concentration of staurosporine within the range of 10-50nM led to a dose-dependent
increase of PI fluorescence from SH-SY5Y cells (10nM: 5.0±1.3%, 20nM: 12.8±0.8%, 30nM:
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16.0±1.2%, 50nM: 31.8±8.4%, n=4). The PI fluorescence was normalized by the PI
fluorescence from Triton X-100 lysed condition. Data were presented as mean±S.E.M.
2.6 Caspase-3 Activity Measurement
2.6.1 Principle of Caspase-3 Activity Measurement
As mentioned in the previous sections, activated caspase-3 is the executor of
apoptosis, and the measurement of caspase-3 activity can reflect the intensity of
caspase-dependent apoptosis. Caspase-3 has a substrate specificity for the amino
acid sequence Asp-Glu-Val-Asp (DEVD). In order to detect the caspase-3 protease
activity, the assay contains a specific substrate, rhodamine 110-derived substrate Z-
DEVD-R110. The DEVD peptides suppress the fluorescence of R110, however the
addition of activated caspase-3 cleaves DEVD leading to the release of a fluorescent
R110. Fluorescence of R110 can be detected with peak excitation and emission
wavelengths of 496 nm and 520 nm. This fluorescence is continuously measured for
15 minutes, and the rate of increasing fluorescence reflects the activity of caspase-3.
2.6.2 Methods of Caspase-3 Activity Measurement
The protocol for caspase-3 activity measurement has been described previously
(Chau et al., 2010). Caspase-3 activity was measured according to the
manufacturer's instruction of the EnzChek® Caspase-3 Assay Kit #2 (Life
Technologies, Paisley, UK). For the assessment of caspase-3 activity, cells were
plated on the 10-cm plate for at least 2 days and treated with either staurosporine,
for 4 hours, or 6-OHDA, for 8 hours, before measurement. First the cells were
scraped and the resulting cell suspension spun at 4 °C , 21000g for 5 minutes. Then
the supernatant was removed and the cell pellets suspended and washed in PBS.
After another centrifugation under the same conditions as before, the supernatant
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was again removed and the pellets re-suspended in lysis buffer, which contained 10
mM TRIS, pH 7.5, 0.1 M NaCl, 1 mM EDTA, 0.01% TRITON X-100 and frozen. Once
thawed, supernatant was obtained by centrifugation at 4 °C, 7500g for 5 minutes
reaction mixture was made according to the ratio: 1ml reaction mixture includes
added to each well. The Z-DEVD-R110 substrate was cleaved by caspase-3 to give
rise to fluorescence (excitation/emission, 496/520 nm) which was measured by
Synergy HT plate reader (BioTek, Winooski, US) 30 minutes after incubation. The
measurement took 15 minutes and the mean velocity of increased fluorescence
was recorded. AC-DEVO-CHO caspase-3 inhibitor was applied to certain wells and
the readings from those wells represented the non-specific cleavage of substrate.
2.6.3 Validation of Caspase-3 Activity Measurement
In principle, apoptotic inducers are able to increase the caspase-3 activity.
However, due to the dynamic nature of apoptosis, a successful monitoring the
activation of caspase-3 depends highly on the timing. For example, Gomez-Lazaro
et al found that the activation of casapse-3 induced by 6-OHDA peaks at 12 hours
after treatment and returns to normal at 24 hours(Gomez-Lazaro et al., 2008). Also,
some studies had demonstrated many toxins induce apoptosis at lower doses and
necrosis at higher doses(Zong and Thompson, 2006). So there are two purposes to
the validation. Firstly, the measurement should be able to demonstrate the
increase of caspase-3 activity upon apoptotic inducers. Secondly, it should identify
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an appropriate dose and duration of toxin treatment to induce the activation of
caspase-3.
Figure 2-8 reveals the titration of treatment duration of 500nM staurosporine.
Four-hour treatment induced the highest caspase-3 activity compared with 2, 6 and
8 hour treatments. It suggests that 500nM staurosporine treated for 4 hours is
superior to longer treatments for the investigation of the intensity of apoptosis. On
the other hand, figure 2-9 shows the titration of treatment duration of 100µM 6-
OHDA. Caspase-3 activity began to surge after 8 hours after treatment. Therefore,
this timing was applied in the following experiments.
Fig 2-8
Fig 2-8. The titration of duration of 500nM staurosporine treatment-induced increased
caspase-3 activity on SH-SY5Y cells. The caspase-3 activity was normalized by the average
activity of non-treated conditions. According the graph, 4 hours treatment activated the
most caspase-3 (1206.9±15.5%, n=2) and the activity decreased in 6 and 8 hours treatment.
Data were presented as mean±S.E.M.
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Fig 2-9
Fig 2-9. The titration of duration of 100µM 6-OHDA treatment-induced increased caspase-3
activity on SH-SY5Y cells. The caspase-3 activity was normalized by the average activity of
non-treated condition. According the graph, there was no significant increase of caspase-3
activity between 2-6 hours treatment until 8 hours treatment activated the most caspase-3
(502.1±67.8%, n=5). Data were presented as mean±S.E.M.
2.7 Cytochrome c Release Measurement
2.7.1 Principle of Cytochrome c Release Measurement
In the apoptotic process, MMP leads to the release of mitochondrial apoptotic
factors, such as cytochrome c and AIF. In the cytosol, cytochrome c results in the
formation of apoptosomes and initiates further caspase activation. By short-term
usage of hypotonic cell extraction buffer, the cell membrane will break down and
the cytosolic cytochrome c comes out into the bathing buffer, whereas the
mitochondrial cytochrome c remains inside the mitochondria, these can then be
separated by centrifugation. The amount of cytochrome c present was detected by
an enzyme-linked immunosorbent assay (ELISA) kit (Life Techonologies, Paisley, UK).
A monoclonal capture antibody specific for cytochrome C is coated onto the wells
of the 96-well plate. Both mitochondrial and cytosolic fractions are loaded into
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these wells, including a cytochrome c standard. Then, a biotin-conjugated antibody
is added which binds to the cytochrome c attached to the first antibody.
Streptavidin-HRP is now added which binds to the biotin-conjugated antibody,
followed by the substrate solution to form the colored products. The reaction is
then terminated by addition of acid and light absorbance measured at 450 nm.
2.7.2 Methods of Cytochrome c Release Measurement
The cells were grown on 6-well plates for a least two days and treated with
staurosporine 3 hours before experiment. Following this, the cells were scraped and
collected into the medium. The cell suspension was then spun at 21,000g for 5
minutes at 4°C, the supernatant removed and the cell pellet washed by PBS. Then,
the pellet re-suspension was spun again under the same conditions as before. After
remove supernatant, the cell pellet was re-suspend in cell extraction buffer, (10
mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, and 10% glycerol) for 10
minutes, before the suspension received another centrifugation at 11,000g for 5
minutes at 4°C. The supernatant was then transferred to a new eppendorf and
represented the cytosolic fraction. The cell pellet was re-suspend by cell extraction
buffer plus 1% TRITON X-100 for 10 minutes and then spun at 21,000g for 5
minutes at 4°C. This supernatant represented the mitochondrial fraction of
cytochrome c. Five microliter of either cytosolic or mitochondrial fraction of
Standard Diluent Buffer and incubated for 2 hours at room temperature. Different
concentration of standard cytochrome c was also loaded to corresponding wells in
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c Biotin Conjugate solution was added into each well and incubated for 1 hour at
to each well and incubated for a further 30 minutes. After washing away
to each well which should cause the solution in the wells to change from blue to
yellow. The plate was read from the absorbance at 450 nm by Synergy HT plate
reader (BioTek, Winooski, US). The absolute cytochrome c concentration was
known when the OD from each well was applied to the formula of standard curve.
This concentration was also corrected by the protein concentration obtained by the
BCA assay.
2.7.3 Validation of Subcellular Fractionation
Appropriate subcellular fractionation is mandatory for detecting the release of
cytochrome c from mitochondria to cytosol. Mitochondria and cytosol-specific
proteins were used to validate the subcellular fractionation and avoid the possibility
of mitochondrial contamination to cytosolic fraction. Fig 2-10 demonstrated that
there was no detectable TOM20, a mitochondrial outer membrane protein in the
cytosolic fraction, which ruled out the possibility of mitochondrial contamination in
the cytosol and indicated the cytochrome c from the cytosolic fraction was purely
contributed by the release from mitochondria during apoptosis.
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Fig 2-10
Fig 2-10. Representative western blot for validation of the subcellular fractionation on SH-
SY5Y cells. Sample was processed according to the descriptions in the section of 2.7.2.
Equal amount of proteins from cytosolic (Cyt) and mitochondrial (Mito) fractions were
loaded in to the gel and stained for anti-GAPDH and anti-TOM20 antibodies. There was no
mitochondrial TOM20 detected in the cytosolic fraction.
2.8 Mitochondrial Staining by Tetramethylrhodamine, Methyl Ester,
Perchlorate (TMRM)
2.8.1 Principle of TMRM Staining
TMRM is a fluorescent derivative of rhodamine 123. It is a cell-permeable and
lipophilic cation. Once inside a cell, it accumulates in mitochondria due to the
mitochondrial membrane potential and binds to both inner and outer aspects of
the inner mitochondrial membrane. The amount of TMRM in mitochondria is
proportional to the mitochondrial membrane potential. Measurement of TMRM
fluorescence using a fluorescent microscope provides a good indicator of
mitochondrial membrane potential and mitochondrial morphology as well.
2.8.2 Methods of TMRM Staining and the Images Acquisition by Confocal
Microscopy
Fluorescence of TMRM from cells grown on 22 mm coverslips was measured by
real-time confocal imaging as previously described (Duchen et al., 2003; Gandhi et
al., 2009). The images were obtained by a Zeiss 510 laser scanning microscope
Cyt Mito
GAPDH (37kDa)
TOM20 (20kDa)
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equipped with an additional Enterprise UV laser source and a cooled charge
coupled device camera. The cells were bathed in standard phenol red-free Hank’s
Buffered Salt Solution at room temperature. Mitochondria were stained by 25 nM
TMRM for 30 minutes and the fluorescence was excited using the 543 nm laser line
and measured using a 560 nm long pass filter.
2.8.3 Images Analysis: Quantification of Mitochondrial Membrane
Potential
Images were analysed by ImageJ software (National Institutes of Health, Maryland,
U.S.) following protocols of analysis that have been previously described (Koopman
et al., 2005; Koopman et al., 2006). Briefly, raw images were background corrected,
linearly contrast optimized, applied with a 7 x 7 ‘top hat’ filter, subjected to twice 3
x 3 median filter, and then threshold, to generate binary images. The background-
corrected images were merged with the binary images in order to correct the
mitochondrial content and then the average intensity of TMRM staining could be
obtained by the histogram analysis.
2.9 Reactive Oxygen Species Measurements
by Aconitase Activity Assay
2.9.1 Principle of Aconitase Activity Assay
Aconitase is an iron-sulphur protein and involved in the citric acid cycle, which is
responsible for converting citrate to isocitrate. Reactive oxygen species can inhibit
aconitase activity by changing the [4Fe-4S] to a [3Fe-4S]cluster within the enzyme.
So aconitase activity is a good indicator for cellular oxidative damage. The Aconitase
Activity assay is composed of two steps. Firstly, citrate is isomerised to isocitrate by
94
by isocitric dehydrogenase. NADPH is generated in the second step and the assay
can be monitored by the rate of NADPH synthesis, measured by the absorbance at
340nm.
2.9.2 Methods of Aconitase Activity Assay
After washing with PBS, SH-SY5Y cells grown on 10cm plate were scraped with and
suspensions with 50 mM Tris-Cl (pH 7.4), 5 mM sodium citrate, 0.6 mM MnCl2, 0.2
mM NADP+ and 1 unit of isocitrate dehydrogenase. This mixture was incubated at
37°C for 20 minutes and then the kinetic increase of absorbance at 340nm was
measured. The mean increase velocity was corrected by protein concentration.
2.9.3 Validation of Aconitase Activity Assay
Since aconitase is sensitive to oxidative stress, it is predicted that 6-OHDA, a
oxidative stress inducer, would damage the enzymatic activity in a dose-dependent
manner. Figure 2-11 reveals that treatment with 6-OHDA at concentrations below
45µM for 24 hours led to a dose-dependent reduction of aconitase activity.
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Fig 2-11
Fig 2-11. Titration of 6-OHDA concentration to validate the aconitase activity assay. SH-
SY5Y cells were treated with 6-OHDA for 24 hours at different concentration revealed a
negative dose-dependent relationship between the concentration of 6-OHDA with the
aconitase enzymatic activity. n=3. Data were presented as mean±S.E.M.
2.10 SDS PAGE
2.10.1 Principle of SDS PAGE
Polyacrylamide gel electrophoresis (PAGE) is a way to separate and analysis
proteins. During electrophoresis, the proteins migrate towards the positive
electrode through the pores in a polyacrylamide gel. The larger the protein size the
more difficult, and therefore slow, the migration. However, if the proteins keep
their native status, some higher-order structure may cause the proteins to get
trapped in the pores. Sodium dodecyl sulfate (SDS), an anionic detergent, removes
all the higher-order structure and turns the sample proteins into their linear form.
In addition, SDS also imparts a negative charge to the linearized proteins. With this
treatment, the speed the sample proteins run in the gel electrophoresis totally
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relies on the electrophoretic mobility, and, in most cases, this mobility is
proportional to the size of protein.
2.10.2 Methods of SDS PAGE
Cell pellets were re-suspended in 100µl solution contained 10 mM Tris–HCl pH 7.5,
0.1% of SDS, 1µl of protease inhibitors (Thermo Scientific, IL, US) and 1µl of DNAse1
(Promega, Wisconsin, US) in 10µl enzyme buffer. The cell suspension was incubated
at 37°C for 30 minutes. Cell lysate underwent BCA assay for protein quantification.
Equal amount of cell lysate was mixed with reducing agent plus sample buffer (both
from Life Technologies, Paisley, UK) and incubated at 70°C for a further 10 minutes.
The lysates were then separated under reducing condition using Novex 4–12% Bis–
Tris gels (NuPAGE, Life Technologies, Paisley, UK) with MOPS SDS Buffer (50 mM
MOPS, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.3).
2.11 Western Blot Analysis
2.11.1 Principle of Western Blot Analysis
The purpose of western blot analysis is to detect specific proteins by an
immunobloting method. Following gel electrophoresis, proteins with different sizes
are separated on the gel. An electric potential can then be used to transfer the
proteins onto a polyvinylidene difluoride (PVDF) membrane. The proteins on the
PVDF membrane are then blocked by incubation with bovine serum albumin or
skimmed milk in preparation for immunoblotting. The immunoblotting includes two
steps: firstly a primary antibody binds to the target protein and next a secondary
antibody binds to species-specific portion of the primary antibody. The secondary
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antibody usually links with horseradish peroxidise, which allows chemiluminescent
detection. The luminesce generated by the reaction between the secondary
antibody with the substrate can be detected by X-ray film or CCD camera.
2.11.2 Methods of Western Blot Analysis
Following the SDS-PAGE, the resolved proteins on the gel were transferred to
PVDF membrane (Immobilon, Millipore, US) using the XCell II blot module (Life
Technologies, Paisley, UK). Relative protein mobility was determined using Multi-
Mark multi-coloured standard (Life Technologies, Paisley, UK). After blocking for 1
hour with 10% skimmed milk (Sigma–Aldrich, St. Louis, US) in PBS, the blot was
incubated with mouse monoclonal anti-HA epitope antibody (clone 16B12,
(Ancam, Cmbridge, UK), 1 in 5000 dilution as the loading control, in PBS containing
5% milk powder and 0.2% Tween-20 for 1 hour with shaking. After washing in 0.4%
Tween-20, the blot was then incubated with mouse and rabbit IgG conjugated with
HRP (Glostrup, Denmark), 1 in 2000–3500 dilution, for 1 hour. This was followed by
washes in PBS with 0.4% Tween-20, and chemiluminescence detected using the
Amersham ECL Western Blotting Detection Reagent (GE healthcare, Little Chalfont,
UK) and Amersham Hyperfilm (GE healthcare, Little Chalfont, UK). The film was
developed and signal intensities in the linear range were quantified by the
‘Alphadigidoc’ software package (AlphaInnotech; San Leandro, USA).
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2.12 Immunocytochemistry
2.12.1 Principle of the Immunocytochemistry
Immunocytochemistry is a way to detect the presence and subcellular localization
of a target protein in the cell by binding with specific antibody. It requires several
steps including: fixation, which immobilises the proteins and the cellular
architecture; permeabilization, to allow the antibody access; and blocking, to
reduce non-specific antibody binding, followed by primary and secondary antibody
binding. The secondary antibody is then conjugated with a fluorescent tag and can
be detected by microscope.
2.12.2 Methods of the Immunocytochemistry
Cells cultured on 13mm cover slips were fixed by 4% paraformaldehyde in PBS for
°C for 15 minutes. The cells were then blocked with 1% BSA (Sigma–Aldrich, St.
Louis, US) in PBS at 37 °C for 1 hour. For the primary rat cortical culture, the rabbit
monoclonal anti-cleaved caspase-3 antibody (Cell Signaling Technology,
Massachusetts, US ), 1 in 1000 dilution, or mouse monoclonal anti neuron specific
were added and incubated for 1 hour at 37°C. After PBS wash, the Alexa Fluor 488
goat antirabbit IgG or Alexra Fluor 568 antimouse IgG (Life Technologies, Paisley,
UK), both 1 in 200 dilution, were added for another 1 hour at 37 °C. For the SH-SY5Y
cells, to confirm the homogeneity of pUL37x1-HA over-expression, the mouse
monoclonal anti-HA epitope antibody (clone 16B12, Princeton, US), 1 in 5000
dilution, was used as primary antibody. To determine the intracellular localization
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of Bax, mouse Anti-Bax (N-terminus) (Millipore, MA, US), 1 in 500 dilution, was used.
Following incubation with the relevant primary and secondary antibodies, the cover
phenylindole (DAPI) dissolved in mounting solution AF1 (CITIFLUOR, London, UK).
Images were captured by Axiophot fluorescent microscope (Carl Zeiss, Oberkochen,
Germany).
MitoTracker Red CMXRos (Life Technologies, Paisley, UK) is a red-fluorescent dye
that stains mitochondria in live cells and is well-retained after aldehyde fixation.
MitoTracker Red was added into culturing medium at a final concentration of 6µM
and stained for 30 minutes. After this time, the medium was changed with fresh
medium for another 30 minutes. Then the cells underwent the fixation and further
immunocytochemistry performed as before.
2.13 Fluoro-Jade C Staining
2.13.1 Principle of Fluoro-Jade C Staining
Fluoro-jade C (FJ-C) is a fluorochrome derived from fluorescein, which is highly
soluble and acidic. It is a neuron-specific dye that identifies degenerating neurons
and can stain several morphological features of neurons including cell bodies,
dendrites, axons, and axon terminals(Schmued et al., 1997). It has been widely used
for detecting neuronal death in immunohistochemistry assay and some reports also
extended the usage to immunocytochemistry(Orellana et al., 2011; Schmuck and
Kahl, 2009). However, the real mechanisms of fluoro-jade staining are still unknown
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and the involvement of the higher anionic characteristic is suspected by some
researchers(Schmued et al., 1997).
2.13.2 Methods of Fluoro-Jade C Staining
The cover slips on which primary rat cortical cultures were grown were fixed with
4% paraformaldehyde for 20 minutes. After 2 washes by PBS, 0.001% of FJ-C
solution was added and staining continued for 30 minutes in room temperature.
Cover slips were then washed twice with distilled water. Once dry, the cover slips
DAPI dissolved in it.
Apototic and dead cells on primary cortical culture cells were counted manually.
From each cover slip with rat primary cortical culture cells treated with different
conditions, 2-4 fileds were selected under 200 times magnification of epi-
fluorescent microscope. Each field contained around 75-150 DAPI staining cells. The
percentage of apoptotic or dead cells was calculated by the ratio between the
number of positive cleaved caspase-3 or FJ-C staining cells to the number of DAPI
staining cells. The cell counting was done by single investigator.
2.13.3 Validation of Fluoro-Jade C Staining
An increase in staining should be observed with increasing of toxin provided that
the FJC staining is able to detect the dead neurons. Also, the stained-cells should
present other nuclear morphological change, such as fragmentation or
condensation. Figure 2-12 demonstrates FJ-C staining on the titration of 6-OHDA
treatment for 24 hours on rat primary cortical culture cells. There was no obvious
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FJ-C stain detected in no-toxin treated cell. 10µM 6-OHDA treatment for 24 hours
resulted in some FJC-positive stained cells, and these cells also demonstrated
themorphological changes of the nucleus expected in cell death (arrow). 20µM 6-
OHDA treatment for 24 hours caused more FJ-C-stained cells. This result indicates
the successful cell death detection by FJ-C in rat primary cortical culture.
Fig 2-12
Fig 2-12. The titration of 6-OHDA treatment on rat primary cortical culture to validate the
Fluoro-Jade C (FJ-C) staining. No-toxin treatment caused no detectable FJ-C-stained cell.
Treatment with 10µM 6-OHDA for 24 hours led to some cells with FJ-C stain. These cells
also exhibited nuclear morphological change, which indicated the cells underwent the
process of death (arrow). Treatment with 20µM 6-OHDA for 24 hours remarkably increase
the number of FJ-C-stained cells.
2.14 Generation of Stable pUL37X1 Over-expression Cell Lines
pUL37x1 cDNA with a 3’ haemagluttinin (HA) epitope was cloned into pcDNA3.1
(Life Technologies, Paisley) and transfected (Superfact, Venlo, Netherlands) into
added to the culture for antibiotics selection. Ninety percent of the cells were lost
after the antibiotics selection and the remaining cells formed colonies. When
colonies grew to a size more than 5mm they were cloned by cloning cylinders.
No-toxin 10 µM 6-OHDA 20 µM 6-OHDA
20 µm
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2.15 siRNA Silencing
2.15.1 Principle of siRNA Silencing
Small interfering RNA (siRNA) is responsible for RNA interference. siRNA is a
double- stranded RNA with a short fragment, 20-25 base pairs, which can be
delivered into cell by transfection. In the cytosol, siRNA is cleaved by Dicer, a
ribonuclease protein and separated into single strand RNAs, followed by integrated
into RNA-induced silencing complex (RISC). RISC can bind with targeted mRNA and
halt its translation. Theoretically, any gene can be knocked down by a synthetic
siRNA so it is widely used for post-transcriptional gene silencing in a variety of
biological experiments.
2.15.2 Methods of siRNA Silencing
In order to get a high efficiency of siRNA transfection, adherent SHSY5Y cells were
trypsinsed to produce a cell suspension in the medium before transfection. For
reagent were added to cell suspension. The medium was replaced 24 hours later.
The efficiency of silencing was confirmed by western blot analysis.
2.16 Liposomal Transfection
2.16.1 Principle of the Liposomal Transfection
The purpose of liposomal transfection is to deliver genetic material into cells. It
serves the same goal as electroporation, calcium phosphate and polymers.
However, the advantages of liposomal transfection include less toxicity, high
efficiency, ease of use and reproducibility. The principle of transfection is to utilize a
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positively charged lipid to wrap a negatively charged nucleic acid and penetrate the
negatively charged cell membrane made by the phospholipid bilayer.
2.16.2 Methods of the Liposomal Transfection
The primary rat cortical cultures were grown as described in section 2.1.2.2. The
culturing media was changed one day before transfection and each well contained
the 2 were combined for a further 30 minutes. Finally, the DNA- Lipofectamine
containing plates. The incubation took 48 hours and there was no need to remove
the transfection reagent.
2.17 Statistics
The sample size (n) in this thesis means the number of “independent replicate
experiments”(Lazic, 2010). Before the experiments, cells were cultured in same
growing condtion but different and independent wells or dishes. Cell lystes, cell
suspension or collected culturing media were kept separated without
contamination to each other. All the experiments had been replicated twice or
more. One-way ANOVA with post-hoc analysis and two-tailed Student’s t-test were
used to investigate the difference and p value less 0.05 was recognized as
significance.
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3 Results: Meclizine
3.1 Meclizine Protected SH-SY5Y Cells against 6-OHDA Cytotoxicity
As the hypothesis is neuroprotection, because loss of nigral dopaminergic neurons
was the most striking observation of Parkinson’s disease brains, it was essential to
investigate the protection from cell death conferred by meclizine on the cell line
used.
3.1.1 The Protection of Meclizine Was Investigated by LDH Release Assay
It was essential to identify any possible toxicity of meclizine before investigating
tested. The concentration was decided according to previous reports (Gohil et al.,
was identical with the previous study(Gohil et al., 2010). Control SH-SY5Y
cells ,treated with DMSO, induced 6.9±2.3% LDH release after 48 hours incubation,
compared with 7.5±1.1% from 195nM meclizine, 5.9±1.0% from 781nM meclizine,
significant difference between each meclizine treated condition compared with
control (Figure 3-1).
6-OHDA is an oxidative stress inducer and has been widely used in
neurodegenerative in vivo and in vitro models. Due to the slowly progressive nature
of neurodegenerative disease, treatment of 6-OHDA was given over 48, not 24
hours. 30µM was selected based on the data of validation (Sec 2.5.1.3): 60µM 6-
OHDA treatment for 24 hours induced significant cell death on SH-SY5Y cells so half
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concentration was tested for twice long treatment. 30µM 6-OHDA treatment for 48
hours induced 20.6±1.2% of LDH release in control SH-SY5Y cells. The concentration
reduction of LDH release: 17.9±0.7% LDH release from 195nM meclizine
simultaneous with 6-OHDA, 16.9±0.8% from 781nM meclizine, 13.3±0.6% from
concentrations of meclizine significantly protected cell death compared with
control (both p<0.001) (Figure 3-1). These results revealed that meclizine at
moderate concentration did not increase spontaneous cell death but provided
protection on SH-SY5Y cells against 6-OHDA induced cytotoxicity.
Figure 3-1
Figure 3-1. Meclizine exhibited a dose-dependent protection against cytotoxicity induced
12.5 M:12.2±0.4%, p<0.001 respectively, n=8). In addition, dosage of meclizine within this
range did not increase spontaneous cell death. Data were presented as mean±S.E.M.
*** ***
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Statistics was performed by one-way ANOVA with Dunnett’s post-hoc analysis. (***,
p<0.001)
3.1.2 The Protection of Meclizine Was Investigated by PI Binding Assay
Another cell death measurement was crucial to confirm the protection of
meclizine seen with the LDH release assay. PI, a fluorescent agent, only enters into
cells and binds to nucleic acids when the cells lose membrane integrity. PI
fluorescence increases 20- to 30-fold when bound to nucleic acids.
hours, compared with control (control: 25.4±1.1%; 195nM: 20.3±0.4%, p<0.01;
782nM: 19.6±1.0%,p p
21.6±0.8%,p<0.05). In addition, dosage of meclizine within this range did not
increase spontaneous cell death (Figure 3-2).
Putting the results of the LDH release and PI binding assays together, moderate
concentrations of meclizine clearly demonstrated a consistent protection against 6-
OHDA induced cytotoxicity. These findings strongly indicate that meclizine protects
against cell death in a neurodegenerative cellular model and proves the hypothesis
that meclizine is neuroprotective.
107
Figure 3-2
Figure 3-2. PI binding assay demonstrated that the concentration of meclizine within the
OHDA treatment foot 48hours treatment compared with control group (control: 25.4±1.1%;
195nM: 20.3±0.4%, p<0.01; 782nM: 19.6±1.0%,p
p<0.05; n=12). Meclizine was applied at the same time with 6-OHDA. In
addition, dosage of meclizine within this range did not increase spontaneous cell death.
Data were presented as mean±S.E.M. Statistics was performed by one-way ANOVA with
Dunnett’s post-hoc analysis. (*, p<0.05, **, p<0.01, ***, p<0.001)
3.2 Meclizine Modulated Mitochondria-dependent Apoptosis
I then sought to identify the mechanism of cell death prevention by meclizine. The
hypothesis is that protection of meclizine against neuronal loss is based on
modulating mitochondria-dependent apoptosis. This modulation is depended on
mitochondrial hyperpolarization, which results from the enhanced glycolysis. This
section evaluates the upstream and downstream processes of apoptosis and, as
expected, meclizine had no influence on the upstream but showed protection from
downstream apoptosis.
3.2.1 Meclizine Did Not Reduce 6-OHDA Induced Oxidative Stress
Mitochondria-dependent apoptosis refers to not only the apoptosis process
activated by the release of mitochondrial contents, but also the triggering factors of
***** **
*
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apoptosis which depend on mitochondria. ROS are recognized as a by-product of
the mitochondrial respiratory chain and excessive ROS are an important factor of
apoptosis initiation. In order to exclude the possible suggestion that protection of
hours after the treatment. The dosage of 6-OHDA and duration of treatment was
based on the data of validation (section 2.9.3): 30µM 6-OHDA treatment for 24
hours induced remarkable decreasing of aconitase activity on SH-SY5Y cells.
2.9±0.2, meclizine: 2.5±0.3 nmole/min/mg, p>0.05). 6-OHDA induced the reduction
of aconitase activity (control: 2.2±0.1, meclizine: 2.0±0.2 nmole/min/mg, p>0.05).
Aconitase is vulnerable to oxidative stress and failure to prevent the loss of
aconitase activity indicates that the protection of meclizine does not result from
ROS scavenging. (Figure 3-3)
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Figure 3-3
induced cell death, did not significantly alter the aconitase enzymatic activity of SH-SY5Y
cells in either no toxin or 30µM 6-OHDA treatment for 24 hours groups compared with
control (no toxin: 2.9±0.2 from control versus 2.5±0.3 from 12.5µM meclizine, 30µM 6-
OHDA: 2.2±0.1 from control versus 2.0±0.2nmole/min/mg from 12.5µM meclizine, n=10).
Meclizine was applied at the same time with 6-OHDA. Data were presented as mean±S.E.M.
Statistics was performed by two-tailed Student’s t-test and p value less than 0.05 was
recognized as significance. (N.S., non-significant)
3.2.2 Meclizine Hyperpolarized Mitochondria and Rescued the 6-OHDA
Induced Depolarization
Mitochondrial hyperpolarization was predicted to be the core anti-apoptotic effect
before the measurement of mitochondrial membrane potential. When no toxin was
present, meclizine induced 32% more polarization of mitochondrial membrane
potential compared with control (control: 100.0±1.5, meclizine: 132.8±6.1%,
p<0.001). The mitochondrial membrane potential was adjusted by mitochondrial
content and normalized by the average of TMRM fluorescence from control SH-
SY5Y cells (Figure 3-4).
N.S.
N.S.
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Mitochondrial depolarization is believed to be an early process of 6-OHDA induced
apoptosis(Lotharius et al., 1999) and meclizine was expected to rescue it to reduce
fluorescence of SH-SY5Y cells dropped more than 20%. Meclizine-treated SH-SY5Y
cells maintained normal polarization under 6-OHDA treatment although some
degree of TMRM fluorescence reduction was observed (control: 77.0±2.8, meclizine:
101.5±4.0%, p<0.001) (Figure 3-4).
Based on this result, meclizine hyperpolarized mitochondria at basal status, which
helped to maintained mitochondrial membrane potential against 6-OHDA induced
depolarization.
Figure 3-4
hyperpolarized mitochondria (control: 100.0±1.5%, meclizine:132.8±6.1%, p<0.001, n=10)
treatment for 1 hour (control: 77.0±2.8%, meclizine: 101.5±4.0%, p<0.001, n=10.)
with adjustment of mitochondrial content and normalized by the average TMRM
fluorescence of non-treated SH-SY5Y cells. Data were presented as mean±S.E.M. Statistics
***
***
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was performed by two-tailed Student’s t-test and p value less than 0.05 was recognized as
significance. (***, p<0.001)
3.2.3 Meclizine Reduced the Caspase-3 Activation Induced by 6-OHDA
Activation of caspase-3 is a late step of apoptosis. The measurement of caspase-3
activity reflects the degree of apoptosis. Several apoptotic inducers, including 6-
OHDA, activate caspase-3 whereas anti-apoptotic agents lessen the activation.
caspase-3 activity compared with control (control: 100.0±5.6, meclizine: 98.7±8.7%,
p>0.05, caspase-3 activity was normalized by the average of non-treated SH-SY5Y
demonstrated a significant induced apoptosis and caspase-3 activity from the data
of validation (section 2.6.3), increased caspase-3 activity. SH-SY5Y cells pre-treated
activity induced by 6-OHDA (control: 1148.0±37.3, meclizine: 937.1±43.4%, p<0.01)
(Figure 3-5).
It can be concluded that meclizine hyperpolarized mitochondria, and thus
prevented 6-OHDA induced depolarization. This effect leads to down-regulation of
the downstream apoptosis process and reduces caspase-3 activation. It also
demonstrates that ROS scavenging is not responsible for the anti-apoptotic effect of
meclizine.
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Figure 3-5
(control: 1148±37%, meclizine:937±47%, p<0.01, n=7). Caspase-3 activity was normalized
by the average of non-treated SH-SY5Y cells. Data were presented as mean±S.E.M.
Statistics was performed by two-tailed Student’s t-test and p value less than 0.05 was
recognized as significance. (N.S., non-significant, **, p<0.01)
3.3 The Protection of Meclizine Was Mitochondrial Hyperpolarization-
Dependent
CCCP, a potent mitochondrial uncoupler, was applied to depolarize mitochondria
to test the mitochondrial hyperpolarization-dependent protection of meclizine. In
both control or 12.5µM meclizine treatment for 48 hours SH-SY5Y cells groups, 1µM
CCCP led to significant mitochondrial depolarization (control: 37.4±6.3, meclizine:
39.4±2.2%, p>0.05). The mitochondrial membrane potential was adjusted by
mitochondrial content and normalized by the average of TMRM fluorescence from
control SH-SY5Y cells (Figure 3-6).
**
N.S.
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Figure 3-6
Figure 3-6. Meclizine treatment failed to maintained mitochondrial membrane potential
treatment for 48 hours significantly hyperpolarized mitochondria (control: 99.3±0.5,
meclizine: 120.3±6.4%, n=4, p<0.05). However, for the cells pre-treated with 12.5µM
meclizine for 48 hours, 1µM CCCP treatment induced mitochondrial depolarization in both
groups without significant difference (control: 37.4±6.3, meclizine: 39.4±2.2%,n=4, p>0.05).
content and normalized by the average TMRM fluorescence of non-treated SH-SY5Y cells.
Data were presented as mean ±S.E.M..Statistics was performed by two-tailed Student’s t-
test and p value less than 0.05 was recognized as significance (*, p<0.05, N.S., non-
significant).
It has been reported that CCCP abolishes the mitochondrial membrane potential
to cause cell death(Korlipara et al., 2004). Pre-treatment with 12.5µM meclizine for
48 hours failed to prevent the cell death induced by 1µM CCCP treatment for 48
hours compared with control (control: 16.5±1.5, meclizine: 21.6±3.5%, p>0.05)
(Figure 3-7).
These results may suggest that the protection of meclizine was mitochondrial
hyperpolarization-dependent and there was no further protection from meclizine if
the hyperpolarization was ablated.
*
N.S.
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Figure 3-7
Figure 3-7. Meclizine failed to protect cell death of SH-SY5Y cells induced by CCCP. 1µM
CCCP treatment for 48 hours induced 16.5±1.5% of LDH release in control SH-SY5Y cells.
Pre-treated with 12.5µM meclizine for 48 hours did not reduce the LDH release (21.6±3.5%,
p>0.05, n=8). Data were presented as mean ±S.E.M..Statistics was performed by two-tailed
Student’s t-test and p value less than 0.05 was recognized as significance (N.S., non-
significant).
3.4 The Anti-apoptotic and Cell Death Protective Effect of Meclizine
were Glycolysis-dependent.
It was noted that meclizine hyperpolarized mitochondria to modulate apoptosis
and protect against 6-OHDA induced cell death in SH-SY5Y cells in section 3.1 and
3.2. Increased glycolysis is thought to be responsible for the protection. However,
anti-histamine and anti-cholinergic effects needed to be excluded as meclizine’s
mechanisms of action and glycolysis inhibitors were applied to confirm the
glycolysis-dependent protection.
N.S.
N.S.
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3.4.1 Meclizine Enhanced Glycolysis in SH-SY5Y Cells , Which Was
Attenuated by Glycolytic Inhibitors.
Although Gohil et al
glycolysis in HEK293, HeLa and STHdhQ7/7 cell lines(Gohil et al., 2010), the glycolysis-
enhancing effect of meclizine had not been confirmed on SH-SY5Y cells. Glycolysis
was measured by XF extracellular flux analyser, which detects small changes of
acidification of medium due to lactic acid synthesis, the end-product of glycolysis.
ECAR compared with control (control: 1405.5±204.3, meclizine: 3613.5±543.6
p<0.01) (Figure 3-8).
In addition, glycolytic inhibitors, 2-deoxy-D-glucose (2DG) and 3-bromopyruvate
(3BP) were applied simultaneously with meclizine. Both inhibitors targeted the
enzymes responsible for glycolysis. 2DG inhibited hexokinase whereas 3BP inhibited
with meclizine for 48 hours demonstrated a trend of down-regulation of glycolysis
induced by meclizine (meclizine: 3613.5±543.6, meclizine+2DG: 2359.0±290.8,
p p<0.01) (Figure. 3-8).
and glycolytic inhibitors, 2DG and 3BP, attenuate this enhancement.
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Figure 3-8
regulated the glycolytic activity which was measured by ECAR. However, co-administration
would markedly reduce the enhancement of glycolysis. (control: 1405±204, meclizine:
3613±544, p
respectively, n=6) Data were presented as mean±S.E.M and statistics were performed by
one-way ANOVA with Dunnett’s post-hoc analysis. (**, p<0.01 )
3.4.2 Meclizine Hyperpolarisation of Mitochondria Was Glycolysis-
dependent
It has been revealed that meclizine hyperpolarizes mitochondria when no toxin is
present. According to previous authors(Cardaci et al., 2012; Iijima, 2006), increased
glycolysis leads to mitochondrial hyperpolarization because F1F0-ATP synthase
consumes glycolysis-generated ATP in order to pump protons out, instead of into,
the mitochondria matrix. Glycolytic inhibitors, such as 2DG and 3BP, were expected
to reverse the mitochondrial hyperpolarization triggered by meclizine.
membrane potential compared with control SH-SY5Y cells (control: 100.0±1.2, 2DG:
**
**
p=0.08
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96.2±2.8, 3BP: 98.1±1.8%, mitochondrial membrane potential was normalized by
the average TMRM fluorescence from control SH-SY5Y cells) (Figure 3-9). However,
meclizine for 48 hours, the hyperpolarization of mitochondria induced by meclizine
was significantly reduced (meclizine alone: 135.3±6.2, meclizine+2DG:
106.9±6.9,p<0.001, 3BP: 118.8±2.9%, p<0.05, mitochondrial membrane potential
was adjusted by mitochondrial content and normalized by the average of TMRM
fluorescence from control SH-SY5Y cells) (Figure 3-9).
These data support the hypothesis that meclizine induces mitochondrial
hyperpolarizaiton by a glycolysis-dependent mechanism.
Figure 3-9
significantly attenuated the mitochondrial hyperpolarization induced by 12.5 µM meclizine
treatment for 48 hours (meclizine: 135±6.2%, meclizine+2DG: 107±1.9%, meclizine+3BP:
of TMRM with adjustment of mitochondrial content and normalized by the average TMRM
fluorescence of non-treated SH-SY5Y cells. Data were presented as mean±S.E.M and
statistics were performed by one-way ANOVA with Dunnett’s post-hoc analysis. (N.S., non-
significant,*, p<0.05, ***,p<0.001)
***
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3.4.3 Meclizine Protection of SH-SY5Y Cells against 6-OHDA Cytotoxicity
Was Glycolysis-dependent
Section 3.4.2 showed that the anti-apoptotic action of meclizine resulted from
glycolysis, but it is important to confirm the association between this glycolysis and
cell death protection. Similar to the previous experimental settings, glycolytic
inhibitors, 2DG or 3BP, which had been proved to reduce the glycolysis caused by
meclizine treatment, were applied with meclizine to investigate the changes in cell
death protection capability against 6-OHDA.
20.1±0.9, 2DG: 21.5±0.4, 3BP: 21.8±2.1%). However, when co-administration with
protection against 6-OHDA (meclizine: 11.8±0.3, meclizine+2DG: 16.0±1.2,p<0.05,
meclizine+3BP: 25.9±1.3%, p<0.001) (Figure 3-10).
In summary, meclizine increased glycolysis in SH-SY5Y cells and glycolytic inhibitors
attenuated this enhancement. Moreover, the key anti-apoptotic mechanism of
meclizine, mitochondrial hyperpolarization, was glycolysis-dependent, as was the
cell death protection of meclizine against 6-OHDA. These findings support the
hypothesis that meclizine modulates mitochondria-dependent apoptosis by
increasing glycolysis. These observations will form the basis for further study to
determine the relevance of these effects to protect against neuronal cell loss in
Parkinson’s disease.
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Figure 3-10
Figure 3-10. The protection of meclizine relied on the effect of increasing glycolysis. Co-
(meclizine: 11.8±0.3%, meclizine+2DG: 16.0±1.1%; meclizine+3BP: 25.8±1.3%, p<0.05 and
<0.001, respectively, n=8). Meclizine, 2DG and 3BP were applied the same time with 6-
OHDA. Data were presented as mean±S.E.M and statistic was performed by one-way
ANOVA with Dunnett’s post-hoc analysis. (*, p<0.05, ***,p<0.001)
3.5 Meclizine Did Not Alter the Expression of Glycolytic Enzymes
levels(Gohil et al., 2010). In addition, increased expression of glycolytic enzymes can
enhance also glycolysis. The present research evaluates the protein expression level
of certain key glycolytic enzymes. Figure 3-11 is the representative western blot
analysis and Figure 3-12 the result of densitometry analysis. According to the graph
of the target proteins, including hexokinase-1 (HK1), hexokinase-2(HK2),
*
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phosphofructokinase (PFKP) and pyruvate kinase isozymes M1/M2 (PKM1/2).
Considering these observations, it remains unclear how meclizine changes cellular
glucose metabolism.
Figure 3-11
Figure 3-12
N.S.
N.S. N.S.
N.S.
121
Figure 3-11 and 3-12. Representative western blot and densitometry analysis revealed that
meclizine did not alter the protein level of certain key glycolytic enzymes, including
hexokinase 1 (HK1), hexokinase 2 (HK2), phosphofructokinase (PFKP), and pyruvate kinase
isozymes M1/M2 (PKM1/2) on SH-SY5Y cells. The expression level was corrected by the
(n=3). Data were presented as mean±S.E.M. and statistical analysis was performed by two-
tailed Student’s t-test. (N.S., non-significant )
3.6 Meclizine Protected Rat Cortical Neurons against 6-OHDA Induced
Apoptosis and Cell Death
SH-SY5Y is a neuroblastoma cell line which usually exhibits higher glycolysis.
However, neurons rely on OXPHOS for ATP synthesis and their glycolytic activity is
usually low. Also, neurons are more vulnerable to toxins compared to SH-SY5Y cells
so the meclizine-mediated protection seen in SH-SY5Y cells may not be
reproducible in neurons. Hence, primary rat cortical cultures were used as another
model to test the neuroprotection of meclizine . All the experiments were
performed on the matured primary rat cortical cultures, which were cultured for
more than 7 days so they presented with obvious neuritics networks.
3.6.1 Meclizine Reduced the Cell Death Induced by 6-OHDA in Rat
Cortical Culture
After culturing of the primary rat cortical culture for 7 days, the culturing media
were changed to phenol-red free ones for further LDH measuring. The initial
concentration of meclizine used was based on the results from SH-SY5Y cells.
the protection. The concentration of 6-OHDA used was decided according previous
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induced significant but not catasthophic cell loss in primary rat cortical culture so
this concentration was chosen.
OHDA treatment for 24 hours, meclizine significantly reduced the LDH release in
primary rat cortical culture (control: 10.8±1.4, meclizine: 6.8±0.8%, p<0.05) (Figure
3-13).
These findings show that moderate concentrations of meclizine do not increase
spontaneous cell loss, but protected against 6-OHDA induced cytotoxicity in
primary rat cortical culture. Therefore, the protection of meclizine on SH-SY5Y cells
can be reproduced on primary cells.
Figure 3-13
LDH release assay (control: 10.8±1.4%,meclizine: 6.8±0.9%,p<0.05, n=8). In addition,
meclizine did not increase spontaneous cell death on primary rat cortical culture. Meclizine
was applied at the same time with 6-OHDA. Data were presented as mean±S.E.M. and
*
N.S.
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statistic analysis was performed by two-tailed Student’s t-test. (N.S., non-significant, *,
p<0.05 )
3.6.2 The Protection of Meclizine against 6-OHDA Induced Cell Death Was
Glycolysis-dependent
It is important to characterise the glycolysis-dependent protection of meclizine on
primary rat cortical cultures because previous reports claim that neurons exhibit
less glycolysis and fail to up-regulate glycolysis in stress-inducing conditions. In
addition, it is necessary to utilise another measurement of cell death to confirm the
protection. Here, the PI binding assay is again introduced to meet these two
requirements .
When the cultures were free from meclizine, 2DG itself did not increase the cell
11.5±0.7, 2DG: 10.2±1.0%, p>0.05). Similar to the results obtained from LDH assay,
challenging (control: 11.5±0.7, meclizine: 6.6±0.7%, p<0.001). This protection was
resulted in a significant higher cell death upon 6-OHDA treatment compared with
meclizine alone (meclizine: 6.6±0.7, meclizine+2DG: 19.0±0.9%, p<0.001) (Figure 3-
14).
These data provide confirmation that first, the protection of meclizine is consistent
on primary rat cortical culture and second, although the glycolytic inhibitor itself
was not toxic, it was able to attenuate the protection of meclizine. This indicates
that the protection of meclizine on primary cells is glycolysis-dependent.
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Figure 3-14
cortical culture cells for 24 hours was confirmed by PI binding assay (control:
11.5±0.7%,meclizine: 6.6±0.7%,p
not increase the toxicity of 6-OHDA, when meclizine was co-administered with 2DG, the
protection of meclizine was lost entirely (meclizie: 6.6±0.7%,meclizine with 2DG:
19.0±0.9%,p<0.001, n=10). Meclizine and 2DG were applied at the same time with 6-OHDA.
Data were presented as mean±S.E.M. and statistic analysis was performed by two-tailed
Student’s t-test. (N.S., non-significant, ***, p<0.001)
3.6.3 Meclizine Reduced Neuron-specific Cell Death Induced by 6-OHDA
Although the primary rat cortical culture has been verified in the previous section,
and the percentage of neurons present was more than 90%, it is still arguable that
the neuroprotection of meclizine is not genuine because the cultures were not pure.
FJ-C, a neuronal degenerative marker was introduced to investigate the absolute
neuronal death and protection of meclizine.
positive cells (control: 6.2±0.9%,meclizine: 7.4±0.4%,p>0.05). However, following
N.S.
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reduced the percentage of FJ-C positive cells in each field(control:
20.4±1.6%,meclizine: 12.7±0.7%,p<0.001) (Figure 3-15).
In summary, meclizine decreases the neuronal death against 6-OHDA in primary
rat cortical culture. The mixed culture nature of cortical culture does not affect or
distort this protection.
Figure 3-15
did not increase the spontaneous neuronal death but significantly reduced the percentage
meclizine: 12.7±0.7%, p<0.001, n=10). Meclizine was applied at the same time with 6-OHDA.
Data were presented as mean±S.E.M. and statistic analysis was performed by two-tailed
Student’s t-test. (N.S., non-significant, ***, p<0.001)
3.6.4 Meclizine Hyperpolarized Mitochondria in Primary Rat Cortical
Culture
Another important issue, after the demonstration of protection from meclizine in
primary rat cortical cultures, was to confirm that meclizine hyperpolarizes
mitochondria in these neurons . Figure 3-16 demonstrated that 3.125µM meclizine
treatment for 24 hours significantly hyperpolarized mitochondria in primary rat
cortical culture (control: 100.0±3.4%,meclizine: 118.5±2.8%,p<0.001, mitochondrial
***
N.S.
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membrane potential was normalized by the average TMRM fluorescence from
control primary rat cortical culture cells). These results indicate that meclizine is
able to modulate mitochondrial membrane potential in primary rat cortical culture
cells in the same way as SH-SY5Y cells. This hyperpolarization is believed to be
responsible for the neuroprotective mechanism of meclizine in neurons.
Fig 3-16
Figure 3-16. 3.125µM meclizine treatment for 24 hours hyperpolarized mitochondria in
primary rat cortical culture cells. Measured by TMRM, meclizine significantly produced
about 20% more polarization of mitochondrial membrane potential compared with control
(control: 100.0±3.4%, meclizine: 118.5±2.8%,p<0.001, n=12, mitochondrial membrane
potential was normalized by the average of control primary rat cortical culture cells). Data
were presented as mean±S.E.M. and statistic analysis was performed by two-tailed
Student’s t-test. (***, p<0.001)
3.6.5 Meclizine Reduced 6-OHDA Induced Apoptosis in Primary Rat
Cortical Culture
It is predicted that meclizine is able to down-regulate apoptosis and thus reduce
the activation of caspase-3, as meclizine hyperpolarized mitochondria in primary
rat cortical culture in the same way as SH-SY5Y cells. Primary rat cortical cultures
***
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6-OHDA treatment for 6 hours. Coverslips were harvested and went through the
process of immuno-cytochemistry. Apoptotic cells were detected by the positive
stain of cleaved caspase-3, an intermediate in the apoptotic cascade (Figure 3-17).
The fields were randomly selected and the percentage of cells with cleaved
percentage of apoptotic cells compared with control (control: 3.9±0.6%, meclizine:
2.0±0.8%,p
percentage of cells with positive cleaved caspase-3 stain (control: 12.4±0.6%,
meclizine: 8.8±0.4%,p<0.001) (Figure 3-18).
In conclusion, meclizine presented a similar protection against 6-OHDA in primary
rat cortical culture compared with SH-SY5Y cells. It hyperpolarizes mitochondria and
is anti-apoptotic as well. In addition, the neuroprotection is glycolysis-dependent.
All of these observations support the hypothesis that by enhancing glycolysis,
meclizine is able to modulate mitochondria-dependent apoptosis and protect
against cell loss in Parkinson’s disease cellular models.
128
Figure 3-17
Figure 3-17. Representative images of cleaved caspase-3 staining (red) to detect apoptotic
cells. The spontaneous apoptosis was scant (left) and 6-OHDA treatment triggered more
apoptotic cell death detected by positive cleaved caspase-3 staining (arrowhead) (right)
( blue: DAPI).
Figure 3-18
cortical culture cells (control: 12.4±0.6% versus meclizine: 8.8±0.4%, p<0.001, n=10). Data
were presented as mean±S.E.M. and statistic analysis was performed by two-tailed
Student’s t-test. (***, p<0.001
***
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4 Results-pUL37x1 over-expression
4.1 Generation and Characterization of Stable pUL37x1 Over-
expressing SH-SY5Y Cell Lines
4.1.1 Three pUL37x1 Over-expressing SH-SY5Y Cell Lines: Western Blot
Analysis Confirmed the Protein Over-expression
Stable pUL37x1 over-expressing cell lines were required to test the hypothesis that
pUL37x1 can modulate mitochondria-dependent apoptosis. pUL37x1 cDNA with a
3’ haemagluttinin (HA) epitope was cloned into pcDNA3.1 plasmid and transfected
antibiotic selection and formed colonies. Several independent colonies were cloned
and maintained under geneticin. Three of these colonies were selected due to the
similarities in growing and death characteristics between them and normal SH-SY5Y
cells. These colonies are named as pUL37x1-1~3 in the following paragraphs. The
whole cell lysate from each cell line was investigated by western blot analysis to
detect the levels of pUL37x1-HA protein expression. As well as SH-SY5Y cells, the
control group also contained another two cell lines to provide over-expressing
controls. The first of these was dsRed-Mito cells. This cell line over-expresses
dsRed-Mito, a fluorescent protein which interacts with mitochondria without
altering their function. The other control cell line was pcDNA Zero cells, which over-
expresses pcDNA3.1(+) plasmid without pUL37x1-HA. In the following sections,
dsRed-Mito is labelled as control-2,and pcDNA Zero as control-3. Those two over-
expressing cell lines were obtained from Dr. Chau. Data which is labelled as control
and pUL37x1 is the combination of each cell line except where specified.
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The representative western blot analysis clearly shows that pUL37x1 over-
expressing cell lines produced a distinctive band at 60kDa as detected by anti-HA
antibody (Figure 4-1). There is no such band detected from either of the three
different control lines. Considering the molecular weight of pUL37x1, it is believed
that the bands at 60kDa are the expression of pUL37x1-HA from the over-
expressing cell lines.
The expression level of pUL37x1-HA in three over-expressing cell lines was
analysed by the densitometry method. As no endogenous pUL37x1 protein has
been detected in previous reports, the expression level from each line was
normalized by pUL37x1-3. Figure 4-2 demonstrated that pUL37x1-1 expressed the
most pUL37x1 (192.2±27.7%), followed by pUL37x1-2 (155.4±9.2%) and pUL37x1-3
(100±0%).
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Figure 4-1
Figure 4-1. Expression construct coding pUL37x1 with an HA-tag at its C-terminus was
delivered into SH-SY5Y cells and upon selection with geneticin. Three over-expressing lines
were generated. Representative western blot image demonstrated the expression of
pUL37x1-HA from three different stable lines of SH-SY5Y. In addition, control-1 was normal
SH-SY5Y cell; control-2 was SH-SY5Y cell over-expressing dsRed-Mito, a red fluorescence
protein targeted on mitochondrial matrix without altering mitochondrial function; control-
loading control.
Figure 4-2
Figure 4-2. Densitometry analysis of pUL37x1 expression level from three pUL37x1 over-
expression lines revealed pUL37x1-1 line expressed the highest level of pUL37x1
(192.2±27.7%), followed by pUL37x1-2(155.4±9.2%) and pUL37x1-3 (100±0%)(n=6). The
control cells did not express detectable pUL37x1-HA. Data were presented as mean±S.E.M.
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4.1.2 Three pUL37x1 Over-expressing SH-SY5Y Cell Lines:
Immunocytochemistry Confirmed the Homogenous Over-
expression in Three Cell Lines
Western blot analysis demonstrated the ectopic expression but failed to establish
the homogeneity of pUL37x1 over-expression. As well as antibiotic selection, to
confirm the purity of ectopic expression required for the immuno-cytochemistry
assay. In SH-SY5Y cells, there was no detectable pUL37x1-HA. In contrast, most of
the cells in pUL37x1 over-expressing lines exhibited a positive pUL37x1-HA staining
(Figure 4-3).
Figure 4-3
Figure 4-3. All three pUL37x1 over-expressing SH-SY5Y cell lines homogenously expressed
pUL37x1-HA which was detected by immunocytochemistry whereas the control SH-SY5Y
cells did not express detectable pUL37x1-HA (green: pUL37x1-HA, blue: DAPI).
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4.1.3 Mitochondrial Localization of pUL37x1
It has been mentioned in the previous sections that the mitochondrial localization
of pUL37x1 is highly associated with the anti-apoptotic effect. A confocal
microscope with a small pinhole provided narrow depth-of-field imaging, thereby
clearly demonstrating the co-localization of pUL37x1 with mitochondria (Figure 4-4).
In the representative image, plenty of pUL37x1-HA (green) is obviously co-localized
with MitoTracker (red), a mitochondrial marker.
Figure 4-4
MitoTracker pUL37x1-HA Merge
Figure 4-4. The mitochondrial localization of pUL37x1 from pUL37x1 over-expressing SH-
SY5Y cells. In the representative image, mitochondria were labelled by MitoTracker (red)
and pUL37x1-HA was detected by anti-HA antibody (green). In the merged image, it
obviously demonstrated plenty of co-localization (yellow).
To summarise, three independent stable pUL37x1 over-expressing SHSY5Y cell
lines were generated. All these cell lines expressed a significant amount of
pUL37x1-HA compared with control. In addition, the antibiotic selection process
resulted in a high purity of over-expression. The over-expressing proteins also
exhibited mitochondrial co-localization.
20
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4.2 pUL37x1 Over-expression Protected Against Toxin-Induced Cytotoxicity
Two cytotoxic agents were applied to SH-SY5Y cells in order to test the
neuroprotection of pUL37X1. 6-OHDA, an oxidative stress inducer, is a common
toxin used in neurodegenerative in vivo and in vitro models to induce neuronal
death. Another toxin is staurosporine, a protein kinase C inhibitor. Staurosporine is
a strong apoptosis inducer and has been widely used to challenge the anti-
apoptotic effect of neuroprotective agents. pUL37x1 over-expression was expected
to reduce the cell death induced by 6-OHDA and staurosporine in SH-SY5Y cells.
4.2.1 pUL37x1 Over-expression Protected Against 6-OHDA Induced
Cytotoxicity
4.2.1.1 The Protection Was Investigated by LDH Release Assay
Stable pUL37x1 over-expressing cell lines do not demonstrate increased
spontaneous cell death compared with control (control: 6.5±0.7%, UL37:
5.8±0.4%,p
expression cell lines did not demonstrate protection compared with control (control:
9.1±0.8%, pUL37x1: 7.5±1.1%, p>0.05). This failure resulted from the sub-lethal
dosage used and treatment time, which only induced less than 10% LDH release in
hours, pUL37x1 over-expression significantly reduced the percentage of LDH
release (control: 30.6±1.9%, UL37: 12.9±0.6%, p<0.001) (Figure 4-5).
The protection of pUL37x1 over-expression also worked following longer toxin
over-expression cell lines resulted in significantly reduced cell death compared with
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control (48 hours, control: 22.8±1.5%, UL37: 15.1±1.9%, p<0.01, n=8; 72 hours,
control: 30.2±1.3%, UL37:15.1±0.6%, p<0.001, n=6) (Figure 4-6). In addition, the
protective trend was consistent in all three lines. There was no relationship
between protection and the pUL37x1 expressing level (supplemet). The dosage and
duration of 6-OHDA treatment was mainly based on the data of validation ( Sec
2.5.1.3).
These results support the hypothesis that pUL37x1 over-expression is
neuroprotective and also provides evidence that over-expression itself is not toxic.
Figure 4-5
Figure 4-5. pUL37x1 over-expression did not increase spontaneous cell death on SH-SY5Y
cells compared with control and significantly decreased the percentage of LDH release
pUL37x1 over-expression, p<0.001, n=6). Data were presented as mean±S.E.M. Statistics
was performed by two-tailed Student’s t- test. The n numbers represented the
experimental repeat of each pUL37x1 over-expressing and control lines. (NS, non-
significant, ***,p<0.001)
***
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Figure 4-6
Figure 4-6. pUL37x1 over-expression significantly decreased the percentage of LDH release
22.8±1.5% in control, 15.1±1.9% in pUL37x1 over-expression, p<0.01, n=8; 72 hours:
30.2±1.3% in control, 15.1±0.6% in pUL37x1 over-expression, p<0.001, n=6). Data were
presented as mean±S.E.M. Statistics was performed by two-tailed Student’s t- test. The n
numbers represented the experimental repeat of each pUL37x1 over-expressing and
control lines (NS, non-significant, **,p<0.01; ***,p<0.001)
4.2.1.2 The Protection Was Investigated by PI Binding Assay
In order to confirm the protection of pUL37x1 over-expression, another cell death
measurement was required. PI, a fluorescent protein which displays a marked
increase its fluorescence when bound with nucleic acid, can only penetrate a cell
membrane with impaired integrity. Two experimental conditions, which
demonstrated the protection of pUL37x1 over-expression against 6-OHDA in the
LDH release assay, were tested by PI binding assay to confirm the results. pUL37x1
OHDA, 24hours: 33.6±1.5% in control, 22.2±2.0% in pUL37x1 over-expression,
p
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over-expression, p<0.05. n=6) (Figure 4-7). In this assay, dsRed-Mito cells were not
included in the control because of the endogenous fluorescence they contain.
The protection conferred by pUL37x1 over-expression against 6-OHDA induced
neuronal death is consistent as shown by both LDH release and PI binding assays.
Figure 4-7
Figure 4-7. pUL37x1 over-expression significantly decreased the percentage of PI
in pUL37x1 over-expression, p
44.7±4.0% in pUL37x1 over-expression, p<0.05. n=6). Data were presented as mean±S.E.M.
Statistics was performed by two-tailed Student’s t- test. The n numbers represented the
experimental repeat from each pUL37x1 over-expression lines and control (normal SH-SY5Y
cells and over-expressing pcDNA Zero SH-SY5Y cells) (*, p<0.05, **,p<0.001)
4.2.2 pUL37x1 over-expression Protected Staurosporine Induced
Cytotoxicity
4.2.2.1 The Protection Was Investigated by LDH Release Assay
Staurosporine is able to induce substantial apoptotic cell death but pUL37x1 over-
expression prevented this toxic effect. pUL37x1 over-expression significantly
reduced the percentage of LDH release induced by 15nM staurosporine treatment
***
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for either 24 or 48 hours treatment (24 hours: 25.4±2.3% in control, 13.9±0.8% in
pUL37x1 over-expression, p<0.01, n=4; 48 hours: 22.8±1.5% in control, 15.1±1.9%
in pUL37x1 over-expression, p<0.01, n=6) (Figure 4-8).
Furthermore, pUL37x1 over-expression significantly reduced the cell death
induced by 30nM staurosporine treatment for 24 hours (22.3±1.3% in control,
13.7±0.5% in pUL37x1 over-expression, p<0.001, n=8) (Figure 4-9). Considering
these results, pUL37x1 over-expression successfully demonstrates the ability to
lower the apoptotic cell death induced by staurosporine. The dosage and duration
of staurosporine was mainly based on the data of validation (Sec 2.5.1.3).
Figure 4-8
Figure 4-8. pUL37x1 over-expression significantly reduced the percentage of LDH release on
SH-SY5Y cells induced by 15nM staurosporine treatment for 24 and 48 hours (24 hours:
25.4±2.3% in control, 13.9±0.8% in pUL37x1 over-expression, p<0.01, n=4; 48 hours:
22.8±1.5% in control, 15.1±1.9% in pUL37x1 over-expression, p<0.01, n=6). Data were
presented as mean±S.E.M. Statistics was performed by two-tailed Student’s t- test. The n
number represented the experimental repeat from each pUL37x1 over-expression lines and
control (normal SH-SY5Y cells, over-expressing pcDNA Zero SH-SY5Y cells and over-
expressing dsRed-mito SH-SY5Y cells) (**,p<0.01).
**
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Figure 4-9
Figure 4-9. pUL37x1 over-expression significantly protected cell death on SH-SY5Y cells
upon either 15 or 30nM staurosporine (STS) treatment for 24 hours (15nM: 25.4±2.3% in
control, 13.9±0.8% in pUL37x1 over-expression, p<0.01, n=4; 30nM: 22.3±1.3% in control,
13.7±0.5% in pUL37x1 over-expression, p<0.001, n=8). Data were presented as
mean±S.E.M. Statistics was performed by two-tailed Student’s t- test. The n number
represented the experimental repeat from each pUL37x1 over-expression lines and control
(normal SH-SY5Y cells, over-expressing pcDNA Zero SH-SY5Y cells and over-expressing
dsRed-mito SH-SY5Y cells) (**,p<0.01, ***, p<0.001).
4.2.2.2 pUL37x1 Protection Was Investigated by PI Binding Assay
The protection of pUL37x1 over-expression against staurosporine was also
confirmed by PI binding assay. Illustrated by figure 4-10, pUL37x1 over-expression
significantly lowered the PI fluorescence induced by either 15nM staurosporine
treatment for 48 hours or 30nM staurosporine treatment for 24 hours (15nM
treatment for 48 hours: 22.9±1.4% in control, 14.7±1.5% in pUL37x1 over-
expression, p<0.001, n=8; 30nM treatment for 24 hours: 12.5±2.4% in control,
6.8±1.3% in pUL37x1 over-expression, p<0.05, n=6). These results confirm the
protection of pUL37x1 over-expression from staurosporine-induced cytotoxicity.
** ***
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Figure 4-10
Figure 4-10. pUL37x1 over-expression reduced the PI fluorescence on SH-SY5Y cells induced
by staurosporine. The protection was noted in either 15nM treatment for 48 hours or
30nM treatment for 24 hours (15nM treatment for 48 hours: 22.9±1.4% in control,
14.7±1.5% in pUL37x1 over-expression, p<0.001, n=8; 30nM treatment for 24 hours:
12.5±2.4% in control, 6.8±1.3% in pUL37x1 over-expression, p<0.05, n=6). Data were
presented as mean±S.E.M. Statistics was performed by two-tailed Student’s t- test. The n
number represented the experimental repeat from each pUL37x1 over-expression lines and
control (normal SH-SY5Y cells, and over-expressing pcDNA Zero SH-SY5Y cells) (*,p<0.05,
***, p<0.001).
4.3 pUL37x1 Over-expression Modulated Mitochondria-dependent
Apoptosis
As mentioned in the introduction, pUL37x1 modulates mitochondria-dependent
apoptosis. Several steps within mitochondria-dependent apoptosis were evaluated
on pUL37x1 over-expressing SH-SY5Y cells, including Bax translocalization, change
of mitochondrial membrane potential, release of cytochrome c and activation of
caspase-3, to test this hypothesis and possibly identify the mechanism(s) of anti-
apoptotic action.
*
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4.3.1 pUL37x1 Over-expression Induced Mitochondria-localization of Bax
Bax is one of the pro-apoptotic proteins in Bcl-2 family. In the absence of toxin,
most Bax protein is in the cytoplasm, however, upon apoptosis, it translocates to
mitochondria and dimerises. The dimer is inserted into the mitochondrial outer
membrane and induces MMP, which results in the release of inner mitochondrial
contents and causes cell death. It has been reported that pUL37x1 leads to the
translocation of Bax from cytoplasm to mitochondria during CMV infection.
However, instead of activating apoptosis, Bax proteins were inactivated after
translocation. This process is thought to be responsible for the anti-apoptotic
mechanism of pUL37x1.
In terms of the pUL37x1 over-expressing SH-SY5Y cells, the translocation of Bax
was also clearly demonstrated by immunocytochemistry investigation. Cells were
co-stained with MitoTracker red, a mitochondrial dye and anti-Bax antibody (green).
Images were obtained by confocal microscope. Control SH-SY5Y cells revealed a
homogenous intracellular distribution of Bax without obvious co-localization with
MitoTracker red. In contrast, pUL37x1 over-expressing cells exhibited a remarkable
translocation of Bax: there were numerous co-localization of Bax with MitoTracker
red, which indicated a mitochondrial translocation of Bax (Figure 4-11).
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Figure 4-11
Control pUL37x1 o/e
Figure 4-11. pUL37x1 over-expression affected the intra-cellular localization of Bax. In
control SH-SY5Y cells, Bax (green) demonstrated a predominant intracellular distribution
with scant co-localization with MitoTracker (red). Nevertheless, in pUL37x1 over-expressing
( pUL37x1 o/e) SH-SY5Y cells, a remarkable co-localization with Bax and MitoTracker was
shown (yellow), which indicated a translocation of Bax from cytoplasm to mitochondria.
Images were obtained from confocal microscope.
4.3.2 pUL37x1 Over-expression Hyperpolarized Mitochondria and
Rescued 6-OHDA Induced Depolarization
Depolarization of mitochondria is a common phenomenon during apoptosis. It has
been reported that mitochondrial depolarization takes place preceding Bax
translocation(Smaili et al., 2001). Also, hyperpolarized mitochondria have been
shown as an anti-apoptosis strategy in the meclizine section of this study.
Considering the importance of mitochondrial membrane potential in apoptosis, it
was worth investigating whether pUL37x1 over-expression affected it or not.
In the absence of toxin, pUL37x1 over-expressing SH-SY5Y cells exhibited
hyperpolarized mitochondria compared with control SH-SY5Y cells (control:
100.0±1.4%, UL37: 175.3±7.4%,p<0.001). This hyperpolarization prevented the
depolarization induced by 100 M 6-OHDA treatment for 1 hour (control: 77.0±2.8%,
UL37: 114.1±3.2%,p<0.001) (Figure 4-12). 100µM 6-OHDA treatment on SH-SY5Y
20
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cells had been proved to induce mitochondrial depolarization 1 hour after
treatment(Lotharius et al., 1999). TMRM fluorescence from each experiment was
normalized by the average of TMRM fluorescence obtained from no-toxin SH-SY5Y
cells. Therefore, pUL37x1 over-expression results in mitochondrial
hyperpolarization in SH-SY5Y cells and protects the apoptosis-triggered
depolarization.
Figure 4-12
Fig 4-12. pUL37x1 over-expression significantly hyperpolarized baseline mitochondrial
membrane potential on SH-SY5Y cells (175.3±7.4% compared with 100.0±1.4% from control,
p<0.001, n=24 from control SH-SY5Y cells and n=8 from each pUL37x1 over-expressing line)
hour (114.1±3.2% compared with 77.0±2.4% from control, p<0.001, n=10 from control SH-
SY5Y cells and n=5 from each pUL37x1 over-expressing line). Mitochondrial membrane
potential was measured by TMRM fluorescence and normalized by the average of TMRM
fluorescence obtained from no-toxin SH-SY5Y cells. Data were presented as mean±S.E.M.
Statistics was performed by two-tailed Student’s t- test. (***, p<0.001 )
4.3.3 pUL37x1 Over-expression Reduced Cytochrome c Release to
Cytoplasm
Mitochondrial contents are released into cytoplasm after MMP and some of these
result in the activation of further apoptotic cascades. Cytochrome c, an electron
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carrier between complex III and IV, is also well-known to induce apoptosis when it
is released into the cytoplasm. pUL37x1 over-expression significantly prevents the
release of cytochrome c from mitochondria to cytoplasm. When no toxin is present,
the cytosolic concentration of cytochrome c was lower in the pUL37x1 over-
expression cells compared with control (control: 0.29±0.04, pUL37x1: 0.17±0.02
ng/mg cell lysate,p<0.05). Following 500nM staurosporine treatment for 3 hours,
cytochrome c concentration surged in the control whereas pUL37x1 over-
expressing cells significantly blocked the release (control: 0.46±0.05, pUL37x1:
0.21±0.03 ng/mg cell lysate,p<0.01) (Fig 4-13). The dosage and duration of
staurosporine is based on previous study (McGinnis et al., 1999). Based on these
findings, pUL37x1 over-expression is able to block the release of mitochondrial
apoptotic contents, such as cytochrome c into cytoplasm and avoid the further
activation of apoptotic cascades.
Figure 4-13
Figure 4-13. pUL37x1 over-expression did not alter the baseline cytochrome c level in
mitochondrial fraction (M) of cell lysate on SH-SY5Y cells. However, it significantly reduced
cytochrome c releasing to cytoplasm (C) in no-toxin status and upon 500nM staurosporine
treated for 3 hours (no-toxin: 0.29±0.04 ng/mg cell lysate in control versus 0.17±0.02
* **
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ng/mg cell lysate in pUL37x1 over-expression lines,p<0.05, n=3; 500nM staurpsoprone:
0.46±0.05 ng/mg cell lysate in control versus 0.21±0.03 ng/mg cell lysate in pUL37x1 over-
expression lines,p<0.01, n=3). Data were presented as mean±S.E.M . The n number
represented the experimental repeat from each pUL37x1 over-expression lines and control
(include normal SH-SY5Y cells, over-expressing dsRed-mito SH-SY5Y cells and over-
expressing pcDNA Zero SH-SY5Y cells). Statistics was performed by two-tailed Student’s t-
test. (*,p<0.05, **, p<0.01)
4.3.4 pUL37x1 Over-expression Reduced Staurosporine Induced
Activation of Caspase-3
The activation of caspase-3 is at the late stage of apoptosis and caspase-3 activity
is recognized as a parameter of apoptosis. pUL37x1 over-expression was expected
to prevent the activation of caspase-3 due to blocking of the upstream apoptosis
process.
In the absence of toxin, pUL37x1 over-expression cells did not alter the activity of
caspase-3 compared with control (control: 112.6±6.3, pUL37x1: 111.9±6.0%,
p>0.05). However, following 500nM staurosporine treatment for 4 hours, pUL37x1
over-expressing SH-SY5Y cells exhibited significantly lower caspase-3 activity
compared with control (control: 1156.5±137.2, pUL37x1: 440.5±56.3%, p<0.001)
(Figure 4-14). The caspase-3 activity was normalized by using the average of activity
pfrom no-toxin SH-SY5Y cells. The dosage and duration of staurosporine treatment
on SH-SY5Y cells was based on previous report from McGinnis et al(McGinnis et al.,
1999).
In conclusion, pUL37x1 over-expression confirms the hypothesis of modulation of
mitochondria-dependent apoptosis. It leads to mitochondrial translocalization of
Bax without initiation of apoptosis. In addition, this anti-apoptotic protein
hyperpolarizes mitochondria and prevents their depolarization during apoptosis.
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These phenomenon result in less mitochondrial cytochrome c release and lower
caspase-3 activity following apoptotic stress induction.
Figure 4-14
Fig 4-14. pUL37x1 over-expression did not alter the baseline caspase-3 activity on SH-SY5Y
cells but significantly lowered the increase of caspase-3 activity upon 500nM staurosporine
treated for 4 hours (1156.5±137.2% in control versus 440.5±56.3% in pUL37x1 over-
expression, p<0.001, n=5, data were normalized by averaged caspase-3 activity from the
no-toxin SH-SY5Y cells). Data were presented as mean±S.E.M.. The n numbers represented
the experimental repeat from each pUL37x1 over-expressing lines and control (include
normal SH-SY5Y cells and over-expressing pcDNA Zero SH-SY5Y cells). Statistics was
performed by two-tailed Student’s t- test. (NS, non-significant, ***,p<0.001 )
4.4 The Protection of pUL37x1 Over-expression Was due to Bax
Inactivation
In section 4.3.1, pUL37x1 over-expression caused mitochondrial translocalization
of Bax without initiation of apoptosis. pUL37x1 is believed to inactivate Bax after
the translocalization. Provided that the inactivation of Bax occurs, pUL37x1 over-
expressing cells would not obtain more protection from Bax ablation, which has
been reported to reduce apoptosis and cell death.
Both control and pUL37x1 over-expressing cells were treated with either scramble
siRNA and Bax siRNA for 3 days. The protein level of Bax was reduced to less than
N.S.
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20% following Bax siRNA silencing compared with scramble siRNA in both control
and pUL37x1 over-expressing cells (Figure 4-15). Challenging with 30nM
staurosporine for 24 hours, Bax siRNA silencing reduced the percentage of LDH
release compared with scramble siRNA silencing in control cells (Scr siRNA: 20.9±1.4,
Bax siRNA: 16.2±1.2%, p<0.01). Under scramble siRNA silencing, pUL37x1 over-
expression remained protective against staurosporine compared with same
condition control (control: 20.9±1.4, pUL37x1: 12.7±0.9%, p<0.001). However, Bax
siRNA silencing failed to produce more protection on pUL37x1 over-expressing cells,
there was no difference of cell death between control and pUL37x1 over-expressing
cells (control: 16.2±1.2, pUL37x1: 15.4±1.5%, p>0.05) (Figure 4-16).
These data indicate that the anti-apoptotic effect of pUL37x1 over-expression is
due to Bax inactivation and Bax siRNA silencing fails to produce more protection, in
contrast to the control cells.
Figure 4-15
Figure 4-15. Representative western blot analysis image demonstrated that 5nM Bax siRNA
silencing for 3 days remarkably lowered the Bax protein level in both control and pUL37x1
over-expressing SH-SY5Y cells compared with scramble siRNA (Scr) silencing.
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Figure 4-16
Figure 4-16. 5nM Bax siRNA silencing for 3 days significant reduced LDH release on SH-SY5Y
cells upon 30nM staurosporine treated for 24 hours (20.94±1.35% in scramble siRNA versus
16.19±1.09% in Bax siNRA, p<0.01, n=8). However, this reduction did not present in
pUL37x1 over-expressing SH-SY5Y cell. In addition, there was no significant difference of
LDH release upon 30nM staurosporine treated for 24 hours between controls with pUL37x1
over-expressing SH-SY5Y cells when both of them underwent 5nM Bax siRNA silencing.
Data were presented as mean±S.E.M. Statistics was performed by two-tailed Student’s t-
test. The n number represented the experimental repeat from each pUL37x1 over-
expression lines and control (include normal SH-SY5Y cells, over-expressing dsRed-mito SH-
SY5Y cells and over-expressing pcDNA Zero SH-SY5Y cells) (NS, non-significant, **,p<0.01;
***,p<0.001)
4.5 The protection of pUL37x1 Over-expression is mediated by
Mitochondrial Hyperpolarization and Glycolysis
It has been demonstrated in section 4.3.2 that pUL37x1 over-expression results in
mitochondrial hyperpolarization at both basal and 6-OHDA treated status. It has
also been proved, in previous literature and present studies with meclizine, that
avoiding mitochondrial depolarization is a protective mechanism . This suggests
that, as well as Bax inactivation, there is another anti-apoptotic effect of pUL37x1.
It was suspected that pUL37x1 induced mitochondrial hyperpolarization through
increased glycolysis by two factors. First, as described section 1.5.3.2,
**
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hyperpolarization can result from complex V inhibition, insufficient ADP supply or
increased glycolysis. However, the two former would impair the ATP synthesis and
lead to energy deficit and because pUL37x1 over-expression does not result in
increased cell death, it is unlikely that the viral protein causes a shortage of ATP.
Second, CMV infection has been found to increase the glucose metabolism in host
cells, which may be associated with pUL37x1.
4.5.1 Mitochondrial Uncoupling Attenuated the Protection
CCCP was applied to test the mitochondrial hyperpolarization-dependent
protection of pUL37x1 over-expression. Figure 4-17 demonstrated that 1µM CCCP
was able to depolarize either control or pUL37x1 over-expressing SH-SY5Y cells
without significant difference (34.3±2.3% compared with 33.0±2.3% from control,
p>0.05) .
Figure 4-17
Figure 4-17. 1µM CCCP depolarized mitochondria in either control or pUL37x1 over-
expressing SH-SY5Y cells (34.3±2.3% compared with 33.0±2.3% from control, p>0.05, n=6).
TMRM fluorescence from each experiment was normalized by the average of TMRM
fluorescence obtained from no-toxin SH-SY5Y cells. Data were presented as mean±S.E.M .
The n number represented the experimental repeat from each pUL37x1 over-expressing
N.S.
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lines and control SH-SY5Y cells. Statistics was performed by two-tailed Student’s t- test.
(N.S., non-significant)
Since CCCP depolarized pUL37x1 over-expressing SH-SY5Y and control cells, it was
applied to test cell death protection. 1µM CCCP treatment for 48 hours resulted in
22.7±2.5% of LDH release in control SH-SY5Y compared to 20.8±2.1% in pUL37x1
over-expressing cells (Figure 4-18). This result suggests that there was no protection
conferred by pUL37x1 over-expression in the absence of mitochondrial
hyperpolarization effect.
Figure 4-18
Figure 4-18. pUL37x1 over-expression failed to protect cell death upon 1µM CCCP
treatment for 48 hours (control: in 22.7±2.5%; pUL37x1 over-expression: 20.8±2.1%,
p>0.05, n=8). The n number represented the experimental repeat from each pUL37x1 over-
expressing lines and control (include normal SH-SY5Y cells, over-expressing dsRed-mito SH-
SY5Y cells and over-expressing pcDNA Zero SH-SY5Y cells). Statistics was performed by two-
tailed Student’s t- test. (N.S., non-significant)
N.S.
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4.5.2 pUL37x1 Over-expression Increased the Glycolytic Activity without
Altering OXPHOS and ADP Phosphorylation Activity
pUL37x1 over-expressing and control SH-SY5Y cells were cultured in a microplate
for XF analysis. Glycolysis was measured by ECAR and OXPHOS was measured by
OCR. pUL37x1 over-expression significantly increased the ECAR compared with
p<0.05). However, this
glycolysis-enhancing effect did not result from OXPHOS inhibition as there was no
significant difference in OCR between control with pUL37x1 over-expressing SH-
p>0.05) (Figure
4-19).
pUL37x1 over-expression affected neither general OXPHOS activity nor the ATP
synthesis capability from each respiratory chain complex. Assessing by ADP
phosphorylation assay, there was no difference between pUL37x1 over-expression
and control SH-SY5Y cells in ATP synthesis capability from each complex ( control:
complex I+II+III+IV: 26.3±3.6, complex II+III+IV: 19.3±2.0, complex IV: 2.7±0.9;
pUL37x1: complex I+II+III+IV: 28.9±2.5, complex II+III+IV: 13.9±1.7, complex IV:
4.6±0.6 pmole ATP/min/mg, p>0.05 in each condition) (Figure 4-20).
These results revealed that pUL37x1 over-expression causes the increased
glycolysis in SH-SY5Y cells without impairing OXPHOS. This finding supports the
speculation that pUL37x1 leads to mitochondrial hyperpolarization due to
enhancing glycolysis.
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Figure 4-19
Figure 4-19. Glycolysis and OXPHOS of SH-SY5Y cells were measured by XF analyser.
pUL37x1 over-expression induced a significant increase of ECAR compared with control
p<0.05, n=10) without impaired
OXPHOS as measure by OCR. Data were presented as mean±S.E.M. Statistics was
performed by two-tailed Student’s t- test. The n number represented the experimental
repeat from each pUL37x1 over-expressing lines and control (include normal SH-SY5Y cells,
over-expressing dsRed-mito SH-SY5Y cells and over-expressing pcDNA Zero SH-SY5Y cells).
(NS, non-significant, *,p<0.05).
Figure 4-20
Figure 4-20. pUL37x1 over-expression did not affect mitochondrial ADP phosphorylation
ability from each respiratory chain complex on SH-SY5Y cells ( control: complex I+II+III+IV:
26.3±3.6, complex II+III+IV: 19.3±2.0, complex IV: 2.7±0.9; pUL37x1: complex I+II+III+IV:
28.9±2.5, complex II+III+IV: 13.9±1.7, complex IV: 4.6±0.6 pmole ATP/min/mg, p>0.05 in
*
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each condition, n=3). The n number represented the experimental repeat from each
pUL37x1 over-expressing lines and control SH-SY5Y cells. (NS, non-significant).
4.5.3 pUL37x1 Over-expression Induced Mitochondrial
Hyperpolarization Was Glycolysis-dependent
Glycolytic inhibitors (2DG and 3BP) were applied to pUL37x1 over-expressing SH-
SY5Y cells 48 hours before measuring mitochondrial membrane potential to verify
glycolysis-dependent mitochondrial hyperpolarization. In control SH-SY5Y cells,
(control: 100.0±2.3, 2DG: 97.0±4.4, 3BP: 97.6±2.3%, TMRM fluorescence was
adjusted by mitochondrial content and normalized by the average TMRM
fluorescence of control SH-SY5Y cells, p>0.05). However, the hyperpolarization
induced by pUL37x1 over-expression disappeared following treatment with either
2DG or 3BP (pUL37x1: 163.6±9.3, pUL37x1+2DG: 103.7±1.9, 3BP: 87.8±2.8%,
p<0.001 in both conditions, TMRM fluorescence was adjusted by mitochondrial
content and normalized by the average TMRM fluorescence of control SH-SY5Y cells)
(Figure 4-21).
This result confirms that the hyperpolarization does depend on the glycolysis-
enhancing effect of pUL37x1 over-expression.
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Figure 4-21
Bromopyruvate (3BP) treatment for 48 hours, significantly reversed the phenomenon of
mitochondrial hyperpolarization resulted from pUL37x1 over-expression ( pUL37x1:
p<0.001
respectively, n=10). The TMRM fluorescence was adjusted by mitochondrial content and
normalized by the average TMRM fluorescence of control SH-SY5Y cells. Data were
presented as mean±S.E.M. Statistics was performed by one-ANOVA with Dunnett’s post-
hoc analysis. The n number represented the experimental repeat from each pUL37x1 over-
expression lines and control SH-SY5Y cells (***, p<0.001 ).
4.5.4 The Protection of pUL37x1 Over-expression against 6-OHDA Was
Glycolysis-dependent
Providing the mitochondrial hyperpolarization and anti-apoptosis of pUL37x1
over-expression is glycolysis-dependent, glycolysis inhibition should, not only
attenuate the potential difference, but also impair the protection. When control
24.1±1.8, 2DG: 28.2±1.9, 3BP: 25.8±2.2%, p>0.05). In contrast, applying these two
glycolytic inhibitors simultaneously with 6-OHDA on pUL37x1 over-expressing cells
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caused significant attenuation of protection (pUL37x1: 11.7±1.2, pUL37x1+2DG:
17.8±1.3, pUL37x1+3BP: 18.0±1.6%, p<0.01 in both conditions)(Figure 4-22).
In conclusion, mitochondrial hyperpolarization is another anti-apoptotic
mechanism of pUL37x1. This phenomenon results from increasing glycolysis and
disappears in the presence of glycolytic inhibitors. Without hyperpolarization, the
protection against 6-OHDA cytotoxicity is lessened. These findings demonstrate
that the protection and anti-apoptotic effects of pUL37x1 were glycolysis-
dependent.
Figure 4-22
p<0.01 respectively, n=6). Data were presented as mean±S.E.M. Statistics was performed
by one-ANOVA with Dunnett’s post-hoc analysis. The n number represented the
experimental repeat from each pUL37x1 over-expressing lines and control (include normal
SH-SY5Y cells, over-expressing dsRed-mito SH-SY5Y cells and over-expressing pcDNA Zero
SH-SY5Y cells)(**, p<0.01 ).
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4.6 pUL37x1 Over-expression Did Not Alter Glycolytic Enzymes
Expression
It remains unclear how pUL37x1 up-regulates glycolysis. Increased expression of
key glycolytic enzymes in host cells have been noted during CMV infection.
However, there is no significant difference in these protein expression levels
between control and pUL37x1 over-expressing cells (representative western blot
analysis: Figure 4-23, densitometry analysis: Figure 4-24). pUL37x1 may, therefore,
regulate glucose metabolism in other ways, such as the cellular glucose uptake or
some post-translational modification of these enzymes.
Figure 4-23
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Figure 4-24
Figure 4-23 and 4-24. Representative western blot and densitometry analysis revealed that
pUL37x1 over-expression did not alter the protein level of certain key glycolytic enzymes,
including hexokinase 1 (HK1), hexokinase 2 (HK2), phosphofructokinase, platelet (PFKP) and
pyruvate kinase isozymes M1/M2 (PKM1/2) on SH-SY5Y cells. The expression level was
presented as mean±S.E.M. Statistics was performed by two-tailed Student’s t- test. . The n
number represented the experimental repeat from each pUL37x1 over-expressing lines and
control (include normal SH-SY5Y cells, over-expressing dsRed-mito SH-SY5Y cells and over-
expressing pcDNA Zero SH-SY5Y cells).
4.7 pUL37x1 Over-expression Protected Apoptosis and Neuronal
Death in Rat Primary Cortical Culture
Since pUL37x1 over-expression successfully demonstrated protection against
toxin-induced apoptosis and cell death in the SH-SY5Y cell model. Next, primary rat
cortical culture was utilized to further test the protection conferred by pUL37x1
over-expression. Liposomal transfecting reagent mixed with control red
fluorescence protein (RFP) plasmid, a kind gift from Dr Guillaume Charras in London
Centre for Nanotechnology, or a mixture of pUL37x1 and RFP plasmids at 10 to 1
ratio were co-incubated with culturing media for 48 hours. In control groups, cells
with red fluorescence were recognized as RFP over-expressing cells. In pUL37x1
PKM1/2
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group, cells with red fluorescence were assumed to over-expressing both pUL37x1
and RFP because of the 10 times difference of the plasmid, which indicates that the
cells expressed RFP have a very high possibility of over-expressing pUL37x1 as well.
The percentage of successful transfection was about 5% and the transfection
reagent did not cause significant cell death (Fig 4-25).
Figure 4-25
Figure 4-25. Mixture of pUL37x1 plasmid and red fluorescence protein (RFP) plasmid at 10
to 1 ratio was incubated with Lipofetamine®2000 and transfected to E18 primary rat
cortical culture. The transfection efficiency was checked three days after transfection and
the average efficiency was 5%. In the representative figure, red fluorescence demonstrated
successful RFP expression while blue was DAPI, a nucleus stain. Image was obtained from
epi-fluorescent microscope.
4.7.1 pUL37x1 Over-expression Reduced 6-OHDA Induced Apoptosis in
Primary Rat Cortical Culture
The anti-apoptotic effect of pUL37x1 over-expression on primary rat cortical
culture was similar to SH-SY5Y cells presented in section 4.3. Apoptosis was
detected by the antibody against cleaved caspase-3, which is the activated form of
caspase-3. Without 6-OHDA treatment, pUL37x1 over-expression did not increased
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apoptosis compared with RFP over-expressing cells (RFP: 7.8±1.3, pUL37x1: 5.7±2.4,
p
expression significantly reduced the percentage of apoptotic cells (RFP: 21.8±1.6,
pUL37x1: 13.3±2.1, p<0.05) (Figure 4-26). These data provide the evidence that, like
the SH-SY5Y cell model, pUL37x1 over-expression protected 6-OHDA induced
apoptosis in the rat primary cortical culture model.
Figure 4-26
Figure 4-26. pUL37x1 expression in primary rat cortical culture cells significantly reduced
compared with RFP expressing ones (21.8±1.6% in RFP-control versus 13.3±2.1% in
pUL37x1 over-expression, p<0.05, n=6). Data were presented as mean±S.E.M. Statistics was
performed by two-tailed Student’s t- test. (NS, non-significant, *,p<0.05 )
4.7.2 pUL37x1 Over-expression Reduced Neuron-specific Death Induced
by 6-OHDA in Primary Rat Cortical Culture
The main outcome of neuroprotection is evaluated by the ability of the
intervention to decrease the neuronal death against toxin. Fluoro-jade C, a specific
marker for degenerative neurons, is a good tool to investigate the protection. In
primary rat cortical culture, pUL37x1 over-expression presented a similar trend of
*
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protection to SH-SY5Y cells model. Without 6-OHDA treatment, over-expressing the
viral protein did not increase neuronal death compared with RFP over-expression
cells (RFP over-expression: 6.6±1.3, pUL37x1 over-expression: 9.9±0.5%, p<0.05).
expression significantly reduced the neuronal death labelled by FJ-C compared with
RFP over-expression (RFP over-expression: 25.3±1.9, pUL37x1 over-expression:
17.4±2.7%, p<0.05) (Fig 4-27).
In conclusion, pUL37x1 over-expression reduced 6-OHDA induced apoptosis and
neuronal death in rat primary cortical culture. These results strengthed the notion
that modulation of mitochondria-dependent apoptosis could be neuroprotective in
Parkinson’s disease.
Figure 4-27
Figure 4-27 pUL37x1 expression in primary rat cortical culture cells significantly reduced
compared with RFP expressing ones (25.3±1.9% in RFP-control versus 17.4±2.7% in
pUL37x1 over-expression, p<0.05, n=6). Also, pUL37x1 over-expression did not significantly
increase the cell death without 6-OHDA (RFP over-expression: 6.6±1.3, pUL37x1 over-
N.S.
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expression: 9.9±0.5%, n=4, p>0.05). Data were presented as mean±S.E.M. Statistics was
performed by two-tailed Student’s t- test. (NS, non-significant, *,p<0.05 )
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5 Discussion-Meclizine
5.1 Summary of Results of Meclizine
The present study demonstrated that meclizine, a glycolysis-enhancing agent,
protected neuronal cells from 6-OHDA induced cytotoxicity. Meclizine exhibited cell
death protection against 6-OHDA on both SH-SY5Y and primary rat cortical culture
cells. The mechanism by which meclizine down-regulated 6-OHDA induced
apoptosis involved mitochondrial hyperpolarization but not ROS scavenging.
Meclizine prevented 6-OHDA induced mitochondrial depolarization, which is one of
the key steps in apoptosis. This protective phenomenon was the same in both SH-
SY5Y and primary rat cortical culture cells. Meclizine induced mitochondrial
hyperpolarization resulted from glycolysis enhancement: co-administering
glycolytic inhibitors with meclizine attenuated the hyperpolarization and cell death
protection. However, it was unclear how meclizine increased glycolysis as it did not
increase the protein level of several key glycolytic enzymes.
5.2 Meclizine Increased Glycolysis
Gohil et al were the first to report that meclizine skewed the balance of cellular
glucose metabolism between OXPHOS and glycolysis and favoured the later. This
effect was noted in several types of cell, including transformed cell lines and
neuronal cells(Gohil et al., 2010). The present study utilized an XF analyser to detect
the acidification of medium due to lactate synthesis, the end-product of glycolysis.
It revealed that meclizine was able to increase the acidification in SH-SY5Y, a
transformed neuroblastoma cell line. The increase of acidification lessened when
co-applying glycolytic inhibitors. These results suggested that the acidification was
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glycolysis-dependent and meclizine enhanced glycolysis as seen in the other types
of cell. It is unlikely that measuring ECAR would truly reflect the glycolysis of
neurons because of the mixed culture characteristics of primary rat cortical cultures.
However, this report demonstrated that meclizine hyperpolarized mitochondria in
primary rat cortical culture like SH-SY5Y cells, which indicated a glycolysis-
enhancing ability of meclizine on primary neurons.
Traditionally, it is believed that neurons in the central nervous system dominantly
rely on OXPHOS for ATP generation because 20% of oxygen consumption takes
place in the brain which accounts for only 2% of body weight. Under conditions of
mitochondrial inhibition, glycolysis is the main ATP source of neurons (Bauernfeind
et al., 2013; Bolanos et al., 2010). It has also been postulated that, when OXPHOS is
compromised, neurons are not able to up-regulate glycolysis sufficiently to meet
the ATP demand, which results in a deficit of ATP, collapse of mitochondrial
membrane potential and cell death (Almeida et al., 2001). However, Zala et al
identified that the energy source for vesicle transport in axonal regions is
independent from mitochondria and inhibition of mitochondrial ATP production
does not significantly affect the transport. Moreover, inhibition or reduction of the
key glycolytic enzyme, GAPDH blocks this transport (Zala et al., 2013). In addition,
neurons are actually able to up-regulate glycolysis by either reduction of glycolytic
enzyme degradation(Herrero-Mendez et al., 2009) or chemicals(Gohil et al., 2010).
These findings indicate that glycolysis is essential for neuronal energy demand and
neurons exhibit certain glycolytic reserves which can be up-regulated under stress
conditions.
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Glycolysis is often recognized as a less efficient method of ATP generation.
Nevertheless, the rapid reactive rate of glycolysis compensates for the low-yield
and enables the energy requirement to be met (Pfeiffer et al., 2001). In the present
study, meclizine treatment alone did not increase apoptosis and cell death in
primary rat cortical culture cells, which also supported the notion that shifting
glucose metabolism from OXPHOS to glycolysis does not stress the neurons.
shunts pyruvates to lactate instead of allowing them to enter mitochondria was a
cells treated with meclizine was found in a previous report(Gohil et al., 2010). The
present study investigated the level of several key glycolytic enzymes following
meclizine treatment, but failed to find any significant difference. There is a
possibility that the increase of glycolysis was secondary to down-regulation of
OXPHOS. Meclizine has been reported to inhibit phosphate cytidylyltransferase 2,
ethanolamine (PCYT2) and lead to rapid accumulation of its substrate,
phosphoethanolamine, which was itself an inhibitor of OXPHOS (Gohil et al., 2013).
5.3 Meclizine Hyperpolarized Mitochondria
Mitochondrial membrane potential is generated by the excretion of protons from
the matrix to the intermembrane space. This electrical gradient is involved in
several aspects of mitochondrial physiology, including ATP synthesis, calcium
homeostasis and mitochondrial fusion/fission balance(Nicholls, 2004; Ishihara et al.,
2003). Depolarization of mitochondria, a dysfunctional condition, is common in
aging and Parkinson’s disease(Nicholls, 2004; Abou-Sleiman et al., 2006). In addition,
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dissipation of membrane potential is strongly associated with apoptosis. Loss of
potential induces MMP and leads to initiation of the intrinsic pathway of apoptosis
(Bernardi et al., 1999; Ly et al., 2003; Nicholls, 2004). Also, the maintenance of
cytochrome c in the intermembrane space relies on this negative charged potential
across the mitochondrial inner membrane. During apoptosis, depolarization of
mitochondria and the subsequent remodelling of the mitochondrial matrix
promotes the release of cytochrome c (Gottlieb et al., 2003; Uren et al., 2005).
That mitochondrial hyperpolarization prevents depolarization and apoptosis
reveals a potential neuroprotective mechanism of meclizine. Physiologically, the
potential difference is expended by the re-entrance of protons to convert ADP to
ATP at complex V. Inhibition of complex V by oligomycin, without inhibiting the
respiratory chain, blocks the proton re-entrance and strengthens the polarization
across the mitochondrial intermembrane (Gottlieb et al., 2003; Otero and Carrasco,
1984). However, oligomycin reduces ATP synthesis from complex V and triggers
apoptosis instead of protection(Li et al., 2004; Wolvetang et al., 1994; He et al.,
2013). Another mechanism by which mitochondria can become hyperpolarized is
to reverse the proton trafficking through complex V. When the intracellular ATP is
sufficient, complex V consumes ATP to pump protons out rather than in(Iijima,
2006). The main source of extra-mitochondrial ATP generation is glycolysis. It is
believed that cancer cells generate ATP predominantly from glycolysis even in
oxygen abundant conditions, which is defined as the Warburg effect(Warburg,
1956). Owing to this alteration of glucose metabolism, cancer cells usually contain
hyperpolarized mitochondria and are less sensitive to apoptosis(Bonnet et al., 2007;
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Heerdt et al., 2005; Lugli et al., 2005). In contrast to complex V inhibition,
mitochondrial hyperpolarization resulting from increased glycolysis would not lead
to ATP deficit and cell death.
In the present study, meclizine has been proven to increase glycolysis in SH-SY5Y
cells and, as a consequence, cause mitochondrial hyperpolarization. This effect was
glycolysis-dependent rather than due to complex V inhibition: while co-
administering glycolytic inhibitors with meclizine, both glycolysis enhancement and
mitochondrial hyperpolarization were not seen. Meclizine also led to a similar effect
in rat primary cortical culture cells: meclizine-treated primary cells exhibited
hyperpolarization of the mitochondrial membrane potential compared with control.
This hyperpolarization phenomenon was the source of the cell death protection
seen with meclizine treatment. CCCP, an uncoupler which affects the proton motive
force, causes toxicity via the depolarization of mitochondria and initiation of
apoptosis (Korlipara et al., 2004). The present study demonstrated that meclizine
was not able to maintain mitochondrial membrane potential upon CCCP treatment
and failed to protect against the cytotoxicity of CCCP compared with control. This
indicated that the protection of meclizine was mitochondrial hyperpolarization-
dependent.
5.4 Meclizine Reduced Apoptosis Induced by 6-OHDA
6-OHDA is a toxic oxidative metabolite of dopamine and the toxicity of 6-OHDA
results from oxidative damage, including DNA damage, mitochondrial inhibition,
and lipid peroxidation, which results in apoptotic cell death. In the SH-SY5Y model,
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6-OHDA treatment causes reduction of glutathione, ATP depletion, mitochondrial
cytochrome c release and activation of caspase(Gomez-Lazaro et al., 2008;
Tirmenstein et al., 2005).
However, meclizine did not prevented 6-OHDA induced oxidative stress. In both
non-treated and 6-OHDA treated cells, meclizine did not preserve aconitase activity,
a parameter of oxidative damage due to its sensitivity to ROS. It has been
postulated that aerobic glycolysis and down-regulation of OXPHOS reduces ROS
generation(Brand and Hermfisse, 1997). However, Bolanõs et al argue that the
increase of glycolysis flux leads to the down-regulation of the pentose phosphate
pathway and, as a consequence, fewer endogenous anti-oxidants and reduced
glutathione generation(Bolanos et al., 2010). As glycolysis-enhancement might
exhibit both positive and negative impacts on cellular ROS level, it is not surprising
that, in the present study, meclizine did not lessen the oxidative damage from 6-
OHDA.
Mitochondrial depolarization is a universal and early phenomenon of 6-OHDA
induced apoptosis (Tirmenstein et al., 2005; Lopes et al., 2010; Tovilovic et al., 2013)
and numerous neuroprotective agents prevent this dissipation of mitochondrial
membrane potential (Meng et al., 2013; Zhang et al., 2012; Huang et al., 2010). The
aforementioned meclizine-induced mitochondrial hyperpolarization accounted for
the protection against 6-OHDA induced apoptosis. Cells treated with meclizine
retained normo-polarized mitochondria under 6-OHDA treatment, compared with
30% loss of mitochondrial membrane potential in control cells facing 6-OHDA
challenging. Maintaining the pressure gradient upon apoptotic stimuli prevented
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the increase of intracellular calcium, released due to the permeabilization of the
mitochondrial membrane, and avoided the resulting mitochondrial cytochrome c
release, which leads to amplification of the apoptotic signal and the ‘point-of-no-
return’ in apoptotic cell death.
Activated caspase-3, the executor caspase, causes apoptosis and cell death.
Meclizine did not directly inhibit the activation of caspase-3: in the absence of 6-
OHDA, there was no change of caspase-3 activity in meclizine-treated cells
compared with control. However, in 6-OHDA treated cells, meclizine modulated the
apoptosis by mitochondrial hyperpolarization and blocked the process of apoptosis
induced by 6-OHDA, which resulted in less caspase-3 activation in both SH-SY5Y and
primary rat cortical cell cultures. The lowering the activation of caspase-3 by
meclizine supported the hypothesis of its modulation of mitochondria-dependent
apoptosis by glycolysis enhancement.
5.5 Meclizine Protected Cell Death from 6-OHDA
The ultimate goal of the present study was to test the protection by meclizine
against cell death. Meclizine demonstrated neuroprotection against 6-OHDA
induced cell death on SH-SY5Y and primary rat cortical culture cells and this
reduction was glycolysis-dependent: glycolytic inhibitors, which resulted in less
lactate synthesis, attenuated the protection.
It is worth mentioning the significance of loss of neurons, especially nigral
dopaminergic neurons, in Parkinson’s disease. Degeneration of more than half of
the nigral dopaminergic neurons is thought to lead to the manifestation of the early
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motor symptoms of Parkinson’s disease(Marsden, 1990). L-dopa treatment is
effective at the beginning of disease, because the remaining dopaminergic neurons
are able to convert the L-dopa to dopamine and buffer the sudden change of
dopamine levels in the synapse. However, the progression of neuronal loss results
in a reduction in this buffering, which causes the drug-related motor complications
associated with long-term treatment(Obeso et al., 2000). 6-OHDA, a widely-used
toxin in Parkinson’s disease models, also induces neuronal death in vivo and in
vitro(Drechsel and Patel, 2008). The present study successfully demonstrated a
protective effect of meclizine against 6-OHDA induced cell death. This protection
was not only shown on SH-SY5Y, a transformed neuroblastoma cell line, but also on
primary rat cortical culture cells. Primary cells, unlike transformed cell line, are
generally more vulnerable to toxin-induced cell death and more difficult to protect.
The protective effect of meclizine obtained from primary rat cortical culture
supported the hypothesis that modulation of mitochondria-dependent apoptosis
may be neuroprotective in Parkinson’s disease. In addition, by using FJ-C, a specific
fluorescent neuronal degeneration marker, it was possible to identify the dead
neurons only and overcome the issues associated with using a mixed culture like
rat primary cortical cultures. The observation that fewer neurons were stained by
FJ-C when they were challenged by 6-OHDA in the presence of meclizine is
evidence of neuroprotection.
It is still important to measure cell death protection after confirmation of anti-
apoptotic effect. In theory, cell death follows two major pathways: apoptosis and
necrosis. In contrast to apoptosis, necrosis presents with different features, such as
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cellular swelling leading to bursting of the plasma membrane and release of the
cytosolic contents to the surrounding tissue, which causes an inflammatory
response (Golstein and Kroemer, 2007). There is a balance between these two
distinct mechanisms of cell death and on some occasions, down-regulation of
apoptosis can promote necrosis. Kalai and colleagues have demonstrated that
caspase inhibition or over-expression of Bcl-2 prevents apoptosis but promotes
necrosis(Kalai et al., 2002). Meilhac et al also showed that over-expression Bcl-2
triggers necrosis and does not protect against cell death induced by oxidized low
density lipoproteins(Meilhac et al., 1999). Fortunately, meclizine down-regulated
apoptosis but is unlikely to affect the levels of necrosis: the anti-apoptosis effect
was in line with the reduction of cell death induced by 6-OHDA.
5.6 Implications of Neuroprotection by Meclizine
The present study demonstrated the neuroprotective effect of meclizine in
Parkinson’s disease cell models. It revealed that increased glycolysis protected the
neurons from 6-OHDA induced cytotoxicity. Although some articles have previously
described the neuroprotective benefit of glycolysis (Newington et al., 2011;
Newington et al., 2012; Williams et al., 2007), this alternative ATP synthesis
pathway receives little attention in the field of neuroprotection. However, it has
long been suggested that cancer cells, which are very resistant to apoptosis and cell
death, exhibit very high glycolytic activity. The alteration of glucose metabolism is
thought to be responsible for this resistance and, therefore, glycolytic inhibition
results in the sensitization of chemotherapy and apoptosis(Loar et al., 2010; Vuyyuri
et al., 2013). For this reason increased glycolysis should not be ignored as a
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neuroprotective approach for Parkinson’s disease, an apoptosis-related
degenerative disease.
Another implication of the present study is the protective role of mitochondrial
hyperpolarization. Despite some evidence suggesting that mitochondrial
depolarization is not a mandatory process during apoptosis (Ly et al., 2003; Scarlett
et al., 2000), hyperpolarization of mitochondria by meclizine was proved to be an
anti-apoptotic approach in Parkinson’s disease models. Physiologically, astrocytes
and myocytes are able to up-regulate glycolysis in order to maintain mitochondrial
membrane potential and resist apoptosis, whereas neurons are more sensitive to
respiratory inhibition or mitochondrial dysfunction as they lack this glycolysis-
enhancement ability (Almeida et al., 2001; Yao et al., 2011). However, meclizine
enhanced glycolysis in neurons and helped to maintain mitochondrial membrane
potential upon exposure to 6-OHDA, which was a protective strategy for the
pathogenesis of Parkinson’s disease, a mitochondrial dysfunction-associated
disease.
The major advantage of meclizine is that it has been prescribed to patients for
decades and has a good safety and tolerability profile. Meclizine can be applied to
either genetic or toxin-induced Parkinson’s disease animal models directly after
confirmation of neuroprotection in vitro. In fact, meclizine has been shown to
reduce the volume of infarction in rat stroke model, and to prevent neuronal
dystrophy and cell death in Caenorhabditis elegans and Drosophila melanogaster
models of polyglutamine toxicity(Gohil et al., 2010; Gohil et al., 2011). It is
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therefore hoped that meclizine will reduce the nigral dopaminergic neuronal loss
and lessen the parkinsonism symptoms in experimental animals.
5.7 Limitations and Future Work on Meclizine
Despite the promising results, the present study exhibited some limitations about
the use of meclizine. High doses of meclizine increased the spontaneous cell death
in both SH-SY5Y and primary rat cortical culture cells. This toxicity might have
resulted from the over-activation of glycolysis which compromised the pentose
phosphate pathway and reduced the synthesis of glutathione, an endogenous anti-
oxidant. Similar conditions have been mentioned by Herrero-Mendez et al, who
claimed that moderate 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
isoform 3 over-expression is protective whereas higher expression levels leads to
rapid death of the neurons by apoptosis(Herrero-Mendez et al., 2009). In future
studies testing meclizine for neuroprotection in animal studies or clinical trials, an
optimal dose which avoids this toxicity needs to be identified first.
The other problem identified is clarification of the mechanism by which meclizine
increases glycolysis. Although the protein level of glycolytic enzymes did not alter in
the present study, some post-translational modifications of the enzymes, which
could affect the glycolytic activity without changing the gross protein level, could
occur and thus required further investigation(Smerc et al., 2011; Mathupala et al.,
modulate glucose metabolism. For instance, activation of receptor tyrosine
kinase/PI3K/AKT/mammalian target of rapamycin signalling cascade could induce
aerobic glycolysis through up-regulation of pyruvate kinase M2 and other glycolytic
173
enzymes(Sun et al., 2011). Therefore, it is worth investigating these glycolytic
profiles to elucidate the full mechanism of glucose metabolism alteration by
mecilizine.
It is essential to mention about the drawbacks of using toxin-induced model in the
research of Parkinson’s disease. A major problem with the classic toxin-induced
models is that they reproduce parkinsonism but not always Parkinson’s disease, a
neurodegenerative disease with the presence of Lewy body inclusion in peripheral
and central nervous system. 6-OHDA and MPTP fail to induce the synuclein
aggregation and Lewy body whereas intravenous rotenone infusion in rat led to the
cytoplasmic inclusion(Beal, 2010). Menwhile, the acute insult from toxin, for
example, 6-OHDA, unliken the slowly progressive characteristic of Parkinson’s
disease. For 6-OHDA, the other problem is the administration. Striatal injection of
6-OHDA induces degeneration of nigral dopaminergic neurons but fail to produce a
widespread neuronal degeneration which had been noted in Parkinson’s
disease(Braak et al., 2003a).
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6 Discussion-pUL37x1
6.1 Summary of Results of pUL37x1
The present study demonstrated the neuroprotective effect of pUL37x1 over-
expression against staurosporine and 6-OHDA-induced apoptosis and cell death in
both SH-SY5Y and primary rat cortical cultured cells. pUL37x1 provided two
different neuroprotective strategies simultaneously, both of which modulated
mitochondria-dependent apoptosis. The first one was Bax-dependent. pUL37x1,
located on mitochondrial outer membrane, led to mitochondrial translocalization
and inactivation of Bax. Silencing of Bax in control cells reduced the staurosporine-
induced cell death but failed to provide further protection on pUL37x1 over-
expressing cells. The other strategy was to hyperpolarize mitochondria by increased
glycolysis. pUL37x1 over-expression increased glycolysis which led to
hyperpolarized mitochondria and blocked 6-OHDA induced depolarization and
further apoptotic processes. Mitochondrial hyperpolarization and cell death
protection was attenuated or lost if glycolytic inhibitors were co-administered.
These results support the concept that controlling mitochondria-dependent
apoptosis is neuroprotective in Parkinson’s disease.
6.2 The pUL37x1 Over-expressing Lines
pUL37x1 is a protein from human CMV. To the best of my knowledge, there is no
endogenous pUL37x1 found in humans. In order to investigate the protection of
over-expressing pUL37x1 in SH-SY5Y cells, stable pUL37x1 expressing lines were
required. Stable expressing lines were defined as the cell’s genome with foreign
gene integration and daughter cells of the transfected cell also expressed the new
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gene. The advantages of using stable expression instead of transient transfection
include long-term gene expression, consistency and the option of further genetic
manipulation(Sparkes et al., 2006). After antibiotic selection and pUL37x1-HA
expression confirmation by western blot analysis, several colonies were identified
as stable over-expressing lines. However, because of the nature of random genome
integration, some colonies could alter basal cellular protein expression. Choosing
three lines instead of one eliminates the impact of possible cloning artefacts.
As there was no reliable anti-pUL37x1 antibody available commercially, an HA-tag
was conjugated to the C-terminus of pUL37x1 in the transfection construct for
detection purposes. In the present study, anti-HA antibody detected pUL37x1-HA
bands from the stable over-expressing lines at 60kD by western blot analysis.
Densitometry analysis revealed that the three lines expressed different levels of
pUL37x1, and the difference between maximum with minimum was nearly one fold
change. However, in the following experiments, there was no significant difference
between three lines in cell death protection, anti-apoptosis and other effects. This
lack of difference was probably because even the lowest expression level of
pUL37x1 was above the effective dosage.
The confirmation of over-expression purity relied on an immunocytochemistry
assay even though the pUL37x1 over-expressing lines had gone through antibiotic
selection and protein expression, had been confirmed. It is essential to establish
this purity because following experiments measured gross cellular outcomes, such
as cell death, apoptosis and expression level of significant proteins. These results
would be unreliable if the cells exhibited a pronounced variation in their over-
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expression. However, all three lines presented a homogenous pUL37X1-HA
expression. Immunocytochemistry results also confirmed the mitochondrial
localization of pUL37x1 in SH-SY5Y cells. Goldmacher et al noted the mitochondrial
localization of pUL37x1 in transfected HeLa cells(Goldmacher et al., 1999) and the
first domain of pUL37x1 has been identified as responsible for mitochondria
targeting and localization(Hayajneh et al., 2001). This similarity indicates that in
present study, pUL37x1 in SH-SY5Y cells behaved in the same manner as previous
results obtained from other cell types.
As well as normal SH-SY5Y cells, two other stable over-expressing cell lines were
also used as controls. The reason for including another two stable over-expressing
controls was to mimic the condition in pUL37x1 over-expressing lines. The first of
these control cell lines stably over-expressed dsRed-Mito, a mitochondrial-localized
fluorescent protein without altering mitochondrial function. It resembles the
mitochondria-localized characteristic of pUL37x1. The other one was a stable
pcDNA empty vector over-expressing line, which was the same plasmid that carried
pUL37x1 genes during transfection.
6.3 pUL37x1 Over-expression Reduced Drug Induced Apoptosis and
Cell Death
The anti-apoptotic property of pUL37x1 has been mentioned in the introduction
(section 1.7.2). In this study, two apoptosis inducers were used to test the
protective effect of pUL37x1 over-expression. 6-OHDA has been described in
section 5.4. The other toxin was staurosporine, a protein kinase C inhibitor which is
isolated from the culture broth of Streptomyces staurospores. Staurosporine
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activates Bax and triggers both caspase-dependent and independent apoptotic
pathways (Zhang et al., 2004; Belmokhtar et al., 2001). Staurosporine-challenge
tests the anti-apoptotic effect of pUL37x1 in neuronal cells, whereas 6-OHDA
provides a neurodegenerative model to investigate the neuroprotection.
The release of cytochrome c from mitochondria to cytoplasm results from MMP.
Cytoplasmic cytochrome c interacts with Apaf-1 protein to form an apoptosome
and activates caspase. Hence, both the release of cytochrome c and the activation
of caspase, especially caspase-3, are the hallmarks of apoptosis processing. Down-
regulating MMP reduces mitochondrial cytochrome c release upon apoptotic
stimuli and down-regulates the following caspase activation related cell death (Yang
et al., 1997; Koya et al., 2000). pUL37x1 over-expressing SH-SY5Y cells reduced the
release of cytochrome c and activation of caspase-3 upon staurosporine treatment
compared with control. Also, pUL37x1 down-regulated casapse-3 activation in both
SH-SY5Y and primary rat cortical cultured cells. These results support the
hypothesis that pUL37x1 is anti-apoptotic in neuronal cells and neuroprotective in
Parkinson’s disease cellular models.
The next crucial question is whether pUL37x1 over-expression provides protection
of neuronal death. The significance of neuronal death in Parkinson’s disease and
the possible discrepancy between apoptosis and cell death has been mentioned in
section 5.5. Not surprisingly, pUL37x1 provided an anti-apoptotic effect to prevent
cell death against staurosporine and 6-OHDA. In SH-SY5Y cells, the protection
presented under several different conditions, including high dose, short-term toxin
treatment and moderate dose, long-term toxin treatment. In rat primary cortical
178
culture cells, pUL37x1 transfection protected neurons from 6-OHDA induced death.
This evidence of anti-apoptosis and cell death protection from pUL37x1 over-
expression supports the original hypothesis.
6.4 pUL37x1 Over-expression Modulated Bax-related Apoptosis
The involvement of Bax in apoptosis has been describe in section 1.4.1.2. In brief,
activated BH3- only proteins induce Bax oligomerazation and mitochondria-
translocalization of Bax. The Bax oligomers insert into the mitochondrial outer
membrane and lead to MMP. Bax also plays a role in apoptosis in Parkinson’s
disease. Tatton el al found that a greater number of Bax-immunopositive cells are
observed in Parkinson’s disease nigral sections compared to aged, control nigral
sections(Tatton, 2000). Hartmann and colleagues also demonstrated that in
Parkinson's disease brains the percentage of Bax-positive melanized nigral neurons
containing Lewy bodies is significantly higher than the overall percentage of Bax-
positive neurons among melanized neurons(Hartmann et al., 2001a). Also, parkin
modulates the ubiquitination of Bax and prevents basal and apoptotic stress-
induced translocation of Bax to the mitochondria(Johnson et al., 2012).
Inactivation of Bax has been found to down-regulate apoptosis. Nicotine enhances
the Ser184 phosphorylation of Bax by Akt and results in the failure of activation and
mitochondria-translocalization of Bax (Gardai et al., 2004; Xin and Deng, 2005).
pUL37x1 is known to cause the mitochondria-translocalization of Bax, which also
takes place during apoptosis. However, this translocalization leads to a
conformational change and inactivation of Bax, as mentioned in section 1.7.2. In
the present study, pUL37x1 over-expression led to mitochondria-translocalization
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of Bax in the absence of toxin. This translocalization was shown to not result in
apoptosis because there was no increase of cytochrome c release or caspase-3
activation under these conditions. This indicated that in stable pUL37x1 over-
expressing SH-SY5Y cells, the ectopic expressing protein induced Bax
translocalization to mitochondria without the initiation of apoptosis, which is in
accordance with previous studies.
Bax siRNA silencing provides a way to investigate the Bax-dependent protection of
pUL37x1 over-expression. Bax ablation has been demonstrated to have an anti-
apoptotic and neuroprotective effect. Vila et al show that Bax deficient mutant
mice were resistant to MPTP neurotoxicity (Vila et al., 2001). In the present study,
Bax siRNA silencing for 3 days caused 80% reduction of Bax protein levels,
compared with Scr siRNA, in both control and pUL37x1 over-expressing cells. The
control group benefitted from cell death protection against staurosporine with Bax
siRNA silencing, whereas pUL37x1 over-expressing cells did not. This suggested that
the strength of Bax inactivation by pUL37x1 over-expression was equal to the
ablation of four-fifths of the intracellular Bax. In addition, the protection of
pUL37x1 was shown to be Bax-dependent. Combining these two pieces of data, it
can be concluded that, in neuronal cells, pUL37x1 over-expression translocalizes
and inactivates Bax on the mitochondrial outer membrane, and this is the
mechanism responsible for the anti-apoptotic effect.
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6.5 pUL37x1 Over-expression Modulated Apoptosis by Glycolysis-
Induced Mitochondrial Hyperpolarization
CMV infection alters cellular metabolism in host cells. Munger et al found that the
levels of metabolites involved in glycolysis, the citric acid cycle, and pyrimidine
nucleotide biosynthesis markedly increased after CMV infection measuring by liquid
chromatography-tandem mass spectrometry (Munger et al., 2006). Later, the same
group also demonstrated the increase of glycolytic flux during CMV infection
(Munger et al., 2008). These findings indicated that CMV infection is associated
with up-regulation of glycolysis. The present study showed that pUL37x1 over-
expression markedly up-regulated glycolysis. This increase did not result from
inhibition of OXPHOS: there was no impairment of either oxygen consumption rate
or ADP phosphorylation activity from pUL37x1 over-expressing cells. In fact, the
glycolysis-enhancement effect led to the hyperpolarization of the mitochondrial
membrane potential and prevented 6-OHDA induced mitochondrial depolarization.
Glycolytic inhibitors attenuated the hyperpolarization and cell death prevention
provided by pUL37x1 over-expression, which indicated that part of the protection
of pUL37x1 was glycolysis-dependent. It is a novel finding that pUL37x1 controlled
mitochondria-dependent apoptosis not only relies on the well-known Bax
inactivation, but also mitochondrial hyperpolarization. That pUL37x1 can present
two different approaches to MMP modulation during apoptotic stimuli could be
particularly relevant to neuroprotection.
However, the present study failed to identify the mechanism by which pUL37x1
increased glycolysis. There was no alteration in the protein levels of several
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essential glycolytic enzymes. There remains the possibility that pUL37x1 over-
expression does not directly up-regulate glycolysis, but acts through another signal
transduction pathway. For instance, CMV infection increases glycolysis by activation
of calmodulin-dependent kinase kinase (CaMKK) and, inhibition of CaMKK severely
attenuates production of viral progeny and blocked viral DNA replication(McArdle
et al., 2011). CaMKK up-regulates glycolysis through activation of either CaM kinase
I or AMP-activated kinase to phosphorylate phosphfructokinase-2, a key rate-
determine enzyme of glycolysis ( reviewed by (Rider et al., 2004; Towler and Hardie,
2007). Increased intracellular calcium is able to activate CaMKK and it has been
shown that pUL37x1 can cause the release of Ca2+ from the endoplasmic reticulum
into the cytosol (Sharon-Friling et al., 2006). This association leads to the
speculation that pUL37x1 over-expression could increase glycolysis through a
calcium and CaMKK-dependent pathway, a hypothesis supported by the results
from the present study where pUL37x1 over-expression increased glycolysis
without changing the protein level of glycolytic enzymes.
6.6 Implications on Neuroprotection of pUL37x1
The encouraging results of neuroprotection by pUL37x1 over-expression suggests
that modulating mitochondria-dependent apoptosis is a promising approach to
prevent nigral dopaminergic neuronal loss in Parkinson’s disease. Moreover,
pUL37x1 provides more than one anti-apoptotic mechanisms to confer
neuroprotection. As described in the section 1.5.1, MMP can be manipulated by
several factors. pUL37x1 is superior to other agents in the modulation apoptosis
because of its dual anti-apoptotic effect: Bax inactivation and mitochondrial
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hyperpolarization by glycolysis. It has similarities to the concept of ‘cocktail’ therapy,
which has been widely used in the treatment of cancer, autoimmune diseases and
human immunodeficiency virus infection. The idea of cocktail therapy in
neuroprotection of Parkinson’s disease has been raised due to the multi-factorial
characteristic of the disease pathogenesis (Hirsch, 2007). With two protective
mechanisms, one can compensate for the other’s drawbacks. For instance, pUL37x1
is able to inhibit Bax-related apoptosis but not Bak, the other pro-apoptotic Bcl-2
family protein (Arnoult et al., 2004). Mitochondrial hyperpolarization boosted by
glycolysis covers this deficit due to its more general effect on modulating
mitochondria-dependent apoptosis. In addition, this strategy would be able to
reduce the toxicity and side effects from a high dose-single approach.
Furthermore, the present study is one of the first to test the neuroprotective
effects of viral anti-apoptosis products. Numerous anti-apoptotic strategies have
been noted from viruses that allow them to escape apoptosis by the host cell
(reviewed by (Benedict et al., 2002), and utilizing a safe viral protein to prevent
apoptosis-related neurodegeneration provided may provide opportunities for
researchers to achieve the goal of neuroprotection in the future.
6.7 Limitations and Future work of pUL37x1
Despite the promising results of neuroprotection by pUL37x1, there are still some
limitations with the present study. The first issue is the use of 6-OHDA to induce
neuronal apoptosis and death as the use of toxin-induced models in Parkinson’s
disease is still of uncertain relevance . 6-OHDA increases oxidative stress and local
injection of 6-OHDA in substantia nigra causes loss of dopaminergic neurons.
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However, it fails to produce the core pathological feature of Parkinson’s disease,
Lewy body formation, in experimental animals and this raises the question as to
whether the 6-OHDA model is able to reflect the real pathogenesis of Parkinson’s
disease. Genetic Parkinson’s disease models provide an alternative. However, they
also trigger debate because genetic mutations account for less than 10% of the
etiology of Parkinson’s disease. Moreover, some mutation models do not lead to
Lewy body formation or progressive loss of nigrostriatal dopaminergic
neurons(review by (Chesselet et al., 2008).
Another issue with the present study is the use of primary rat cortical culture
instead of midbrain culture while testing the protective effect. There is no doubt
about the significance of nigral dopaminergic neuron loss in Parkinson’s disease.
However, the low-yield of tyrosine hydroxylase positive neurons in the culture and
highly variable nature of midbrain culture limits the application. In addition, plenty
of evidence, as mentioned in previous sections, shows that there is widespread
neuronal degeneration in the whole brain as the disease progress, which supports
the use of cortical cultures to test the protective effect of pUL37x1 over-expression.
In the future, the protection of pUL37x1 could be tested on induced pluripotent
stem cell-differentiated ventral midbrain dopaminergic neurons, which provides a
more powerful Parkinson’s disease cellular model.
The next stage of testing the neuroprotection provided by pUL37x1 expression is
in animal studies. However, this generates another concern about the use of
pUL37x1. Viral vectors are required to express pUL37x1 in neurons and the safety of
viral vectors and pUL37x1 would be an issue. Fortunately, there has been no
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troubling safety problem reported in recent decade of gene therapy trials of
Parkinson’s disease ( review by (Bartus et al., 2014). Added to this, CMV is
recognized as a low-virulence virus and only causes severe infection in immune-
compromised patients. Therefore, in terms of toxicity, pUL37x1 treatment is
expected to be minimal.
In conclusion, pUL37x1, a protein with dual anti-apoptotic mechanisms, is a
promising agent to protect against the neuronal degeneration associated with
Parkinson’s disease. It is worth investigating the neuroprotection of pUL37x1 in
experimental animals in the future.
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Supplementary Data
S1. pUL37x1 over-expression did not increase spontaneous cell death but
protected 6-OHDA and staurosporine-induced cytotoxicity: presented by
individual control and pUL37x1 over-expressing line
S1-1
Figure S1-1. pUL37x1 over-expressing SH-SY5Y lines did not increase spontaneous cell
death in no-toxin status compared with control. Data were presented as mean±S.E.M.
Statistics was performed by one-way ANOVA with Dunnett’s post-hoc analysis. (n=6)
S1-2
Figure S1-2. 30µM 6-OHDA treatment for 24 hours caused less than 10% of LDH
release in SH-SY5Y cells (control-1). There was no significant difference between
control and pUL37x1 over-expressing cells in the percentage of LDH release.
Data were presented as mean±S.E.M. Statistics was performed by one-way ANOVA
with Dunnett’s post-hoc analysis. (n=6
216
S1-3
S1-3. pUL37x1 over-expression reduced the percentage of LDH release
compared with control SH-SY5Y cells (control-1). All three lines exhibited
significant protection against 6-OHDA. Data were presented as mean±S.E.M.
Statistics was performed by one-way ANOVA with Dunnett’s post-hoc analysis. (n=6,
***, p<0.001)
S1-4
S1-4. pUL37x1 over-expression reduced the percentage of LDH release against
30µM 6-OHDA treatment for 48 hours compared with SH-SY5Y cells (control-1).
Data were presented as mean±S.E.M. Statistics was performed by one-way
ANOVA with Dunnett’s post-hoc analysis. (n=8)
*** *** ***
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S1-5
S1-5. pUL37x1 over-expression reduced the percentage of LDH release against
30µM 6-OHDA treatment for 72 hours compared with control SH-SY5Y cells
(control-1). All three lines exhibited significant protection against 6-OHDA. Data
were presented as mean±S.E.M. Statistics was performed by one-way ANOVA
with Dunnett’s post-hoc analysis. (n=6, ***, p<0.001)
S1-6
S1-6. pUL37x1 over-expression reduced the percentage of PI fluorescence
against 60µM 6-OHDA treatment for 24 hours compared with control SH-SY5Y
cells (control-1). pUL37x1-1 and 2 lines exhibited significant protection against
6-OHDA. Data were presented as mean±S.E.M. Statistics was performed by one-
way ANOVA with Dunnett’s post-hoc analysis. (n=6, ***, p<0.001)
***
*** ***
*** ***
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S1-7
S1-7. pUL37x1 over-expression reduced the percentage of PI fluorescence
against 30µM 6-OHDA treatment for 48 hours compared with control SH-SY5Y
cells (control-1). pUL37x1-1 line exhibited significant protection against 6-OHDA.
Data were presented as mean±S.E.M. Statistics was performed by one-way
ANOVA with Dunnett’s post-hoc analysis. (n=6, *, p<0.05)
S1-8
S1-8. pUL37x1 over-expression reduced the percentage of LDH release against
15nM staurosporine treatment for 24 hours compared with control SH-SY5Y
cells (control-1). All three pUL37x1 over-expressing line exhibited significant
protection against staurosporine. Data were presented as mean±S.E.M.
Statistics was performed by one-way ANOVA with Dunnett’s post-hoc analysis.
(n=4, *, p<0.05, **, p<0.01)
*
*
****
**
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S1-9
S1-9. pUL37x1 over-expression reduced the percentage of LDH release against
15nM staurosporine treatment for 48 hours compared with control SH-SY5Y
cells (control-1). pUL37x1-1 over-expressing line exhibited significant protection
against staurosporine. Data were presented as mean±S.E.M. Statistics was
performed by one-way ANOVA with Dunnett’s post-hoc analysis. (n=6, *, p<0.05)
S1-10
S1-10 pUL37x1 over-expression reduced the percentage of LDH release against
30nM staurosporine treatment for 24 hours compared with control SH-SY5Y
cells (control-1). All pUL37x1 over-expressing lines exhibited significant
protection against staurosporine. Data were presented as mean±S.E.M.
Statistics was performed by one-way ANOVA with Dunnett’s post-hoc analysis.
(n=8, ***, p<0.001)
*
*** *** ***
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S1-11
S1-11. pUL37x1 over-expression reduced the percentage of PI fluorescence
against 30nM staurosporine treatment for 24 hours compared with control SH-
SY5Y cells (control-1). Data were presented as mean±S.E.M. Statistics was
performed by one-way ANOVA with Dunnett’s post-hoc analysis. (n=6)
S1-12
S1-12. pUL37x1 over-expression reduced the percentage of PI fluorescence
against 15nM staurosporine treatment for 48 hours compared with control SH-
SY5Y cells (control-1). pUL37x1-2 over-expressing line exhibited significant
protection against staurosporine. Data were presented as mean±S.E.M.
Statistics was performed by one-way ANOVA with Dunnett’s post-hoc analysis.
(*, p<0.05, n=6)
*
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S2 pUL37x1 over-expression modulated mitochondria-dependent apoptosis-
presented by individual control and pUL37x1 over-expressing line
S2-1
S2-1. pUL37x1 over-expression hyperpolarized mitochondria compared with
control SH-SY5Y cells. pUL37x1-1 and 3 lines significantly hyperpolarized
mitochondrial membrane potential in no-toxin status whereas all three over-
expressing lines significantly maintained mitochondrial membrane potential
upon 100µM 6-OHDA treatment for 1 hour. Mitochondrial membrane potential
was measured by TMRM fluorescence and normalized by the average of TMRM
fluorescence obtained from no-toxin SH-SY5Y cells. Data were presented as
mean±S.E.M. Statistics was performed by one-way ANOVA with Dunnett’s post-
hoc analysis. (**, p<0.01, ***, p<0.001 )
S2-2
S2-2. pUL37x1 reduced the cytochrome c release upon 500nM staurosporine
treatment for 3 hours. pUL37x1-1 line demonstrated a significant reduction of
cytosolic cytochrome c concentration upon 500nM staurosporine treatment for
***
**
**
*** ***
*
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3 hours compared with control SH-SY5Y cells. Data were presented as
mean±S.E.M. Statistics was performed by one-way ANOVA with Dunnett’s post-
hoc analysis. (*, p<0.05)
S3. The protection of pUL37x1 over-expression was Bax-dependent: presented
by individual control and pUL37x1 over-expressing lines
S3. pUL37x1 over-expression demonstrated the protection of cell death against
staurosporine when silencing with Scr siRNA compared with SH-SY5Y cells
(control-1). However, there was no significant in the percentage of LDH release
between pUL37x1 over-expressing lines with control SH-SY5Y cells when
silencing with Bax siRNA. Data were presented as mean±S.E.M. Statistics were
performed by one-way ANOVA with Dunnett’s post-hoc analysis. (*, p<0.05, **,
p<0.01, ***, p<0.001)
*
***
**
**
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S4 The protection of pUL37x1 Over-expression Was Mitochondrial
Hyperpolarization and Glycolysis-dependent: presented by individual control and
pUL37x1 over-expressing line
S4-1
S4-1 pUL37x1 over-expression failed to protect cell death upon 1µM CCCP
treatment for 48 hours. There was no significant difference in the percentage of
LDH release between SH-SY5Y cells (control-1) with all pUL37x1 over-expressing
lines. Data were presented as mean±S.E.M. Statistics were performed by one-way
ANOVA with Dunnett’s post-hoc analysis.
S4-2
S4-2. Glycolytic inhibitors reversed the hyperpolarization from pUL37x1 over-
expression. pUL37x1-1 and 3 lines demonstrated a significant reduction of
hyperpolarization upon either 10µM 2-deoxyglucose (2DG) or 5µM 3-
Bromopyruvate (3BP) treatment. Data were presented as mean±S.E.M. Statistics
were performed by one-way ANOVA with Dunnett’s post-hoc analysis. . (**, p<0.01,
***, p<0.001)
***
**
***
***
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S4-3
S4-3. Glycolytic inhibitors attenuated the cell death protection of pUL37x1 over-
expression. There was no significant change of the percentage of LDH release
when either 10µM 2-deoxyglucose (2DG) or 5µM 3-Bromopyruvate (3BP) co-
applied with 6-OHDA in control cells. However, in pUL37x1 over-expressing lines,
there was a significant increase of the percentage of LDH release at that
condition. Data were presented as mean±S.E.M. Statistics were performed by one-
way ANOVA with Dunnett’s post-hoc analysis. . (*, p<0.05, **, p<0.01)
**
*
*
